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ABSTRACT 
Down syndrome (DS) is a developmental disorder caused by a triplication of human 
chromosome 21, which contains approximately 550 genes. DS is the most common 
autosomal aneuploidy occurring with an incidence of 1 in 793 live births. Hallmarks of 
DS include abnormal central nervous system (CNS) development and function resulting 
in intellectual disability (ID), motor dysfunction, and early onset Alzheimer’s 
neuropathology. Studies have elucidated widespread neurohistological abnormalities in 
brains of fetuses with DS as early as 20 weeks of gestation, suggesting that early 
dysfunction in neural development may set the stage for exacerbated CNS abnormalities 
throughout life. Additionally, the complex constellation of symptoms associated with DS 
changes over the lifespan, particularly in adolescence and in middle to old age. Thus, 
these periods may represent opportune windows for age-specific therapeutic 
interventions. Due to ethical and practical constraints, use of human samples is alone 
insufficient to characterize the etiological underpinnings of DS phenotypes across the 
lifespan. Furthermore, while human data are instructive for drug development, preclinical 
trials are necessary for target validation, to establish dosage, and to prove safety and 
  viii 
efficacy of any proposed therapeutic. With the advent of mouse models of DS, 
informative studies on the neurobiology of DS as well as preclinical testing of proposed 
therapies are possible. Here, we use a multi-pronged approach to assess molecular, 
neuroanatomical, and behavioral phenotypes indicative of brain and SC function in three 
distinct mouse models of DS: Ts1Cje, Ts65Dn, and Dp16. We identify 
neurodevelopment phenotypes, cytoarchitectural aberrations, bioenergetic abnormalities, 
myelination deficits, and motor/cognitive dysfunction at multiple ages spanning the 
period between embryonic day 12.5 and 6-7 months in trisomic mice.  Additionally, we 
show that while Ts65Dn mice recapitulate all known phases of histological, functional, 
and behavioral phenotypes typical of DS starting from prenatal development and into 
middle age, this is not true for the Ts1Cje or Dp16 models. Lastly, we present promising 
outcomes of two possible therapies for cognitive and motor dysfunction in Ts65Dn mice. 
Altogether our findings provide insights into the underlying neurobiology of ID and 
motor dysfunction in DS and elucidate molecular changes that can be targeted for future 
therapeutic intervention.   
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CHAPTER 1: GENERAL INTRODUCTION 
Chapter 1.1 – General Overview  
Down syndrome (DS) is a developmental disorder caused by a triplication of human 
chromosome 21 (Hsa21). Approximately 550 genes are located on Hsa21, 222 of which 
encode proteins while 325 encode microRNAs, long-noncoding RNAs, and other 
regulatory elements1.  DS is highly prevalent (1 in 793 live births) with approximately 
5,300 babies with DS born annually in the U.S.2, 3. One hallmark of DS is abnormal 
central nervous system development and function resulting in intellectual disability (ID), 
motor dysfunction, and early onset Alzheimer’s neuropathology4-10. To better understand 
the etiology underlying specific DS phenotypes, several aims and hypotheses are 
discussed in this dissertation. In Chapter 2, we explore the usefulness of three distinct 
mouse models for the study of the neurobiology of DS over the lifespan by testing three 
hypotheses: 1) that gene dosage alone drives the manifestation of DS phenotypes, 2) that 
the number of triplicated genes in the models is a direct correlate of phenotype severity, 
and 3) that postnatal behavioral phenotypes are dependent upon embryonic corticogenesis 
phenotypes in the mouse. In Chapter 3, we investigate the role of spinal cord 
development and function in DS and test the hypothesis that trisomy 21 leads to abnormal 
histogenesis and patterning of the spinal cord via actions of Oligodendrocyte 
transcription factor 2 (OLIG2). In Chapter 4, we investigate bioenergetic abnormalities 
in DS and test the hypothesis that mitochondrial quality control and oxidative 
phosphorylation underlie the oxidative stress burden seen in DS. In Chapter 1, a general 
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background on typical central nervous system development is presented. Lastly, in 
Chapter 5, a summary of findings and overarching themes are discussed. 
 
Chapter 1.2 – CNS Ontogeny in Humans 
Human central nervous system development begins during the 3rd gestational week (GW) 
and extends at least into late adolescence, with increasing evidence that it might actually 
persist throughout life11.  This protracted process relies on a concert of inductive signals 
to progress appropriately. Specifically, it is governed by cell-autonomous signals, such as 
gene expression, as well as environmental cues, such as morphogen gradients. Together, 
the fine-tuned convergence of these signals drives proper development and directly 
affects neural outcomes throughout life. Importantly, these signals are not prescriptive 
and can be augmented by adaptive processes that emerge during development, pushing 
differentiation and functional distinction in response to constantly changing inputs11.  
 
CNS development begins with the establishment of the neural crest, which folds to form 
the neural tube during neurulation as early as GW3 in humans11-13. The fusion of the 
neural tube leads to formation of the neuroepithelium, a single-cell layer comprised of 
multipotent stem cells12. Various graded paracrine signals generate distinctive 
neuroepithelial niches within the dorsal, ventral, anterior, and posterior sections of the 
neural tube14, 15. These unique neuroepithelial progenitor cells (NEPs) contribute to the 
regionalization of the neural tube and over time proliferate, migrate, and differentiate, 
leading eventually to the formation of unique structures within the brain and spinal cord 
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(SC)14. NEP position along the anteroposterior and dorsoventral axes of the neural tube 
defines their identity and imbues their progeny with similar properties through exposure 
to regional patterning signals14. Adhering to this principle, by GW4, specialized NEPs in 
the anterior portion of the neural tube give rise to 3 vesicles—the prosencephalon, 
mesencephalon, and rhombencephalon—that would later become the forebrain, midbrain, 
and hindbrain, respectively11, 12, 14, 16. The prosencephalon, which later gives rise to the 
forebrain, is the anterior-most vesicle12. Sequential development and subdivision of the 
prosencephalon leads to the formation of two vesicles known as the telencephalon, which 
gives rise to the cerebral cortex and the limbic system, and the diencephalon, which gives 
rise to thalamus and hypothalamus12. Similarly, the posterior region of the neural tube 
becomes the SC14. Signals mediating the anteroposterior organization of the neural tube 
are complex and are beyond the scope of this discussion. On the other hand, dorsoventral 
patterning is primarily achieved by the actions of two opposing gradients—Bone 
Morphogenetic Protein from the roof plate (dorsal neural tube), and Sonic hedgehog 
(SHH) from the floor plate (ventral neural tube)14. Importantly, SHH signaling is 
essential for SC patterning and will be discussed in greater detail below. In conjunction 
with these extrinsic molecules, patterning is achieved through the actions of specific 
transcription factors which confer a specific fate, function, or maturation status14, 17.  The 
telencephalon will be the focus of studies in Chapters 2 and 4 while the SC will be the 
focus of Chapter 3.  
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By GW5, neuron production (i.e. neurogenesis) begins18, peaking between GW8 and 
GW25, and largely concluding by midgestation13, 19. Embryonic neurogenesis takes place 
in specialized regions along the ventricle, where cerebrospinal fluid circulates. These 
specialized areas of rapid and robust proliferation of NEPs are known as germinal zones, 
and will be discussed in greater detail below. A governing principal of neural 
development is that the multipotency of neural progenitors is progressively restricted 
over time and with rounds of cell division14. Therefore, cells only become fate-restricted 
late in their developmental history14. As such, by GW8 once multiple rounds of cell 
division have occurred, neural precursors begin to differentiate into postmitotic 
neurons12.  These fate-restricted postmitotic neurons migrate away from their birthplace 
near the ventricle to populate the cortical plate, a transient structure that will give rise to 
future layers of the neocortex11, 19-21. Neuronal migration peaks between GW12 and 
GW20 and is completed by GW2912, 19, 22. Thus, neocortical lamination, or subdivision 
into 6 distinct layers, is encoded early during gestation23, 24. Once neuronal migration 
begins, layer formation proceeds in an inside-out fashion with deeper layers (i.e. those 
closer to the ventricle) forming prior to superficial layers (i.e. those closer to the pia)19, 24-
26. The positional identity of differentiating neurons is determined by a combination of 
factors, mainly birthdate, transcription factor expression, and numerous extracellular 
cues14, 24.  
 
Similar to neurogenesis, gliogenesis, or the generation of (macro)glial cells within the 
CNS occurs during embryonic development19, 27. The peak of gliogenesis of astrocytes 
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and oligodendrocytes from NEPs takes place during gestation between GW20 and 
GW40, after the peak of neurogenesis has passed13, 19. Oligodendrocytes (OLs) are the 
myelin-producing cells of the CNS, and only this subtype of glia will be discussed in 
more detail. As a general rule, oligodendrogenesis always follows neurogenesis and 
typically arises from the same brain and SC regions as neurons19, 28. Mature OLs produce 
a lipid-rich membrane, known as myelin, to insulate axons and increase the conduction 
velocity of action potentials. The process of myelination begins at GW12 in the SC29 and 
GW14 in the brain30, becoming robust only during the first postnatal year, and continuing 
into the third decade of life19, 30, 31.  
 
Another process occurring during embryonic development is the formation of synaptic 
connections between neurons. The earliest synapses are observed around GW8 in the 
spinal cord, and GW9-10 in the brain12, 19, 32-35. After the formation of the cortical plate in 
the forebrain, cortical synaptogenesis gradually increases, peaking at GW28 12, 19, 32-34. 
Postmortem neuroanatomical studies coupled with magnetic resonance imaging (MRI) 
have shown that neurons at this point connect in a rudimentary network that drives the 
generation of major fiber pathways by the end of gestation36, 37. Thus, the basic 
framework for the brain connectome is generally set by the end of the prenatal period. 
However, synaptic connections exhibit dynamic changes throughout life in response to 
experience and environmental changes11, 12. Several concerted process refine synaptic 
connections over time38. These processes include, but are not limited to, dendritic 
arborization39, axonal growth, spine formation then pruning, neurotransmitter synthesis, 
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and apoptosis of superfluous cells38, 40. While neocortical expansion, myelination, and 
synapse formation are achieved during gestation, brain growth is still robust post-
parturition. In fact, only by age 6 does the brain finally reach 90% of its adult volume, 
having increased in size 4-fold during adolescence11, 41. Growth of specialized cortical 
regions continues well beyond this age and into adulthood19, 42. Continual reorganization 
of synaptic connections postnatally is the underlying principal of neural plasticity43; 
however; it is clear that the framework established during embryonic development sets 
the stage for neural outcomes and function throughout postnatal life. All of the processes 
described above have been shown to be altered in people with DS. A review of the 
neurohistopathology of DS can be found in Chapter 2.  
 
Chapter 1.3 – Telencephalic Germinal Zones: What We Know From Primate 
and Rodent Studies 
Two telencephalic germinal zones line the lateral ventricles in the mammalian forebrain: 
1) the dorsal germinal zone (dGZ), and 2) the ventral germinal zone (vGZ) (Illustration 
1.1). As discussed above, these germinal zones are the transient sites of neuro- and glio-
genesis in the embryonic brain and SC. These zones originate from a single layer of 
NEPs that line the neural tube. Multipotent NEPs in the dGZ and vGz generate 
specialized cellular subtypes preferentially in spatiotemporally-restricted manner. These 
postmitotic cells then follow defined migratory routes to populate regions of the cortex. 
The dGZ and vGZ are discussed in detail below.  
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Dorsal Telencephalic Germinal Zone 
Excitatory Neuron Progenitors  
Upon fusion of the neural tube, NEPs begin a period of robust and successive cellular 
division44. Mitotic events in NEPs take place at the apical surface lining the lateral 
ventricle after their nuclei undergo a brief displacement towards the basal surface, known 
as interkinetic nuclear migration44, 45. At this time, each round of symmetrical division 
leads to the generation of two identical daughter cells that populate the rudimentary 
pallium44. Due to this nuclear translocation, the neuroepithelium appears stratified and 
through successive divisions, radially expands to contain additional layers (described in 
detail below, Illustration 1.1). After a vigorous expansion in NEP density, neurogenesis 
finally begins at embryonic day E10 in mice and GW5 in humans46-48. This process may 
be modulated by low levels of Shh49. Unlike the symmetrical divisions preceding the 
onset of neurogenesis, asymmetrical divisions of NEPs lead to the formation of both 
postmitotic neurons and neural progenitors50, 51 The earliest type of neural progenitor 
produced from NEPs is the radial glial cell (RGC)47, 48, 52. The stem cell-like RGCs 
continue undergoing symmetrical and asymmetrical divisions, both to self-renew and to 
expand the postmitotic excitatory neuronal population, respectively18, 48, 50, 53. RGCs span 
the thickness of the pallium, with apical processes extending to the ventricular surface 
and basal processes extending to the pia14, 54. Postmitotic neurons migrate radially along 
RG fibers to populate the developing neocortex25, 55, 56. Asymmetric divisions of RGCs 
also generate multiple classes of intermediate progenitors known as apical intermediate 
progenitors (aIPCs), basal intermediate progenitors (bIPCs), and basal radial glia 
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(bRGs)50, 53, 57-61. Because additional cell types have been identified in primates, 
population size and diversity of progenitors are thought to contribute to increased 
heterogeneity of postmitotic neurons and structural complexity of the human neocortex.  
 
Layers of the dGZ 
Due to the morphology and distribution of progenitors within the growing pallium, the 
rodent dGZ is classically subdivided into several layers (Illustration 1.1). Starting at the 
ventricle, is the aptly named ventricular zone (VZ)52, 62. This is the only visible zone 
during NEP symmetrical divisions. Over the neurogenic window, the VZ expands to its 
maximal size at the peak of neurogenesis then gradually disappears45. RGCs and aIPCs 
both reside within the VZ and have processes that contact the ventricles53, 57, 58. 
Immediately dorsal to the VZ is the subventricular zone (SVZ) where bRGs and bIPCs 
actively divide63, 64. Histological staining of proliferating cells within the dGZ shows that 
many cluster in a thick band within the SVZ, indicating that this is an area of vigorous 
proliferation. Dorsal to the SVZ is the intermediate zone (IZ) which houses a small 
transient population of dividing cells and a large population of postmitotic neurons that 
migrate towards the cortical plate (CP)47, 48. The CP emerges at E13.5 in mice and houses 
postmitotic neurons65. The CP expands in an inside-out fashion, eventually leading to the 
formation of the 6 layers of the neocortex, whereby early born neurons populate the 
deepest layers, while late born neurons populate the most superficial layers of the 
neocortex18, 25, 45, 55.  
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Ventral Telencephalic Germinal Zone 
Neurogenesis in the vGZ is governed by similar principles to those discussed above; 
however, instead of excitatory neurons, the NEPs within the vGZ first generate inhibitory 
interneurons (INs) then OLs that migrate tangentially to populate the forebrain66-70 
(Illustration 1.1). The vGZ is localized within a transient structure known as the 
ganglionic eminence (GE), present only during embryonic development56, 71. The GE is 
subdivided into three substructures known as the medial ganglionic eminence (MGE; 
subdivided into a dorsal and ventral portion by a dorsoventral gradient of SHH72), the 
lateral ganglionic eminence (LGE), and the caudal ganglionic eminence (CGE)66-68 
(Illustration 1.1). Regional origin, as well as timing, specify distinct IN subtypes which 
can be identified morphologically, electrophysiologically, and/or by their expression of 
specific proteins68, 73. As with excitatory neurons, INs laminate in an inside-out fashion 
with the earliest born INs residing in the deepest neocortical layers67, 74. Table 1.1 
provides a brief description of 3 distinct IN subclasses marked by their expression of the 
calcium binding proteins Parvalbumin (PV), Somtatostatin (SS), and Calretinin (CR)73, 75-
78. 
 
Oligodendrogenesis occurs in three spatiotemporally distinct waves69, 79, 80. RGCs divide 
asymmetrically to generate oligodendrocyte precursor cells (OPCs), which then divide 
symmetrically to expand their numbers. The first wave of oligodendrogenesis takes place 
at E11.5 in the MGE while the second wave of oligodendrogenesis begins at E15 in the 
LGE and CGE80-82 (Illustration 1.1). Interestingly, the third wave of OPCs are generated 
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postnatally from the dGZ82 (Illustration 1.1). For unknown reasons, once OPCs from the 
first wave arrive at the cortex, they undergo apoptosis and are later replaced by OPCs 
arising from the third wave of oligodendrogenesis82. Importantly, OPCs undergo a 
stepwise maturation process from precursors to fully mature, myelinating OLs83-85. These 
maturation states can be identified through expression of stage-specific proteins 
(described in Chapter 3)86. Interestingly, both INs and OLs originating in the vGZ arise 
from progenitors expressing Oligodendrocyte transcription factor 2 (OLIG2)68, 87. While, 
postmitotic INs downregulate OLIG2 expression, cells derived from the OL-lineage 
continue to express OLIG2 regardless of maturation state.  
 
Several perturbations in cortical development have been described in brains of fetuses 
with DS (reviewed in Chapter 2). As such, examination of the above processes in mouse 
models of DS is a requisite for better understanding the neurobiology of cognitive 
dysfunction in DS. 
 
Chapter 1.4 – Spinal Cord Development 
Dorsoventral and rostrocaudal patterning of the SC have been the focus of numerous 
studies over the past two decades. Because transcriptional codes initially drive the 
cytoarchitectural organization of the cord, elucidating their expression and regulation has 
been at the forefront of neurodevelopmental research88. In addition, the SC has been used 
as a model to better understand the intrinsic cellular programs that specify lineage and 
terminal differentiation of neurons. Of interest are cues along the dorsoventral axis of the 
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ventral portion of the SC. Patterning in this plane arises from opposing gradients of 
several BMPs and SHH that emanate from the roof plate and floor plate of the neural 
tube, respectively. While BMPs specify dorsal progenitor domains, we will be focusing 
on ventral domains induced by SHH17, 89-92. SHH-induced transcription factors in neural 
progenitors along the ventricle in the ventral portion of the rostral neural tube act as 
intermediaries in neural patterning17, 91, 93-95.  
 
These transcription factors convert graded extracellular signals into cell-fate decisions 
allowing for the genesis of all classes of spinal cord neurons as well as macroglia91, 94-102. 
The end result of this combinatorial fate-restricting code is the generation of 12 distinct 
progenitor domains that together give rise to all classes of spinal cord neurons. Of these, 
5 are the ventral domains designated p0, p1, p2, pMN, and p3. Through the actions of 
many homeodomain (such as ISL1, ISL2, HB9) and homeobox (NKX2.2, NKX6.1, 
CHX10) transcription factors these progenitor domains generate V0-V2 inhibitory INs, 
V3 excitatory INs, motor neurons (MN), and OLs88, 91-94, 96, 97, 103-111. INs are further 
subdivided into subclasses that play distinct roles in innervation by integrating in unique 
local networks. Additionally, further specification of spinal MNs is needed to allow 
proper target-finding and establishment of the neuromuscular unit. During development, 
positions of MN soma in the spinal cord become organized based on the relative position 
of target muscles112, 113. This musculotopic patterning of the cord is intrinsic and depends 
on genetic cues that determine neuronal subtype identity as well as establish a pattern of 
migration and connectivity112, 114, 115.  
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In addition to SHH and transcription factors, and similar to the telencephalon, studies 
have shown that timing of neurogenesis in the SC contributes to the diversification of 
neuronal and glial populations116. Along with dorsoventral morphogen gradients affecting 
transcription factor expression, birthdating experiments show that dorsoventral and 
rostrocaudal temporal gradients of neurogenesis specify neuronal subtypes, especially 
those participating in locomotor circuits within the mature SC116-118. This birthdate-
dependent generation of spinal cord populations is further illustrated by the sequential 
generation of motor neurons and OLs from the pMN106, 119-122. MNs are first generated 
from neuroepithelial cells in this domain from E9.5 (5 GW in humans) to approximately 
E11.5, then on E12.5 oligodendrogenesis begins122. This MN-OL connection is quite 
interesting and the fate-switch in these progenitors, driven by OLIG2, is well described98, 
108, 123, 124. As such, we focus in Chapter 3 on the pMN progenitors and the role of OLIG2, 
which is triplicated in DS, in patterning of the ventral horn of the SC.  
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Marker Birthplace Birthdate 
Parvalbumin (dorsal) MGE E10-E15.5 
Calretinin 
(ventral) MGE 
CGE 
E12.5-E15.5 
 
Somatostatin (ventral) MGE E12.5-E15.5 
 
Table 1.1- Summary of interneuron subtypes and their origins within the ganglionic eminences. 
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Illustration 1.1-Schematic of E15.5 mouse brain. 
The illustration shows an E15.5 mouse brain that is subdivided into the dorsal and ventral 
germinal zones. Within the dorsal germinal zones, there are 4 layers starting at the 
ventricle and extending out towards the pia. They are designated as follows: 1) the 
ventricular zone (VZ), 2) the subventricular zone (SVZ), 3) the intermediate zone (IZ), 
and 4) the subplate/cortical plate (SP/CP). During embryogenesis, the dorsal germinal 
zone is the birthplace of excitatory neuronal progenitors. The CP expands to give rise to 
the 6 layers of the neocortex. 
 
The ventral germinal zone is located within the ganglionic eminences, a set of transient 
structures that collectively give rise to interneurons and oligodendrocyte progenitors 
during embryogenesis. Only the lateral and medial ganglionic eminences (LGE and 
MGE, respectively) are depicted, because the caudal ganglionic eminence (CGE) is not 
observed in this coronal section.   
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CHAPTER 2 – COMPARISON OF FOREBRAIN DEVELOPMENT, GENE 
EXPRESSION AND BEHAVIOR IN THE TS1CJE, TS65DN AND DP(16)1YEY/+ 
MOUSE MODELS OF DOWN SYNDROME  
The work presented below is the result of a collaborative effort by Nadine Aziz, Dr. 
Faycal Guedj, Dr. Jeroen Pennings, Dr. Luis Olmos Serrano, Dr. Tarik Haydar, and Dr. 
Diana Bianchi.  
 
Specific experimental contributions by Nadine Aziz are as follows: 
 Animal husbandry and tissue generation for all Ts65Dn experiments 
 Animal husbandry and tissue generation for all Dp16 experiments at embryonic 
ages 
 Tissue processing and immunohistochemical analyses of Ts1Cje, Ts65Dn, and 
Dp16 at all ages sampled 
 
Chapter 2.1 – Introduction 
Down syndrome (DS) is a developmental disorder caused by a triplication of human 
chromosome 21 (Hsa21). Approximately 550 genes are located on Hsa21, 222 of which 
encode proteins while 325 encode microRNAs, long-noncoding RNAs, and other 
regulatory elements1. DS is the most common autosomal aneuploidy with an incidence of 
1 in 793 live births. Approximately 5,300 babies with DS are born annually in the U.S.2, 3. 
Hallmarks of DS include abnormal central nervous system development and function 
resulting in intellectual disability (ID), motor dysfunction, and early onset Alzheimer’s 
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neuropathology4-10. Additionally, DS is associated with a constellation of abnormalities 
that affect other organ systems, including congenital heart defects, childhood leukemia, 
gastrointestinal disease, thyroid disease, and sleep apnea125-128.  
 
Existent therapies have been successful at alleviating symptoms arising from organ 
system abnormalities; however, neurocognitive interventions have been lagging far 
behind129. While several preclinical trials of potential neuropharmacotherapies have been 
conducted in mouse models of DS, none have been fully vetted to show comprehensive 
rescuing of brain defects in the mice and, to date, no resultant clinical trials have been 
successful130, 131. Because DS-related neuropathology evolves in a spatiotemporal 
manner, therapies or a combination of therapies that target distinct periods over the 
lifespan are integral in combating the associated ID132, 133. A notable exception would be 
treatment that can fully silence the extra chromosome during gestation. Furthermore, 
while it is still not fully understood how brain changes during fetal development relate to 
postnatal behavior and later observed brain defects, over the past 5 years interest in 
prenatal therapy has been growing within the DS research community134-136. Recent 
studies have shown that neuropharmacotherapies are more restorative and have longer 
lasting effects when administered during phases of neural development than when given 
to adult mice133, 134, 137. With the advent of highly accurate noninvasive prenatal testing as 
early as 10 weeks of gestation and rapid developments in personalized medicine, 
clinicians are now for the first time uniquely positioned to therapeutically target the 
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prenatal window in order to exploit the critical period of fetal development when the 
CNS is experiencing dynamic changes and rapid growth138, 139. 
 
Recent studies have shown that the neuropathological consequences of trisomy 21 begin 
during fetal development and that cognitive deficits emerge throughout life.  
Neurohistopathology is detectable as early as 20 weeks of gestation in postmortem brains 
from fetuses with DS, and is characterized by an increase in apoptosis in the ventricular 
zone and within the developing neocortex and white matter140, 141. This is accompanied 
by a decrease in prenatal neocortical neurogenesis and synaptogenesis, as well as 
cerebellar and frontal lobe hypoplasia7, 125, 142-146. Notably, cerebellar dysgenesis is 
concomitant with impaired proliferation within the precursor cell population but not 
increased apoptosis, suggesting that the observed hypocellularity arises specifically from 
impaired cerebellar neurogenesis and not loss of cells147.  A decrease in cellular migration 
and neurotransmitter levels has also been observed in brains from fetuses with DS141, 148, 
149.  
 
Postnatal studies show that infants with DS exhibit abnormal cellular differentiation, 
altered cortical lamination, reduced dendritic branching, decreased synapse formation, 
microcephaly, hippocampal hypoplasia, reduced cerebellar and brainstem volumes, and 
decreased overall brain weight145, 150-156. Delayed myelination and alterations in various 
white matter tracts have also been reported150, 157, 158. Throughout adolescence and into 
adulthood, morphological, cellular, and subcellular parameters of brain structure and 
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function continue to diverge in individuals with DS compared to people with typical 
development4. By adulthood, the brains of individuals with DS show a 24% reduction in 
size, with a decrease in volume of multiple brain areas including the cerebellum (33% 
smaller), hippocampus (27% smaller), frontal cortex (17% smaller), dorsolateral 
prefrontal cortex, anterior cingulate gyrus, inferior temporal and parietal cortices, and 
parietal white matter along with a narrower superior temporal gyrus and simplified 
gyrification10, 153, 159-165. Interestingly, increases in volume of the parahippocampal gyrus 
have also been observed164.   
 
Along with these neuroanatomical deficits, atypical cognition during infancy and 
childhood is a hallmark of DS. Aside from motor deficits at birth, early learning 
impairments are present at 6 months of age leading to a progressive decline in intellectual 
quotient after the first year of life, delayed language acquisition and development, and 
altered hippocampal-dependent explicit and spatial memory in individuals with DS166-174. 
Additionally, by approximately 40 years of age, almost all adults with DS will exhibit 
Alzheimer’s neuropathology; however, not all will display clinical signs of Alzheimer’s 
dementia175, 176. Furthermore, anomalous cholinergic, noradrenergic, and GABA-ergic 
neurotransmission has been reported in individuals over the age of 40159, 177.   
 
Due to these distinct spatiotemporal changes in individuals with DS, interventional 
therapies need to be target- and life stage-specific in order to be efficacious. For example, 
treatments designed to be advantageous during embryonic brain development likely need 
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to be distinct from those designed to abrogate early onset Alzheimer’s pathology. 
However, neurocognitive interventions aimed at ameliorating DS-related intellectual 
disability have been underdeveloped largely because human studies alone have so far 
been insufficient in generating longitudinal molecular, biochemical, and functional data 
to elucidate specific, targetable mechanisms underlying DS phenotypes over the lifespan 
of affected individuals129.  
 
The synteny between Hsa21 and mouse chromosomes (Mmu) 10, 16, and 17 has allowed 
for the generation of approximately one dozen mouse models to better characterize the 
relationships between gene perturbations and cellular, subcellular, and molecular aspects 
of brain development and function in people with DS. Despite a substantial body of work 
by many groups over the past two decades, lack of standardized testing paradigms has 
generated conflicting reports and hindered direct comparisons of DS phenotypes among 
the different models1, 8, 178-180. Thus, there is a large unmet need for an intra-species 
comparative screen that better links the triplicated orthologous genes in various 
segmental trisomy models with DS phenotypes.   
 
Here we longitudinally compare gene expression, brain histopathology and behavior in 
three of the mouse models with the highest degree of genetic similarity to DS—Ts1Cje, 
Ts65Dn, and Dp16 mice. All three models exploit the large segments of Hsa21-
orthologous genes on Mmu16. Each model was engineered using distinct methodology. 
First, the Ts65Dn mouse model of DS was generated by cesium irradiation that induced a 
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reciprocal translocation of the most distal portion of Mmu16 onto a marker chromosome 
containing the centromeric portion of Mmu17, almost three decades ago181. 65 clones 
were needed to produce this translocation181 (Figure 2.9). Since this triplication is carried 
as an additional chromosome, it mirrors the aneuploidy observed in 95% of DS cases182. 
The triplicated segment consists of 104 Hsa21 orthologous genes and 60 nonorthologous 
centromeric Mmu17 genes that are irrelevant to DS183 (Figure 2.9). Of these 60 unrelated 
genes, ~35 are protein coding183. Despite this genetic flaw, Ts65Dn has been the most 
widely used mouse model of DS.  Approximately a decade later, in 1998, the Ts1Cje 
mouse model of DS was derived from the Ts65Dn to better understand the role of a 
particular gene184. It was generated via a reciprocal translocation of the distal portion of 
Mmu16 onto the telomeric region of Mmu12 (Figure 2.9). This created an elongated 
Mmu12 carrying an additional dose of 71 Hsa21 orthologues (Figure 2.9). The fusion of 
Mmu16 genes onto Mmu12 led to the monosomy of 7 telomeric genes183 (Figure 2.9). 
Despite lack of non-orthologous triplicated genes in this model, a smaller triplication 
segment and loss of a functional copy of Superoxide dismutase 1 led to scarce use of this 
model.  Finally, in 2007, the Dp16 mouse model of DS was generated using cre-mediated 
recombination of the entire Hsa21 syntenic region on Mmu16185 (Figure 2.9). This 
allowed the addition of the entire 23.3Mb segment of Hsa21 orthologues onto the distal 
portion of Mmu16185 (Figure 2.9). Similar to the Ts1Cje, the additional genetic material is 
encompassed in an elongation of Mmu16 and not in an additional freely segregating 
chromosome185 (Figure 2.9). However, due to the increase in size of the triplicated 
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segment and lack of perturbation of non-orthologous genes, Dp16 may be the most 
faithful murine representation of the genetic landscape of DS. 
 
Using a standardized battery of tests, we examined these mice at three different life 
stages to eliminate confounding variables arising from experimental design or 
experimenter bias. We provide evidence of distinct phenotypes across the lifespan in each 
model and compare our findings to human studies. These data indicate that each model 
manifests different phenotypes and appearance of atypical neural function at varied times 
during the lifespan suggesting that these models have varying degrees of human-relevant 
defects that may be useful for development of interventional therapies for people with 
DS. Furthermore, these data provide an objective screen to aid in the selection of 
adequate mouse model(s) to test prenatal and postnatal therapeutic molecules, and to 
identify molecular, cellular and behavioral endpoints that can be used to test the efficacy 
of proposed therapies. 
 
Chapter 2.2 – Materials and Methods 
We developed a comprehensive standardized protocol to evaluate the molecular, cellular 
and behavioral phenotypes in the Ts65Dn, Ts1Cje and Dp16 mouse models of DS at 
embryonic, neonatal and adult stages. This enabled a direct comparison of models as well 
as to the known changes in individuals with DS. While some of the subsets of data on 
individual models have been previously published by our groups186-191, this section 
describes all of the methods used.  
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Animal Breeding and Genotyping 
Animal breeding  
All murine experiments were conducted according to international ethical standards and 
approved by the Institutional Animal Care and Use Committees (IACUC) of Boston and 
Tufts Universities. Animals were housed in cages with standard bedding and a nestlet 
square. Rodent chow and water were available ad libitum. The colonies were maintained 
on a 12:12 light/dark cycle, with lights on at 7:00 AM. 
 
B6.Cg-T(12;16)1Cje/CjeDnJ mice (Ts1Cje; stock number 004838), B6EiC3Sn.BLiA-
Ts(1716)65Dn/DnJ (Ts65Dn; stock number 005252) mice and B6129S-Dp(16Lipi-
Zfp295)1Yey/J (Dp16; stock number 013530) mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). Ts65Dn female mice were bred with B6EiC3Sn.BLiAF1/J 
(F1 hybrid; stock number 003647) males. Ts1Cje and Dp16 males were bred with 
C57BL/6J (Jackson Laboratory, Bar Harbor, ME) or C57BL/6N females (Charles River 
Laboratories, Wilmington, MA). In order to test the contribution of background strain 
and maternal uterine environment on observed phenotypes, both Dp16 and Ts1Cje 
females were bred with C3Sn.BLiA-Pde6b+/DnJ males and resultant progeny were bred 
in the following ways: 1) Dp16 B6EiC3Sn.BLiAF1/J F1 hybrid females were bred  with 
B6EiC3Sn.BLiAF1/J F1 hybrid males to generate B6129SC3Sn-Dp(16Lipi-
Zfp295)1Yey/NJ in a manner that mimics Ts65Dn breeding; and 2) Ts1Cje 
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B6EiC3Sn.BLiAF1/J F1 hybrid males were bred with euploid B6EiC3Sn.BLiAF1/J F1 
hybrid females to generate B6EiC3Sn.Cg-T(12;16)1Cje/CjeDnJ mice.  
Studies were performed at three different life stages: 1) embryonic: embryonic day 
(E)15.5 for global brain gene expression, gross anatomy, and neuroanatomy/neurogenesis 
experiments, 2) neonatal: between birth and postnatal day (P)21 for neonatal behavior 
and excitatory/inhibitory neuronal density experiments, and 3) adult: between 3 and 7 
months for behavioral and cerebellar, hippocampal, and cortical gene expression 
experiments. 
 
Genotyping 
Phenol/chloroform DNA extraction was performed on embryonic limb buds or postnatal 
tail clippings after digestion with proteinase K (Denville Scientific, Holliston, MA). 
Genotyping and determination of sex were performed by PCR using primers specific for 
the Ts1Cje192, Ts65Dn193, or Dp16188 translocation breakpoints and the SRY region along 
with an internal positive control (Supplementary Table 2.1).  
 
Tissue Collection 
Embryonic brain collection- Global gene expression 
Breeding pairs were established so that vaginal plugs could be checked twice daily. The 
presence of a vaginal plug was designated as E0.5. A 10% weight gain at E10 was used 
to confirm pregnancy194. Pregnant dams were euthanized at E15.5. Embryos were 
extracted, identified as E15.5 using Theiler staging and decapitated in ice-cold 1x 
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phosphate buffered saline (PBS) containing RNAprotect® cell reagent (Qiagen, 
Germantown, MD). Embryonic forebrains were rapidly removed and brain hemispheres 
dissected on a cold platform and snap frozen in liquid nitrogen before storage at -80°C. 
 
Embryonic brain collection- Histology/Neuroanatomy 
E15.5 embryos were collected and fixed for 24h in 4% paraformaldehyde (PFA) at 4°C. 
Embryos were then washed 3 times in 1x PBS and brains were dissected for gross 
measurements. After measurements were completed, fixed brains were placed in 30% 
sucrose for 16-36h at 4°C then frozen in Optimal Cutting Temperature Compound (OCT; 
Sakura, Torrance, CA). Tissue blocks were stored at -80°C until use. 16μm thick serial 
coronal sections were cut using a cryostat, mounted on Superfrost® Plus charged slides 
(ThermoFisher Scientific, Waltham, MA), and stored at -80°C. 
 
Neonatal brain collection- Histology 
P15 male mice were anesthetized with a xylazine/ketamine cocktail according to IACUC 
regulations. Mice were transcardially perfused with 4% PFA, and brains were extracted 
and post-fixed for 16h in 4% PFA at 4°C. Brains were then prepared as described above.  
 
Adult tissue collection- Global gene expression 
For adult gene expression studies, 6-7 month old male mice were anesthetized with 2.5% 
isoflurane in a 3/7 O
2
/N
2
O mixture and euthanized by decapitation. Brains were removed 
  
26 
from the skull and dissected on a cold platform. Cerebral cortex, hippocampus and 
cerebellum were dissected and snap frozen in liquid nitrogen and stored at -80°C. 
 
Gene Expression Studies 
For gene expression studies, total RNA was isolated from the developing forebrain using 
the RNA II kits following the manufacturer’s instructions (Macherey-Nagel, Bethlehem, 
PA). RNA was processed and hybridized on the GeneChip® Mouse Gene 1.0 ST array as 
described previously195. Statistical analyses were carried out on the normalized data using 
R software (version 3.1.2 or later). Normalization output consisted of data for 21,225 
probe sets corresponding to unique Entrez Gene IDs. Gene expression data from Ts1Cje, 
Ts65Dn, and Dp16 tissue were compared to their respective euploid littermates using an 
unpaired Student’s t-test.  P-values for the combined comparisons included in this study 
were jointly corrected for multiple testing using the Benjamini-Hochberg False Discovery 
Rate (FDR)196. Genes were identified as differentially expressed (here after referred to as 
DEX genes) if the p-value was < 4.55 x 10-4, which corresponded to an overall FDR of 
20% for the study. For functional pathway analysis, we used the top 1% up-and down-
regulated genes (2 x 212 genes, here after referred to as affected genes) for 
overrepresentation using DAVID197. Gene Ontology or KEGG terms were considered 
significantly enriched if the DAVID p-value was <0.05. 
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Neuroanatomical Studies 
Embryonic Brains 
Gross Measurements 
All measurements of brain growth were conducted as previously described in Chakrabarti 
et al., 2007186, and Goodliffe et al., 2016188. Briefly, embryos were imaged using an 
Olympus MVX10 brightfield microscope coupled with a Zeiss AxioCam MRc camera. 
Somatic and gross brain measurements were determined using Axiovision software 
(Zeiss, GER). All embryo crown-rump lengths were measured from the top of the head to 
the base of the tail. For gross brain measurements, brains were removed and cleared of all 
other tissue and the maximal rostrocaudal and mediolateral lengths of each telencephalon 
were measured.  
 
Pallial Expansion Measurements 
Embryonic brain sections were stained with either 1 mM TO-PRO®-3 (Thermo Fisher 
Scientific, Waltham, MA) according to the manufacturer’s protocol or with DAPI 
(Vector Laboratories, Burlingame, CA). After staining, slides were mounted with 
Vectashield (Vector Laboratories, Burlingame, CA) and sealed. Slides were then scanned 
with an LSM710 Zeiss confocal microscope as described below. The dorsal pallium was 
subdivided into the ventricular and sub-ventricular zones (VZ/SVZ), the intermediate 
zone (IZ), and the subplate/cortical plate (SP/CP) based on the shape and density of 
nuclei. The thickness of each subdivision was then measured and quantified and the 
overall pallial thickness was also determined.  
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Neurogenesis Assay 
Pregnant dams were injected with a 50 mg/kg body weight solution containing a 
thymidine nucleoside analog known as 5-ethynyl-2'-deoxyuridine (EdU) (Thermo Fisher 
Scientific, Waltham, MA). These females were sacrificed 24h post injection at E15.5 and 
embryonic tissue collection proceeded as described above. A modified protocol was 
established to stain for EdU utilizing Click-iT® technology (Thermo Fisher Scientific, 
described in detail in Goodliffe et al., 2016). 
  
Immunohistochemistry 
When necessary, depending on the tissue-penetrance and antigen recognition ability of 
the antibody used, antigen retrieval was performed by microwaving slides in 10mM 
sodium citrate buffer for 1min at maximum power, followed by 10min at minimum 
power. Slides were then washed in 1xPBS and incubated in blocking solution (5% normal 
donkey or normal goat serum, 0.2% Triton® X-100 in PBS) for 1h at room temperature. 
This was followed by incubation in primary antibody overnight at room temperature. 
Slides were washed in 1xPBS and incubated with secondary antibody solution for 1h at 
room temperature. Slides were mounted in Vectashield with DAPI (Vector Laboratories, 
Burlingame, CA). Primary antibodies used: rabbit anti-Oligodendrocyte Transcription 
Factor 2 (1:300, Millipore, AB9610), rabbit anti-phosphorylated Histone 3 (1:500, 
Millipore, 06-570), rat anti-Somatostatin (1:50, Millipore, MAB354), rabbit anti-
Parvalbumin (1:1000, Swant, PV25), rabbit anti-Calretinin (1:1000, Swant, 769913), and 
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rabbit anti-Tbr1 (1:1000, gift from Hevner laboratory). The following secondary 
antibodies were used (1:250 dilution, Thermo Fisher Scientific, Waltham, MA): donkey 
anti-rabbit 555 (A31572), goat anti-rabbit 546 (A11035), goat anti-rabbit 488 (A11008), 
and goat anti-rat 488 (A11006). 
 
Confocal Microscopy and Cell Population Analysis in Embryonic and Postnatal Tissue 
Using a combination of DAPI and TOPRO-3 staining, we demarcated the different 
germinal layers within the dorsal telencephalon at the level of the future somatosensory 
cortex. We used staining pattern as well as nuclear shape to subdivide the developing 
pallium into three zones: 1) the ventricular and sub-ventricular zones (VZ/SVZ), 2) the 
intermediate zone (IZ), and 3) the subplate/cortical plate (SP/CP). All sections were 
imaged using a Zeiss LSM 710 confocal microscope system. Sixteen 1μm thick z-stacks 
(at 1024x1024 resolution) of each region of interest were acquired using a 20x objective 
(N.A.: 0.80). Labelled cells were then either automatically counted using Volocity 
(Perkin Elmer, Waltham, MA) software following manual validation of randomly 
selected samples, or manually counted using ImageJ and LSM Image Browser software. 
Where noted, cell distribution was determined by measuring cell positions in reference to 
the ventricular wall. Analysis was limited to the dorsal pallium and medial ganglionic 
eminence at the level of the future somatosensory cortex in embryonic samples, and to 
the level of the somatosensory cortex and dorsal hippocampus in postnatal animals. DAPI 
staining was used to determine neocortical and hippocampal layer boundaries. Both 
females and males were included in prenatal analyses but postnatal analyses were limited 
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to males only to allow for comparison of the current work with previously published 
literature. 
 
Behavioral Studies 
All behavioral experiments were conducted in the light phase, between 8:00 AM and 1:00 
PM. To minimize olfactory cues from previous trials, each apparatus was thoroughly 
cleaned with Sani-Cloth Plus between trials (PDI Healthcare, Hamilton, NJ). For each 
day of testing, mice were left in their home cages in the room used for the experiment at 
least 1 hour prior to the onset of the study. Pups were placed with nesting material in a 
bowl positioned on a heating pad at 37°C. The Morris water-maze task was the last 
experiment in the series. For all experiments, the investigator was blind to the genotype.  
 
Neonatal Developmental Milestones  
Male and female Ts1Cje, Ts65Dn, Dp16 and euploid littermates were tested as 
previously described189, 198, 199. Briefly, a set of neonatal behavioral tests were chosen to 
measure different sensory and motor development parameters in neonatal mice from birth 
until P21. These tests measured four broad categories of perinatally acquired skills: 1) 
body righting and coordination (surface righting, air righting and negative geotaxis); 2) 
motor strength (cliff aversion and forelimb grasp); 3) sensory system maturation 
(auditory startle, ear twitch and eye opening); and 4) extinction of rotatory behavior 
(open field). The amount of time to achieve a developmental milestone (latency) and the 
presence or absence of a reflex was recorded and analyzed by a single experimenter who 
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was blind to animal genotypes. A total number of 32 Ts1Cje and 64 euploid littermates, 
23 Ts65Dn and 34 euploid littermates, and 30 Dp16 and 72 euploid littermates was 
studied. Statistical analyses were also performed to test whether males and females 
performed similarly in each task. 
 
Adult Behavior 
The SHIRPA behavioral screen, open field, rotarod, contextual fear conditioning, and 
Morris water-maze tests were used to investigate adult behavior in Dp16 (n=17) and 
euploid littermates (n=18), Ts65Dn (n=12) and euploid littermates (n=12), Ts1Cje (n=13) 
and euploid littermates (n=15). 
 
SHIRPA Primary Behavioral Screen 
The SHIRPA screen enables a rapid semi-quantitative assessment of multiple primary 
body functions, including those that relate to muscle and motor neuron, spinocerebellar, 
sensory, neuropsychiatric, and autonomic systems200. The experimenter was blind to the 
genotype, and the performance of each mouse was scored according to the scale provided 
in Table S2.14.  
 
Exploratory Behavior and Spontaneous Locomotor Activity 
Exploratory behavior and locomotor activity were assessed using the open field test as 
described previously201. Briefly, the mouse was placed in an open field arena consisting 
of a white opaque plastic box 40cm (L) x 40cm (W) x 40cm (H) divided into a center 
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zone measuring 20cm (L) x 20cm (W) x 20cm (H) and periphery. Exploratory behavior 
was tracked during a 60min unique trial using the Ethovision 10.5 animal tracking system 
(Noldus, Leesburg, VA). The total distance traveled (cm) in the center versus periphery 
as well as the average velocity (cm/s) were analyzed for each genotype. Data were 
collected as time bins of 20min and as total time over the course of the experiment. 
Motor Coordination 
Motor coordination was investigated using the rotarod test (Med Associates, Fairfax, VT) 
using two different protocols (fixed speed protocol on day 1 and accelerating speed 
protocol on day 2). Prior to testing with the fixed speed protocol on day 1, each mouse 
was given two 120s practice sessions at 16 RPM. After practice, mice were tested at 3 
different fixed speeds (16 RPM, 24 RPM then 32 RPM) for two 120 s trials at each speed 
and with an inter-trial interval of 15min. On day 2, mice were tested in two trials under 
conditions of increasing difficulty in which the speed of the rotation gradually increased 
from 4 to 40 RPM over a 5min period. The latency (in seconds) to fall was recorded and 
analyzed for each mouse. Unexpectedly, the euploid littermates of Ts65Dn mice 
performed poorly compared to euploid littermates of Dp16 and Ts1Cje mice. We 
therefore pooled two cohorts of euploid C57Bl6/C3HSn mice to increase the number of 
subjects and to eliminate confounds. 
 
Hippocampal-Dependent Contextual Memory 
Hippocampal-dependent memory was analyzed using the fear conditioning test in a 
conditioning chamber containing a stainless-steel grid floor, an electric aversive 
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stimulator and a house light. This chamber is enclosed within a sound attenuating cubicle 
with an exhaust fan (Med Associates, Fairfax, VT). On day 1 (training session), each 
mouse was individually placed for 5min into the conditioning chamber and allowed to 
explore freely (habituate) for 180s. Following exploration/habituation, 2 mild foot shocks 
(0.5 mA for 2s) were administered at 180s and 240s. On day 2 (testing session), the mice 
were placed into an identical conditioning chamber for 5min with no foot shocks. Each 
mouse was monitored for freezing (fear) behavior. The extent of (or percent of time 
spent) freezing, was analyzed in bins of 60s and as a total over the course of the 
experiment using the Freeze View software (Med Associates, Fairfax, VT). These 
measurements were used as a proxy of the animal’s memory of a noxious stimulus. 
 
Hippocampal-Dependent Spatial Memory 
Hippocampal-dependent spatial memory was analyzed using the Morris water-maze 
(MWM) test in a 125cm diameter circular as described previously189. Mice were trained 
using an extended protocol containing the following sequence of trials: Cued, hidden 
platform, probe trial, reversal platform and a final probe trial. Each trial lasted for a 
maximum period of 60s after which the mouse was guided to the platform and allowed to 
recover for 15s before being gently removed by the experimenter. 24h after the hidden 
platform and the reversal platform training sessions, each mouse was subjected to a probe 
trial to test reference memory. During this test, the platform was removed and mice were 
allowed to swim once freely for 60s. Video tracking was performed using the Ethovision 
software (Noldus Actimetrics, Wilmette, IL). Latency to reach the platform, swimming 
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speed, total distance, time spent in the center versus periphery, as well as the time spent 
in each quadrant were recorded and analyzed. All groups were tested using an identical 
protocol differing only in the number of days in each phase of testing. Testing ended 
when: 1) trisomic animal performance matched euploid animal performance, or 2) 
performance in the trisomic experimental group plateaued indicating a lack of ability to 
match euploid performance. Importantly, our extended MWM paradigm gave us the 
ability to qualify whether deficits in spatial learning and memory in trisomic mice are 
permanent202 or merely delayed189. We also utilized the elongated testing period to 
diminish confounding factors that would impact the interpretation of MWM results203 
such as thigmotaxic behavior, jump-offs, and swim-overs previously reported in Ts65Dn 
mice189. Additionally, we employed a platform reversal phase to uncover additional 
cognitive defects189. Studies in a variety of mutant mouse models with drug treatments 
that show small or no difference during hidden platform testing have found significant 
deficits during reversal training204. 
 
Statistical Analyses 
For all histological and immunohistochemical assessments, unpaired Student’s t-tests 
were performed to determine statistical significance between trisomic animals and their 
euploid controls. All data points were included except those deemed as outliers using 
Tukey’s boxplot method. For behavioral studies, parametric t-test or two-way repeated 
measure ANOVA and post-hoc Tukey test were used for normal distributions. Non-
parametric Mann-Whitney and Kruskal-Wallis tests were used if values did not follow a 
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normal distribution. For developmental milestone analyses, non-parametric Mann-
Whitney and Wilcoxon signed-rank tests were used for single and repeated measures, 
respectively, to determine significant differences between groups. Fisher Exact test (FET) 
was used to determine differences between data points. Statistical significance was 
reached with a p-value < 0.05. 
 
Chapter 2.3 – Results 
Below we report gene expression, histogenesis, and behavioral aberrations in Ts1Cje, 
Ts65Dn, and Dp16 mice, generated through a combinatorial study to compare and 
contrast these models at E15.5, P0-P21, and in adulthood. Data show that Ts65Dn exhibit 
consistent deficits at every age, while Ts1Cje and Dp16 lack expected prenatal DS-
related brain phenotypes yet manifest postnatal behavioral phenotypes at different ages. 
Analysis of the number of DEX genes in embryonic and adult brains shows similar 
dysregulation in Ts65Dn and Ts1Cje mice, but not in Dp16 mice. A more detailed 
analysis of gene identity, function, regional expression, and contribution to pathway 
perturbations shows marked differences among the three models.  
 
Embryonic Brain Gene Expression Studies 
Data from previous work188, 191 by our group were reanalyzed to yield subsets of these 
results.  
 
Differentially expressed (DEX) genes at FDR 20%  
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At E15.5, Ts65Dn and Ts1Cje brains had the same number of DEX genes (64) when 
compared to their euploid littermates (Figure 2.1A, Table S2.1). Over 50% of these DEX 
genes mapped to the Mmu16 trisomic region (45 and 36 DEX genes for Ts65Dn and 
Ts1Cje, respectively) (Figure 2.1C, Table S2.1). Some mapped to the trisomic region on 
Mmu17 (10 genes in Ts65Dn) or the monosomic region on Mmu12 (4 genes in Ts1Cje), 
while the remainder mapped to other unaffected chromosomes (9 and 24 DEX genes, 
respectively) (Figure 2.1C, Table S2.1). Despite the fact that the Dp16 model contains the 
largest number of triplicated genes of the 3 models analyzed, Dp16 embryonic forebrain 
showed the lowest number of dysregulated genes (only 30 DEX genes) compared to their 
euploid littermates (Figure 2.1A, Table S2.1). 22 of these 30 genes mapped to the Mmu16 
trisomic region (Figure 2.1C, Table S2.1). In contrast to the other two mouse models, 
only 8 DEX genes mapped to non-affected chromosomes in Dp16 mice (Figure 2.1C, 
Table S2.1). 
 
When the 3 mouse models were compared, Ts65Dn and Ts1Cje shared 32 DEX genes, all 
of which except Rfx5, mapped to the Mmu16 triplicated region (Figure 2.1B). Dp16 
embryonic brains shared 18 DEX genes with Ts65Dn and 12 DEX genes with Ts1Cje, 
which all mapped to the Mmu16 triplicated region (Figure 2.1B). Only 12 DEX genes 
(Sod1, Mis18a, Urb1, Synj1, Son, Donson, Cryzl1, Ttc3, Dyrk1A, Psmg1, Brwd1and 
Zfp295) were found to be common among all 3 models (Figure 2.1B, Table S2.1). 
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Expression of non-orthologous aneuploid genes in the Ts65Dn and Ts1Cje models  
In addition to the Mmu16 triplicated genes, Ts65Dn mice carry a triplication of ~35 
protein-coding Mmu17 genes that are not orthologous to Hsa21 genes183. Our microarray 
studies found that 10 of these genes (i.e., Rps6ka2, Tmem242, Tfb1m, Fgfr1op, Arid1b, 
Gtf2h5, Scaf8, Tulp4, Serac1 and Pde10a) are significantly up-regulated in the Ts65Dn 
embryonic forebrain compared to euploid littermates (Table S2.5).  
 
Ts1Cje mice also contain a monosomy of 7 genes on Mmu12183. Four of these genes 
(Itgb8, Tmem196, Sp4 and Sp8) are significantly downregulated while 1 (Dnahc11) is 
upregulated (Table S2.6). 
 
Genome-wide effects using top 1% affected genes 
Differential gene expression resulting from trisomy largely vacillates between 0.5- and 2.0-
fold difference compared to control samples. This is because in trisomy there is only a 1.5-
fold gene dosage imbalance in affected chromosomes that yields a large proportion of DEX 
genes. Excluding the trans effects of aneuploid genes on euploid genes elsewhere in the 
genome, the commonly accepted 5% FDR cut-off is too stringent to accurately convey 
gene dysregulation in this context. In fact, in our study using a 20% FDR still yielded a 
relatively low number of DEX genes that could not be subjected to many of the common 
bioinformatics platforms. Therefore, as described in the Methods, we considered the top 
1% up- and down-regulated affected genes to investigate the genome-wide effects of the 
trisomy in each mouse model. Ts65Dn and Ts1Cje embryos have 51 affected genes in 
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common (37 upregulated and 14 downregulated). Similarly, Ts65Dn and Dp16 models 
shared 48 affected genes in common (34 up-regulated and 14 down-regulated), and only 
14 affected genes were common to all three models (10 upregulated and 4 downregulated). 
Most upregulated genes mapped to the Mmu16 triplicated region, and few euploid genes 
were affected in all three models including Trgj4, Rfx5, Rpl29, Ucp2 and Xist (full data not 
shown, subset shown in Figure S2.1A). 
 
miRNA expression 
MicroRNAs (miRNAs) are short noncoding RNAs that play a crucial role in gene 
expression through silencing and post-transcriptional regulation205, 206. Several studies have 
analyzed the roles of specific Hsa21-encoded miRNAs in different disease contexts, but 
global miRNA expression in fetal brains with DS has not yet been investigated207-209. 
Additionally, a miRNA expression study in adult Ts65Dn brains showed genome-wide 
miRNA dysregulation and left an open question about miRNA status in embryonic brains 
of these mice along with the Ts1Cje and Dp16 mice210. We, therefore, elected to assess 
global miRNA representation in the top 1% affected genes. Interestingly, a large number 
of miRNAs (37 miRNAs) were found to be affected in the Dp16 embryonic forebrain 
(Table S2.7 and Table S2.8, Figure S2.1B). Thirty-two of these miRNAs were upregulated 
and only 5 were downregulated (Table S2.7 and Table S2.8, Figure S2.1B). By contrast, 
only 7 miRNAs were affected in the Ts65Dn embryonic forebrain, 6 of which were 
downregulated (Table S2.7 and Table S2.8, Figure S2.1B). Ts1Cje embryonic forebrain 
had 9 affected miRNAs, only one of which was in common with Dp16 embryos (Mir137) 
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and none were in common with Ts65Dn embryos (Table S2.7 and Table S2.8, Figure 
S2.1B). 
 
Dysregulated pathways and cellular processes 
We performed a pathway analysis using the top 1% up- and down-regulated genes. 
Summary of the results is presented in Tables S2.5.1. G-protein signaling and olfactory 
receptor activity were significantly downregulated in the Ts1Cje embryonic forebrain, 
unaffected in the Ts65Dn embryonic forebrain, and upregulated in the Dp16 embryonic 
forebrain (Table S2.3, S2.4, and S2.5). Translation of mRNA was downregulated in both 
Ts1Cje and Dp16 embryonic forebrain (Table S2.3, S2.4, and S2.5). In addition to G-
protein signaling and mRNA translation, Ts1Cje embryos displayed a significant 
dysregulation of cell cycle/kinetochore organization, amino acid-mediated 
transmembrane transport and dopamine neuron differentiation. Ts65Dn embryonic 
forebrain showed significant dysregulation of neuronal differentiation (particularly 
dopaminergic neuron differentiation), axonal guidance, cell fate determination, neuronal 
apoptotic process and genes implicated in cerebellar granule cell differentiation (Table 
S2.3, S2.4, and S2.5). Dp16 embryonic forebrain also showed a significant upregulation 
of miRNA-mediated gene silencing (Table S2.3, S2.4, and S2.5). 
 
Neuroanatomy and Neurogenesis 
Where noted, previous data187, 188 from our group were used to generate subsets of these 
results.   
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Body and brain growth measurements in DS model embryos  
Growth abnormalities have been widely reported in babies with DS during gestation and 
at birth (reviewed in Introduction). These abnormalities extend to brain growth which can 
be detected in utero. Only Ts65Dn embryos showed stunted somatic growth 
(97.24%±0.72 compared to euploid littermates; p<0.01) while Dp16 embryos showed a 
trend towards an increase in body size (110.17%± 5.07 of euploid; n.s.), and Ts1Cje 
embryos showed no change (Figure 2.2A-B). Ts65Dn embryos were also the sole 
trisomic model that exhibited a decrease in rostrocaudal brain length (97.39%±1.38 of 
euploid; p<0.05) but showed no difference in mediolateral brain length (Figure 2.2C-D). 
Neither Ts1Cje nor Dp16 embryos had any measurable gross brain defects at E15.5 
(Figure 2.2D). 
 
Ts65Dn males are infertile; therefore, Ts65Dn breeding relies on trisomic females to pass 
the trisomy onto offspring. Unlike Ts65Dn males, Ts1Cje and Dp16 males are fertile and 
typically used in breeding. Because only the Ts65Dn colony relies on trisomic females to 
pass the trisomy onto offspring, it became important to test whether the maternal uterine 
environment could be contributing to observed embryonic growth deficits in Ts65Dn 
mice compared to Ts1Cje and Dp16. Additionally, the hybrid background on which 
Ts65Dn mice are bred differs from the C57BL6 inbred background of Ts1Cje and Dp16. 
Thus, we generated distinct breeding paradigms to explore the impact of the maternal 
uterine environment and background strain on embryonic brain phenotypes. In order to 
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mirror the breeding scheme used for production of the Ts65Dn mice we bred both Ts1Cje 
and Dp16 C57BL6 females with C3HSn males to generate F1 Hybrid B6C3H progeny. 
B6C3H euploid females were then bred with B6C3H Ts1Cje males in order mimic the 
Ts65Dn background. On the other hand, B6C3H Dp16 females were bred with B6C3H 
euploid males in order to mimic both the background and maternal trisomy inTs65Dn. 
We then analyzed growth in embryos from each breeding at E15.5. In these hybrid 
breeding experiments, no changes in crown-rump, or mediolateral and rostrocaudal brain 
lengths were observed in the Ts1Cje and Dp16 mice compared to their euploid littermates 
(Figure S2.2A-B). These results indicate that neither maternal trisomy nor background 
strain influence the prenatal phenotypes in the Ts65Dn model.  
 
Expansion of the dorsal pallium during embryonic neurogenesis  
Measurements of the thickness of the neocortical layers demonstrated that Ts1Cje had no 
significant change in VZ/SVZ, SP/CP, or total pallial thickness compared to euploid 
littermates (Figure 2.2E-F). However, there was a significant increase in the thickness of 
the IZ (121.53%±5.34 of euploid; p<0.05) (Figure 2.2F, orange bars). Ts65Dn embryos 
showed no change in VZ/SVZ thickness but showed a significant decrease in IZ 
thickness (87.00%±1.46 of euploid; n= 9 euploid, 9 Ts65Dn; p<0.05) and overall pallial 
thickness (92.71%±1.69 of euploid; p<0.05) along with a trend towards a decrease in 
SP/CP thickness (88.31%±1.92 of euploid; p=0.10) (Figure 2.2F, green bars). Dp16 mice 
showed no significant changes in any layer of the dorsal germinal zone or in the overall 
dorsal pallium (Figure 2.2F, blue bars). 
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Quantification of neurogenesis and neurogenic output in the dorsal and ventral 
telencephalic germinal zones  
Neurogenesis was previously assessed in Ts65Dn at E14.5 using BrdU pulse labeling and 
was shown to be decreased in the dorsal telencephalon but increased in the ventral 
telencephalon186, 187. However, these neurogenesis abnormalities were not observed in 
Dp16 mice188. Here, we assessed all three models side by side at E15.5 using an in vivo 
EdU pulse neurogenesis assay and quantification of progenitor numbers to determine 
whether neurogenesis in either germinal zone is different in trisomic mice compared to 
their respective euploid littermates (Figure 2.2G).  
 
Our data confirm that there is a significant reduction in neocortical neurogenesis in 
Ts65Dn forebrains. Specifically, we found a decrease in the percent of EdU labeled cells 
in the VZ/SVZ of the dorsal telencephalon (88.48%± 0.44 of euploid; p<0.01). No 
change in neurogenesis was observed in Ts1Cje or Dp16 forebrains (Figure 2H-J).  
 
Additionally, we measured mitosis and progenitor cell number and distribution within the 
medial ganglionic eminence (MGE) of the ventral germinal zone, the birth place of OLs 
and tangentially migrating cortical INs (Figure 2.2K and Figure 2.2M). In Ts65Dn MGE, 
phosphorylated Histone 3 (pH3) staining showed an increase in mitotically active 
progenitors (137.28%±8.76 of euploid; p<0.05; Figure 2.2N green bar; previously 
reported in Chakrabarti et al., 2010187). These mitotically active cells were found in 
  
43 
higher numbers within the SVZ of the MGE, suggesting that there is a larger and actively 
dividing progenitor pool contributing to the observed increase in postnatal postmitotic IN 
populations (Figure 2.2P; Figure 2.4D and Figure 2.4G). To characterize the types of 
progenitors within this pool we used OLIG2 to specifically mark OL and IN progenitors 
119, 211, 212. The number of OLIG2+ cells was indeed shown to be increased in Ts65Dn 
animals (Fig. 2L, green bar). In contrast, no significant changes in pH3 labelling or 
OLIG2 labelling were found in Ts1Cje MGE (except a decrease in pH3 staining in one 
abventricular bin at 160μm; Figures 2.2L, 2.2N, and 2.2O; orange bars) or Dp16 MGE 
(Figures 2.2L, 2.2N and 2.2Q; blue bars; data previously shown in Goodliffe et al., 
2016188). 
 
Neonatal Behavior 
Newborns with DS exhibit abnormal reflexes and delays in achieving developmental 
milestones213. Using the experimental paradigm established in Olmos-Serrano et al., 
2016189, we investigated early postnatal development and growth in Ts1Cje, Ts65Dn, and 
Dp16 mice along with their euploid littermates from birth until P21 (Figure 2.3, Figure 
S2.3-Figure S2.6.). Despite the mild abnormalities in embryonic corticogenesis in Ts1Cje 
and lack thereof in Dp16 mice, analysis of perinatal behavior was conducted to pinpoint 
the onset of behavioral defects and inform whether more pronounced CNS abnormalities 
occur close to birth or in adulthood in these mice. Body weight and length, as well as 
motor strength, coordination, and acquisition of neurological reflexes were all analyzed 
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in a single combined cohort of males and females. Subsequently, male and female 
performance was independently analyzed.  
 
Previously generated data188, 189, 191 from our group were reanalyzed to yield subsets of 
these results.  
 
Ts1Cje: both sexes combined 
Combined analysis of both sexes showed that weight and body lengths were significantly 
decreased in Ts1Cje pups compared to euploid littermates (p<0.05, Figure S2.3A and 
S2.3B). When the percent of mice meeting criteria for each task was analyzed daily, data 
showed that Ts1Cje performed worse on surface righting, negative geotaxis, cliff 
aversion, ear twitch response, air righting, and auditory startle (p<0.05, Figure S2.3C, D, 
E, H, J, and K). Also, fewer Ts1Cje pups opened their eyes on postnatal days (PNDs) 14-
16 compared to euploids (p<0.05, Figure S2.3I). Ts1Cje pups performed similarly to 
euploid pups on the forelimb grasp and open field tasks (Figure S2.3F and S2.3G). 
Overall, Ts1Cje mice performed significantly worse on both early- and late- acquisition 
tasks (Figure S2.3). 
 
Ts1Cje: males vs. females 
When assessed separately, both Ts1Cje males and females performed similarly and 
experienced delays mostly in achieving late-acquisition tasks (Figure 2.3 and Figure 
S2.6).  Ts1Cje males had significantly delayed acquisition of surface righting (p<0.05), 
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cliff aversion (p<0.05), air righting (p<0.0001), and auditory startle (p<0.01) responses 
compared to euploid males (Figure 2.3). Females had significantly delayed acquisition of 
negative geotaxis (p<0.01), cliff aversion (p<0.01), air righting (p<0.01), auditory startle 
(p<0.05), and ear twitch (p<0.05) responses compared to euploid females (Figure S2.6).  
 
Ts65Dn: both sexes combined 
Weight was significantly decreased in Ts65Dn pups compared to euploid littermates 
(p<0.05, Figure S2.4A). When the percent of mice meeting criteria for each task was 
analyzed daily, data showed that Ts65Dn pups performed worse on surface righting, 
negative geotaxis, cliff aversion, open field, and air righting tasks compared to euploid 
littermates (p<0.05, Figure S2.4B, C, D, F, and I). Ts65Dn performed similarly to euploid 
pups on the forelimb grasp, ear twitch, eye opening, and auditory startle responses 
(Figure S2.4E, G, H, and J). Similar to Ts1Cje mice, Ts65Dn mice performed 
significantly worse on both early- and late- acquisition tasks (Figure S2.4). 
 
Ts65Dn: males vs. females 
Ts65Dn males performed considerably worse than Ts65Dn females (Figure 2.3 and 
Figure S2.6).  While Ts65Dn females showed a significantly delayed acquisition of the 
cliff aversion response only (p=0.05, Figure S2.6), Ts65Dn males showed a significant 
delay in achieving surface righting (p<0.01), negative geotaxis (p<0.001), cliff aversion 
(p<0.001), air righting (p<0.01), and auditory startle responses (p<0.05, Figure 2.3). 
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Thus, Ts65Dn males showed significant impairment in achieving both early- and late-
acquisition tasks, but Ts65Dn females were minimally affected.  
 
Dp16: both sexes combined 
Analysis of both sexes showed that weight and body length were significantly decreased 
in Dp16 pups compared to euploid littermates (p<0.05, Figure S2.5A and S2.5B). When 
the percent of mice meeting criteria for each task was analyzed daily, data showed that 
Dp16 performed worse on ear twitch, air righting, and auditory startle responses (Figure 
S2.5H, J, and K). Also, fewer Dp16 pups opened their eyes on PNDs 15-16 compared to 
euploid littermates (p<0.05, Figure S2.5I). Dp16 performed similarly to euploid pups on 
the surface righting, negative geotaxis, forelimb grasp, and open field tasks (Figure 
S2.5C, D, F, G). Surprisingly, a significantly higher percent of Dp16 mice achieved 
criteria in the cliff aversion task compared to euploid littermates (p<0.05, Figure S2.5E). 
Overall, Dp16 mice performed significantly worse only on late-acquisition tasks (Figure 
S2.5). 
 
Dp16: males vs. females 
Both Dp16 males and females performed similarly and experienced delays mostly in 
achieving late-acquisition tasks (Figure 2.3 and Figure S2.6).  Dp16 males had 
significantly delayed acquisition of air righting (p<0.01), auditory startle (p<0.001), and 
ear twitch (p<0.05) responses compared to euploid males (Figure 2.3). However, Dp16 
males achieved criteria earlier for the cliff aversion task (p<0.05, Figure 2.3). Females 
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had significantly delayed acquisition of negative geotaxis (p<0.001), air righting 
(p<0.01), auditory startle (p<0.05), and ear twitch (p<0.001) responses compared to 
euploid females (Figure S2.6). Dp16 females also had a delayed eye opening compared to 
euploids (p<0.01, Figure S2.6). On tasks in which both males and females were affected, 
both sexes performed similarly.  
 
Excitatory and Inhibitory Neuronal Density    
Where noted, previous data187, 188 from our group were used to generate subsets of these 
results. 
 
Postnatal defects in interneuron populations 
To assess the possible underlying etiology of developmental milestone abnormalities in 
Ts1Cje, Ts65Dn, and Dp16 neonates, we examined the cortical and hippocampal cell 
populations that our neurogenesis studies suggested may be perturbed (Figure 2.4). First, 
all nuclei were counted throughout a consistent region of interest within the 
somatosensory cortex at P15. Cell numbers overall and within each layer did not differ in 
Ts1Cje P15 somatosensory cortex (Figure 2.4B). We then used Somatostatin (SS), 
Parvalbumin (PV), and Calretinin (CR) as markers of INs within the somatosensory 
cortex and found no differences in Ts1Cje neocortex both when overall IN numbers were 
counted (Figure 2.4C) and when IN laminar position within a specific layer was 
determined and cell density by layer was calculated (data not shown). In contrast, both 
PV+ and SS+ INs were significantly increased in Ts65Dn in individual neocortical layers 
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as well as overall (Figure 2.4D; p<0.05; layer data in Chakrabarti et al., 2010187). 
However, the overall number of CR+ cells was unchanged in Ts65Dn (Figure 2.4D). In 
Dp16 animals, PV+ and SS+ cell numbers were decreased (p<0.05) but CR+ cell 
numbers trended towards an increase (Figure 2.4E; p=0.07; data shown in Goodliffe et 
al., 2016188). In the hippocampus, which is also populated by interneurons born in the 
MGE, only the Ts65Dn showed an increase in PV+ and SS+ cell numbers (Figure 2.4G; 
p<0.05; data shown in Chakrabarti et al., 2010187); no change was observed in Ts1Cje or 
Dp16 (Figure 2.4G; Dp16 data previously shown in Goodliffe et al., 2016188). 
 
Postnatal defects in excitatory neuron populations 
Tbr1+ excitatory neurons were significantly decreased in Ts65Dn (Figure 2.4I orange 
bar; p<0.05; data from Chakrabarti et al., 2010187) and trended towards a decrease in 
Dp16 (Figure 2.4I blue bar; p=0.07; data from Goodliffe et al., 2016188). In contrast, the 
overall number of excitatory neurons in Ts1Cje was unchanged (Figure 2.4I, orange bar). 
Upon closer examination, we determined that a misallocation of excitatory cells between 
layers IV and VI existed, leading to an increase in cell number within layer VI but a 
decrease in cell number in layer IV (Figure 2.4J, p<0.05). 
 
Adult Behavior 
Learning, memory, and motor deficits are fully penetrant in people with DS and 
constitute major aspects of the associated ID. Since these phenotypes are present 
throughout the lifespan of individuals with DS, in addition to the developmental 
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milestone assessments, we sought to test similar facets of behavior in adult Ts1Cje, 
Ts65Dn, and Dp16 mice. To do so we utilized a battery of tests including SHIRPA, open 
field, Morris water-maze, contextual fear conditioning, and rotarod. This battery of 
behavioral tasks allowed us to specifically assess hippocampal-dependent spatial and 
contextual memory, locomotion, motor reflexes, and motor coordination. 
 
Previous data188, 189 generated by our group were reanalyzed to yield subsets of these 
results.  
 
Reflexive Behavior: SHIRPA test 
Examination of over 40 different basic reflexes using the SHIRPA primary screen 
protocol did not reveal widespread deficits in Ts1Cje, Ts65Dn, or Dp16 animals 
compared to littermate euploid controls. The following minor defects were observed on 
individual tasks: a) Ts1Cje mice moved more frequently (average score=2.23±0.14, 
p=0.06) towards the probe in the probe contact test compared to euploid mice (average 
score=1.81±0.14, Mann-Whitney); b) Ts65Dn mice had a slight pelvic elevation (average 
score=2.50±0.13, p=0.09) compared to euploid mice (average score=2.17±0.17, Mann-
Whitney); and c) Dp16 mice showed significant reductions in the touch escape response 
(average score=1.53±0.13, p<0.003) compared to euploid mice (average 
score=2.13±0.09, Mann-Whitney). The results are summarized in Table S2.14. 
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Exploratory Behavior and Spontaneous Locomotor Activity: Open field test 
When exploratory behavior was analyzed over the 60min open field trial period, total 
distance traveled by Ts1Cje (p<0.01) and Ts65Dn (p<0.05) was significantly higher than 
their euploid littermates (Mann-Whitney test) (Figure S2.7J and S2.7K). Similarly, the 
total distance traveled in the periphery, but not in the center, was also significantly higher 
in these two mouse models (p<0.05 and p<0.001, Mann-Whitney test) (Figure 2.5A and 
2.5B). The total distance as well as the distance travelled in the center versus periphery 
was unchanged in the Dp16 compared to euploids (Figure 2.5C and Figure S2.7L). 
 
Further analysis using 20min time bins showed that both Ts65Dn and Ts1Cje were 
hyperactive during the 3 time bins examined, with trisomic mice from both strains 
traveling significantly more distance in the periphery compared to euploid controls 
(p<0.05, Kruskal-Wallis test) (data not shown). Dp16 mice showed no change compared 
to euploids. Raw data are presented in Table S2.15. 
 
Motor Coordination: Rotarod  
In the static speed (16, 24, and 32 RPM) test (Day 1), Ts1Cje mice fell with a shorter 
latency than euploid littermates only at the highest rotational speed of 32 RPM (p<0.05, 
Mann-Whitney test) (Figure 2.5D). Unexpectedly, Ts65Dn mice showed no differences 
in latency to fall compared to F1 Hybrid euploids at 16 RPM, 24 and 32 RPM (Figure 
2.5E). Dp16 mice fell with a significantly shorter latency than their euploid littermates at 
all speeds tested (Figure 2.5F; p<0.001). In the accelerating speed test (Day 2), both 
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Dp16 and Ts1Cje mice fell with a shorter latency compared to their respective euploid 
littermates, with the Dp16 mice showing the most severe deficits (p<0.001, Mann-
Whitney test; Figure 2.5G and 2.5I). Similar to our findings in the static speed test, 
Ts65Dn mice showed no change compared to their euploid littermates in the accelerating 
speed test (Figure 2.5H). Raw data are presented in Table S2.15. 
 
Hippocampal-Dependent Contextual Memory: Contextual fear conditioning test 
During the 5min training session (Day 1), Ts1Cje mice showed lower freezing 
(21.76±3.17%) at 300s compared to euploids (37.95±5.13%; p< 0.01) while Ts65Dn 
mice displayed higher freezing (28.15±5.47%) compared to euploids (7.48±1.78%; 
p<0.05) at 240s. Dp16 mice showed higher freezing (8.91±3.10%) than their euploid 
littermates (1.63±0.65 %; p<0.05; Mann-Whitney test) before receiving the first shock (at 
180 s) (Figure 2.6D-2.6F). However, the percent of freezing was similar between 
genotypes after the first (at 180s) and second shocks (at 240s) (Figure 2.6D-2.6F). 
 
On testing day (Day 2), Dp16 mice froze significantly less (19.24±4.24%) compared to 
euploids (40.70±4.42 %; p<0.01) between 0s and 60s (Figure 2.6I). Between 60s and 
120s, Dp16 mice also froze less (33.83±6.16 %) compared to euploids (52.54±6.29%) 
(Figure 2.6I; p<0.05). Ts1Cje mice showed a significantly lower freezing percent only 
during the first minute of testing (24.80±4.75%) compared to euploids (38.50±4.50%) 
(Figure 2.6G; p<0.05; Mann-Whitney test). However, Ts65Dn mice showed reduced 
freezing starting after 180 s and reached statistical significance only in the last minute of 
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testing (18.27±5.31 %, p=0.016, Mann-Whitney test) versus euploid littermates 
(40.70±7.21%) (Figure 2.6H). Raw data are presented in Table S2.15. 
 
Hippocampal-Dependent Spatial Memory: Morris water-maze test 
Detailed Morris water-maze (MWM) studies by our group in Ts65Dn189 and Dp16188 
were previously published. Subsets of these data are presented below for comparison 
with Ts1Cje. 
 
Ts1Cje 
We first employed a cued learning protocol to ensure that mice had the ability to learn to 
swim to a visual goal. Both groups significantly decreased their latency to find the visible 
platform over 4 days (p<0.001, data not shown). We did not find significant differences 
between groups (p=0.226, data not shown), indicating that both groups were able to learn 
the basic skill of swimming towards a visible goal and climbing onto the platform before 
being rescued. Analysis of time spent in the periphery during visible platform training 
revealed no significant difference between groups (data not shown). We conclude that 
cued learning ability is similar between genotypes, ruling out procedural deficits.  
 
The day after the visual test ended, both genotypes were tested for their ability to learn 
the location of a hidden platform. Overall, as expected, both genotypes improved their 
performance over successive trial days as measured by decreased latencies (p < 0.001; 
euploid = 13, Ts1Cje = 11; Figure 2.6A) and swimming distance (data not shown). We 
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did not find significant differences between genotypes in the latency (p =0.697; euploid = 
13, Ts1Cje = 11; Figure 2.6A), swimming distance, and speed (data not shown). We also 
did not find significant differences in thigmotaxis, i.e., time spent in the periphery of the 
tank (data not shown). When reversal learning was tested, both genotypes also improved 
their performance over successive trial days as measured by decreased latencies (p < 
0.001; euploid = 13, Ts1Cje = 11; Figure 2.6A) and swimming distance (data not shown). 
Surprisingly, we did not find significant differences between genotypes in the latency 
(p=0.115; euploid = 13, Ts1Cje = 11; Figure 2.6A), swimming distance, and speed (data 
not shown).  
 
We also tested the reference memory the day after the acquisition and reversal period by 
removing the platform and allowing mice to swim freely for 60s. Both probe trials 
revealed a selective quadrant search indicating proper memory consolidation of the 
platform location and no differences between genotypes were found (p =0.991 for probe 
trial and p=0.773 for probe trial after reversal; euploid = 13, Ts1Cje = 11; Figure S2.7B 
and S2.7C). We also tested the reference memory 3 days after the last day of the reversal 
learning period and did not observe any significant differences between genotypes either. 
We did not find significant differences between genotypes in proximity and number of 
virtual platform crossings during the probe trial (data not shown). Overall, these results 
show that Ts1Cje do not exhibit learning and memory deficits using this behavioral 
paradigm. 
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Ts65Dn 
Ts65Dn mice were tested using the same paradigm as Ts1Cje mice. In the cued learning 
protocol, both groups significantly decreased their latency to find the visible platform 
over 4 days (p < 0.001; eup = 14, Ts65Dn = 15; data not shown). We did not find 
significant differences between groups (p = 0.287), indicating that both groups were able 
to learn the basic skill of swimming towards a visible goal and climbing onto the 
platform before being rescued. Euploid mice showed longer swim paths (p = 0.016; data 
not shown), and higher swimming speeds (p = 0.010; data not shown). Ts65Dn mice 
exhibited similar performance in the last two days compared to euploid subjects. Analysis 
of time spent in the periphery during visible platform training revealed no significant 
difference between groups (p = 0.311; data not shown). Again, we conclude that cued 
learning ability is similar between genotypes, ruling out procedural deficits.  
 
The day after the visual test ended, both genotypes were tested for their ability to learn 
the location of a hidden platform. Overall, as expected, both genotypes improved their 
performance over successive trial days, as measured by decreased latencies and 
swimming distance (p < 0.001; euploid = 14, Ts65Dn = 14; Figure 2.6B). We found 
significant differences between genotypes suggesting deficits in learning in Ts65Dn 
mice189. However, previous analysis showed that these differences were due to 
thigmotaxis and that Ts65Dn mice need 3 to 4 days to acclimate to the task before their 
underlying learning and memory capabilities can be fully measured189. Importantly, 
Ts65Dn mice exhibit normal spatial learning and memory following this thigmotaxis 
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period (Figure 2.6B). During the reversal testing phase, we uncovered significant 
differences between groups in the latency (p = 0.011; euploid = 14, Ts65Dn = 14; Figure 
2.6B) and swimming distance (data not shown). This showed a lack of flexibility in 
learning in Ts65Dn mice. 
 
During the probe trial, both euploid and Ts65Dn mice displayed selective quadrant search 
demonstrating that both groups formed a cognitive map to find the platform (p < 0.05; 
Figure S2.7E and S2.7F). However, Ts65Dn spent significantly less time in the target 
quadrant compared to euploid mice after hidden and hidden reversal periods (p < 0.05; 
Figure S2.7E and S2.7F). This pointed to a long-term memory deficit in Ts65Dn. More 
detailed analyses of virtual platform crossings and proximity to the virtual platform 
uncovered distinct behavior in Ts65Dn mice compared to euploids189. Overall, these data 
indicate that Ts65Dn have a spatial long-term memory impairment that is most 
accentuated during reversal periods. 
 
Dp16 
Similar to Ts1Cje and Ts65Dn, Dp16 animals were first tested in a cued learning protocol 
to assess their ability to swim to a visible goal. Both genotypes learned to swim toward a 
submerged platform identified by a flag, significantly decreasing their latency over 4 
days (p < 0.001, data not shown). Two-way repeated-measures ANOVA revealed no 
significant difference between genotypes in the latency to find the cued platform (p = 
0.564), distance traveled (p = 0.220), or thigmotaxis (p = 0.755, data not shown). Dp16 
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animals swam more slowly than euploids to the visible platform (p = 0.003, data not 
shown), but this did not affect their performance.  
 
During the hidden platform testing phase, both genotype groups learned the hidden 
platform location decreasing their latency and swimming distance (p < 0.001; euploid n = 
13, Dp16 n = 11; Figure 2.6C; distance: p < 0.001, data not shown). However, there was 
a significant difference between genotypes in these two measures (latency: p = 0.006; 
distance: p = 0.044; euploid n = 13, Dp16 n = 11; Figure 2.6C). Post hoc Tukey test 
comparisons indicated that Dp16 mice performed particularly worse on Days 1 and 5 in 
both latency and distance (p < 0.05; euploid n = 13, Dp16 n = 11; Figure 2.6C). There 
was no overall difference between genotypes in swimming speed (data not shown) and 
neither genotype exhibited thigmotaxic behavior (data not shown). Interestingly, the 
reversal phase revealed strong deficits in Dp16 in latency and distance swam 
(latency:  p < 0.001; euploid n = 13, Dp16 n = 11; Figure 2.6C; distance: p < 0.001, data 
not shown). Importantly, no difference was seen in swimming speed between groups (p = 
0.144, data not shown).  
 
Both probe trials revealed a selective quadrant search, indicating proper memory 
consolidation of the platform location (p < 0.001, euploid n = 13, Dp16 n = 11; Figure 
S2.7H and S2.7I). In particular, both euploid and Dp16 animals spent more time in the 
proper quadrants in the acquisition and reversal periods, respectively; p < 0.05; Figure 
S2.7H and S2.7I). However, Dp16 mice spent significantly less time in the proper 
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quadrant during the reversal probe trial indicating memory deficits in Dp16. We also 
found significant differences between genotypes in proximity and the number of virtual 
platform crossings for both the initial 30 s and the entire 60 s during the probe trial in the 
reversal period (p < 0.01; data not shown). Overall, these results demonstrate that, similar 
to Ts65Dn mice, Dp16 animals exhibit learning and memory deficits specific to memory 
extinction and relearning. 
 
Adult Brain Gene Expression Studies 
Differentially expressed (DEX) genes at FDR 20% 
Ts1Cje cortex, hippocampus, cerebellum had 19, 83, and 83 DEX, respectively (Figure 
2.7A, Table S2.9-S2.11). Ts65Dn cortex, hippocampus, and cerebellum had 77, 32, and 
76 DEX genes, respectively (Figure 2.7B, Table S2.9-S2.11). Similar to the embryonic 
forebrain, Ts65Dn and Ts1Cje mice adult brains had a higher number of DEX genes 
compared to the Dp16 mice adult brain, which exhibited only 8 DEX genes in cortex, 39 
in hippocampus, and 4 in cerebellum (Figure 2.7C, Table S2.9-S2.11).  A list of all DEX 
genes by region is presented in Tables S2.9-S2.11.  Number of common genes among the 
models is shown by brain region Figures 2.7A’-2.7C’. Chromosomal distribution of all 
the DEX genes is presented by region in Figure 2.8.   
 
miRNA expression 
Ts1Cje cortex, hippocampus, and cerebellum had 16, 7, and 5 affected miRNAs, 
respectively (Table S2.13). Ts65Dn mice displayed the highest average number of 
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affected miRNAs in cortex (18 out of 19 total were downregulated) and cerebellum (14 
out of 17 total were downregulated) (Table S2.13). Ts65Dn hippocampus had only 7 
downregulated miRNAs (Table S2.13). Unexpectedly, Dp16 mice adult brain did not 
show as many affected miRNAs compared to Dp16 embryonic forebrain with 11 in 
cortex, 7 in hippocampus, and 9 in cerebellum (Table S2.13). 
 
Genome-wide effects using the top 1% affected genes 
Analysis of similarities among the top 1% up- and down-regulated genes revealed that 
Ts1Cje, Ts65Dn and Dp16 mice share limited number of common genes in the three 
brain regions examined (23, 29, and 26 genes in the cerebral cortex, hippocampus and 
cerebellum, respectively). Interestingly, Ts1Cje and Dp16 showed more common 
affected genes in the hippocampus and cerebellum (92 and 91 genes, respectively) 
compared to the Dp16 and Ts65Dn (47 and 54 genes, respectively), and Ts65Dn and 
Ts1Cje (48 and 47 genes, respectively) (data not shown). In cortical tissue, Ts1Cje had 
68 affected genes in common with Ts65Dn, and 65 in common with Dp16. Dp16 and 
Ts65Dn cortices had only 40 affected genes in common (full data not shown, subset 
shown in Figure S2.1A). 
 
Dysregulated pathways and cellular processes  
Summarized data from our pathway analysis using the top 1% affected genes in adult 
tissue are presented in Table S2.12. Briefly, data show that embryonic forebrain changes 
are more pronounced than adult brain changes in all 3 models. Dysregulated pathways in 
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adult mice included G-protein signaling (particularly olfactory receptor activity), immune 
response, JAK-STAT signaling, interferon signaling, and mitochondria/oxidoreductase 
activity. Notably, miRNA-mediated gene silencing was not significantly perturbed in 
adult Dp16 brains.  
 
Multimodal Assessment of Ts1Cje, Ts65Dn, and Dp16: Summary across the Models    
Gross assessment of embryo and brain growth in Ts1Cje, Ts65Dn, and Dp16 mice 
showed that only Ts65Dn mice had reduced body length and brain size at E15.5. 
Neocortical expansion was also reduced in Ts65Dn at E15.5, but was largely unaffected 
in Dp16 and Ts1Cje (Figure 2.2, Table 2.1). Additionally, neurogenesis was decreased in 
the VZ/SVZ of the dorsal pallium of Ts65Dn but was unchanged in Ts1Cje and Dp16 
mice (Figure 2.2, Table 2.1). Ts65Dn also exhibited an increase in mitotic events as well 
as progenitor cell numbers within the medial ganglionic eminence (Figure 2.2, Table 2.1). 
None of these changes were observed in Ts1Cje or Dp16 brains (Figure 2.2, Table 2.1). 
However, Ts1Cje showed an increase in the thickness of the IZ of the dorsal germinal 
zone and a decrease in the number of mitotic cells within a 20μm bin approximately 
160μm away from the ventricle (Figure 2.2, Table 2.1). Previous studies show that 
changes in neural precursors during embryogenesis correlate with changes in the size of 
postmitotic neural cell groups in the postnatal forebrain of trisomic animals. For example, 
postmitotic IN populations were previously shown to be perturbed in both Ts65Dn and 
Dp16 neocortex187, 188, and recent work has also shown a pronounced OL defect in 
Ts65Dn158.  Indeed, postnatal analyses of neuronal populations in the somatosensory 
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cortex and hippocampus at P15 showed that there is an increase in specific cortical and 
hippocampal interneuron subtypes in Ts65Dn along with a decrease in cortical excitatory 
neurons (Figure 2.4, Table 2.1). In Ts1Cje mice, overall cell numbers, inhibitory INs 
populations, and excitatory neurons were unchanged (Figure 2.4, Table 2.1); however, a 
shift in laminar distribution in neocortical excitatory neuronal populations was observed. 
Specific subtypes of cortical INs as well as excitatory neurons were decreased in the 
Dp16 somatosensory cortex, but hippocampal INs were unchanged (Figure 2.4, Table 
2.1). 
 
In the cohorts tested, Ts65Dn and Ts1Cje pups exhibited deficits in achieving early and 
late developmental milestones (Figure 2.3, Figure S2.3-Figure S2.6, Table 2.1). Dp16 
mice, on the other hand, only exhibited deficits in achieving late developmental 
milestones (Figure 2.3, Figure S2.3-Figure S2.6, Table 2.1). Sex differences were 
observed in the Ts65Dn mice, with males showing delays in a greater number of tasks 
(Figure 2.3, Figure S2.3-Figure S2.6, Table 2.1). This sex difference was not observed in 
the Ts1Cje and Dp16 populations (Figure 2.3, Figure S2.3-Figure S2.6, Table 2.1).  
 
Adult mice exhibited complex behavioral profiles that showed varying degrees of 
dysfunction in learning/memory and motor coordination. On hippocampal-based tasks, 
all 3 models showed CFC abnormalities but only Ts65Dn and Dp16 showed MWM 
abnormalities (Figure 2.5, Figure 2.7, Figure S2.6, Figure S2.7, Table 2.1). This is despite 
the fact that Ts65Dn exhibited the least number of DEX genes in the hippocampus 
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compared to Ts1Cje and Dp16 (Table 2.1). In motor-based tasks, Ts1Cje showed both 
rotarod and open field deficits, Ts65Dn showed only open field deficits, and Dp16 
showed open field and rotarod deficits (Figure 2.5, Figure 2.7, Figure S2.6, Figure S2.7, 
Table 2.1). Again, this is despite the fact that Dp16 cerebellum showed the lowest 
number of DEX genes compared to Ts1Cje and Ts65Dn cerebellum (Table 2.1). 
Reflexive behavior as assessed by SHIRPA was largely unaffected in all 3 models (Table 
S2.14, Table 2.1).  
 
Chapter 2.4 – Discussion 
Our novel intraspecies comparison pinpoints significant differences in brain 
development, gene expression, and behavior throughout prenatal and postnatal life in the 
Ts1Cje, Ts65Dn, and Dp16 mouse models of DS (Figure 2.9). For the first time, through 
a combinatorial side-by-side analysis, we show that major dissimilarities exist among the 
models during prenatal development, perinatal development, and adulthood. The breadth 
of differences is unexpected since it has been widely accepted that Mmu16 segmental 
trisomy is a valid model for triplication of Hsa21 (Figure 2.9). The numerous contrasts 
among these models that have been identified by this study prevented the identification of 
common mechanisms underlying observed DS phenotypes. These data reframe 
interpretation of previous findings and have important implications for future use of these 
models in understanding the neurobiology of DS and in drug discovery. 
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Ts1Cje and Dp16 mice lack DS-specific prenatal brain development phenotypes 
Our previous demonstration of a lack of forebrain morphogenesis defects in Dp16 was 
extremely surprising188. We expected to observe an exaggerated or at least similar 
phenotype during embryonic development compared to Ts65Dn based on the increased 
number of triplicated syntenic genes in Dp16. In this study, we independently confirmed 
previous Dp16 results and showed that E14.5 is not a unique time point. We also 
employed a relatively new cell cycle marker, EdU, which has increased sensitivity 
compared to BrdU214. As expected186, 188, we found developmental abnormalities in the 
Ts65Dn embryos but again found no prenatal brain development phenotype in Dp16 
embryos at E15.5. We also found no DS-related brain development phenotypes in Ts1Cje 
embryos using the experimental paradigm described herein.  
 
These Ts1Cje findings were unexpected and are in stark contrast to previous reports 
which showed that Ts1Cje embryos had smaller brains and decreased corticogenesis at 
E14.5215. These studies also showed an increase in proliferation in the MGE at E14.5 
followed by enlarged ventricles and decreased hippocampal proliferation postnatally215, 
216. In contrast, our data indicate a slight increase in neurogenesis at E15.5, no change in 
number of total cells or in excitatory and inhibitory neuronal populations perinatally, and 
normal cortical/hippocampal histogenesis overall. Additionally, our transcriptome data 
indicate that markers of cerebral cortex development and cell proliferation are 
upregulated in E15.5 Ts1Cje forebrains. While it is difficult to definitively pinpoint why 
our groups observed such different phenotypes, perhaps the difference in the analysis 
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time point or the updated methodology contribute to the differences in findings between 
the two studies.  
 
Thus, cumulative data from our group indicate that Ts65Dn, but not Ts1Cje and Dp16, 
exhibit decreases in somatic growth and corticogenesis. Importantly, we found no impact 
of uterine environment and/or background strain on prenatal phenotypes in Ts1Cje and 
Dp16 embryos. 
 
Gene expression alterations during embryonic brain development  
Overall, our data show that the number of DEX genes was higher in Ts65Dn and Ts1Cje 
brains compared to Dp16 brains. These gene expression changes may be partly 
responsible for the developmental phenotypes observed in these mice. The upregulation 
of miRNAs in the Dp16 embryonic brain might provide an explanation for the lack of 
prenatal phenotypes in this model, and warrants further studies. Furthermore, our gene 
expression data illustrate that differential regulation of several non-orthologous genes that 
are aneuploid in Ts65Dn (10 Mmu17 genes) and Ts1Cje (5 Mmu12 genes) is occurring, 
indicating that these genes might contribute partly to the prenatal phenotype observed in 
these two models. Adult gene expression data followed a similar trend. Both embryonic 
and adult microarray results further illustrate that the number of DEX genes alone is not 
predictive of phenotype and that more significant information can be obtained from the 
assessment of the identity of dysregulated genes and their downstream targets.  
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On the pathway level, we found more contrasts than similarities among these three mouse 
models. Ts65Dn embryonic forebrains displayed significant dysregulation of genes 
associated with neurogenesis, synaptogenesis and neuronal differentiation, whereas 
Ts1Cje embryonic forebrains showed significant dysregulation of cell cycle 
checkpoint/kinetochore formation, amino-acid transport, and G-protein signaling 
associated genes. G-protein signaling and miRNA associated gene-silencing were 
significantly upregulated in Dp16 embryonic forebrains. Interestingly, adult pathway 
perturbations were milder than in embryos. In adult animals, similar pathways were 
altered among the three models but the gene members and their magnitude of change 
differed. 
 
Lack of discernable gene expression-phenotype relationships in our data point to possible 
additional contributions from epigenetic and other regulatory elements, including 
miRNAs and long non-coding RNAs, to observed defects. These non-protein coding gene 
products should be the focus of more in depth studies. Lastly, the data suggest that 
protein expression abnormalities and post-translational modifications also likely impact 
cognitive phenotypes. 
 
Gene dosage-hypothesis vs. aneuploidy—gene/phenotype relationship 
The assertion that gene dosage, i.e. allelic number of Hsa21, underpins DS phenotypes 
has long governed mechanistic studies aimed at elucidating relationships between 
particular genes and observed phenotypes187, 217-219. Testing this hypothesis in humans has 
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been extremely complex and impractical given the scarcity of tissue and the inability to 
alter single genes, or groups of genes, to test outcomes. Thus, mouse models have 
become an invaluable tool in the quest to characterize the contributions of specific genes 
to DS phenotypes. Tissue-specific transcriptomic analyses in Ts65Dn and Ts1Cje have 
shed light on the fact that dysregulation in gene expression is subtle, yet not uniform, and 
that widespread genomic aberrations are also present, revealing complex regulation that 
is not solely explained by allelic number188, 190, 191, 220-223. These gene expression findings 
also hold true in humans158, 224. Other work investigating the DS critical region (DSCR) 
in mice reinforced the fact that, unlike in single-gene mutation disorders (i.e. Fragile X or 
Tay-Sachs disease), dysregulation in single genes or even smaller subsets of genes is not 
sufficient to produce a DS-relevant phenotype, but that the unique genetic landscape 
arising from the additive global effect of Hsa21 syntenic gene triplication is in itself 
necessary to produce the common phenotypes associated with DS225.  
 
Indeed, the hypothesis that small cumulative genetic or epigenetic changes manifest as 
DS phenotypes may offer an explanation for the presence of histological phenotypes in 
Ts65Dn but not Ts1Cje brains, since they have more triplicated genes. However, this is 
largely contradicted by the lack of phenotype in Dp16 embryos and neonates. Since 
somatic and brain growth abnormalities are measurable during gestation in fetuses with 
DS, we would expect that DS phenotypes recapitulated by Ts65Dn mice would be 
exacerbated as the number of triplicated genes within the Mmu16 syntenic region 
increases (i.e. in Dp16). Our data show that this is not the case. Thus, the gene dosage 
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hypothesis alone is not sufficient to explain the sequelae of Hsa21 triplication. 
Significant factors to consider are the physical state of triplicated chromatin and the 
presence of an additional chromosome, or aneuploidy, in 95% of cases of DS182. The 
amplified developmental instability hypothesis states that most DS phenotypes may be a 
result of a non-specific disturbance in chromosomal balance, leading to disrupted 
homeostasis. This hypothesis was proposed in an attempt to explain the similarities 
between different aneuploid states and the dissimilarity in phenotype severity among the 
95% of people with DS who contain an identical triplication of Hsa21217. Thus, 
aneuploidy itself may be a major determinant in the manifestation of DS phenotypes.  
 
Aneuploidy has been studied in multiple organisms, including yeast226, Drosophila227, 
rice228, mice229, and humans230, 231. Karyotype abnormalities in mammals, particularly in 
humans, are extremely deleterious and often lead to miscarriage or cognitive 
impairment230, 232, 233. In fact, only aneuploidies of chromosomes containing the smallest 
number of genes are typically tolerated, allowing for a full gestation and parturition. 
Taken together, studies on aneuploidy in humans, non-human primates, and mice show 
that certain phenotypes are remarkably similar despite the affected chromosome(s). One 
such phenotype is cell proliferation. A study on cell proliferation and cell cycle dynamics 
in four primary mouse cell lines carrying distinct aneuploidies showed that the individual 
triplication of Mmu 1, 13, 16, and 19 led to similar slowing of the cell cycle and in altered 
cellular metabolism230. Additionally, elongation of the cell cycle led to a decrease in cell 
number and proliferation rate230. Similar in vitro results were seen in primary fibroblast 
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cultures from six individuals with DS231. Notably, on the organismal level, a number of 
studies showed that most trisomic mice exhibit stunted embryogenesis and widespread 
hypoplasia compared to euploids no matter which chromosome is triplicated, including 
the Ts16 mouse model of DS, in which the full Mmu16 chromosome is triplicated230, 234-
236. This work on Ts16 has shown similar somatic and brain development abnormalities 
to Ts65Dn during gestation235, 236. Further work has shown that Ts65Dn embryos and 
neonates exhibit decreased proliferation and elongation of cell cycle in the brain and in 
peripheral tissue148, 186, 237, 238. Furthermore, gene expression analysis in these mice 
pinpointed a specific decrease in regulators of G(2)/M and G(1)/S cell cycle transition237. 
Thus, we posit that cell cycle aberration due to the presence of an additional chromosome 
in Ts65Dn may be necessary in conjunction with the dosage imbalance for the induction 
of prenatal brain morphogenesis phenotypes. This is a possible explanation for why 
Ts1Cje and Dp16 mice show more subtle brain development deficits that manifest only 
after birth. Further supporting this idea, previous studies assessing synaptic integrity, 
dendritic branching, and spine morphology in adult Ts65Dn and Ts1Cje showed that 
some of the Ts65Dn cellular phenotypes were present but were significantly less severe 
in Ts1Cje mice239. In addition to our current work, other Dp16 studies show functional 
and behavioral deficits, but none have yet compared cellular or subcellular fitness in adult 
animals to Ts65Dn180, 188, 240-243. 
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Comparison of models to human phenotypes 
In evaluating the utility of each mouse model, one must objectively assess how the 
murine phenotypes compare to the human condition. Neurocognitive abnormalities are 
not easily modeled in less complex organisms, yet a minimum threshold of phenotypic 
similarity is important to establish, especially when drug development is ultimately a 
goal. This current work establishes a minimum essential screen that distinguishes each 
model by its similarity and difference compared to human DS phenotypes.  
 
Spatiotemporal changes are well documented in humans and can be used as a metric to 
identify suitable models for basic and translational studies. In fetuses with DS, abnormal 
histogenesis is widely observed in the brain by 20 weeks of gestation140, 141. Cell 
proliferation is decreased and is accompanied by hypoplasia in the cerebellum and frontal 
lobe7, 143-145. Upon birth, babies with DS show behavioral symptoms of CNS 
abnormalities, including hypotonia and altered reflexes4, 153, 244, 245. Early intervention can 
aid in ameliorating these motor abnormalities and delayed acquisition of developmental 
milestones. However, cognitive function continues to follow a distinct developmental 
trajectory, leading to a sustained decrease in intellectual function170, 245, 246. Underlying 
brain abnormalities persist and become more exacerbated in adolescence and into 
adulthood in individuals with DS, leading to age-dependent cognitive decline4. Ts65Dn 
mice model this symptomatological arc quite well: brain abnormalities are observable 
pre- and post-natally, developmental milestone defects are present upon birth, learning 
and memory deficits are seen throughout adulthood, and age-dependent decline in 
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performance has been reported186-189, 239, 243, 247-251. On the other hand, until now, Ts1Cje 
and Dp16 mice had not undergone the rigorous tests to which Ts65Dn mice were 
subjected and previous data related to these two models are scarce and somewhat 
contradictory. Previous work has shown that Ts1Cje mice mimic Ts65Dn phenotypes but 
to a significantly smaller extent. Yet other work, including our current study, shows that 
Ts1Cje lack brain histogenesis abnormalities and perform inconsistently on behavioral 
tasks, and as such may not classically recapitulate all of the learning and memory deficits 
associated with DS184, 191, 192, 252-254. Similarly while behavioral analyses have shown that 
adult Dp16 mice have learning and memory deficits, anatomical, ultrastructural, cellular, 
and subcellular analyses are lacking in these adult animals188, 240, 242.  
 
Model selection for preclinical studies 
Preclinical trials showing clear and incontrovertible efficacy of proposed therapeutics are 
essential. As such, model selection is a critical first step for establishing an experimental 
paradigm with high translational value255, 256. Our cross model comparison sheds light on 
commonalities and differences among the Ts1Cje, Ts65Dn, and Dp16 mouse models and 
how they compare to human phenotypes and their timing of onset.  This will aid in model 
selection based on mechanism of action and timing of drug administration.  Additionally, 
based on our gene expression analyses, the underlying basis of observed common 
phenotypes seems to vary among models and by age. It is therefore evident based on our 
data that available mouse models need to be considered based on their overall similarity 
to humans at specific life-stages and not just the number of triplicated genes. Importantly, 
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spatiotemporal targeting of therapeutic interventions is likely to be the most effective 
strategy for combating symptoms developing at specific ages. Thus, caution should be 
taken when using models that have not undergone a longitudinal phenotypic screen for 
preclinical trials.  
 
Study Limitations 
We acknowledge that some limitations to our current study exist. Until now, no studies 
have specifically addressed the contribution of the non-syntenic genes triplicated in the 
Ts65Dn mice to the observed phenotypes. We show in our current study that differential 
expression of some of these genes is taking place uniquely in Ts65Dn brains during 
development and in adulthood. We cannot fully determine whether the severity of 
phenotypes in Ts65Dn depends on the triplication of these non-syntenic genes. Similarly, 
seven genes on Mmu12 are monosomic in Ts1Cje, leading to dysregulated expression of 
those genes and again we cannot fully determine their contribution to Ts1Cje-specific 
phenotypes. Additionally, Ts65Dn is the only model of aneuploidy assessed in the current 
study. Therefore, we cannot determine the specific contribution of the additional 
chromosome to the observed phenotypes. Future work to compare Ts65Dn and its 
genocopy Ts2Cje257, which contains the same triplicated genes but is not a model of 
aneuploidy, could directly address this possibility. Lastly, the effect of the duplication 
and chromosomal elongation in Dp16 on chromatin access is unknown. 
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Chapter 2.5 – Future Work 
It is important to note that this study is a springboard for additional comparative studies. 
Our gene expression data point to key biological processes also disturbed in the brains of 
people with DS such as myelination, synaptogenesis, and neuroinflammation158. All of 
these processes can be further explored and then targeted for treatment. While we focused 
solely on forebrain development, subcortical, cerebellar, and brainstem abnormalities 
have been reported in people with DS and in some mouse models. These other structures 
undoubtedly play a role in behavioral phenotypes associated with DS. Also, while we 
surveyed important time points during distinct life stages, a longitudinal study of 
transcriptome, brain morphology, and behavior would help us better identify causal 
relationships between specific gene dysregulations and observed brain and behavioral 
phenotypes. Lastly, we focused on molecular, structural, and behavioral abnormalities in 
Ts1Cje, Ts65Dn, and Dp16 mice. Much work is still needed to assess subcellular, 
cellular, and electrophysiological function in these mice.  
 
Chapter 2.6 – Conclusions 
The relationship between prenatal and postnatal phenotypes in DS is still not well 
understood. However, cognitive impairment and neurohistopathology during gestation 
always occur jointly in the DS population. Consequently, identifying the correct sequence 
of neurobiological events leading to intellectual disability is extremely challenging; 
however, relying on mouse models of DS has helped shed light on vital processes that are 
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perturbed as a result of trisomy. Many key findings have successfully translated to 
humans.  
 
Our data show that Ts65Dn mice faithfully recapitulate all known phases of histological, 
functional, and behavioral phenotypes typical of DS starting from prenatal development 
and into old age. Yet this is not true for Ts1Cje or Dp16. They may instead be useful in 
elucidating cognitive changes occurring in the absence of prenatal effects on brain 
development. In addition, combinatorial use of all 3 models may also prove useful in 
tackling important unanswered question in DS research, such as the relationship between 
pre- and post-natal phenotypes in DS and the impact of aneuploidy.  
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Chapter 2.7 – Figures  
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Figure 2.1- Number of DEX genes in Ts1Cje, Ts65Dn, and Dp16 embryonic 
forebrains.  
(A) Overall number of DEX in each model. Ts1Cje and Ts65Dn display approximately 
double the number of DEX genes as in Dp16. 
(B) Venn diagram showing similar and dissimilar DEX genes among the models. 
(C) Number of DEX genes by chromosome in each model.   
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Figure 2.2- Embryonic somatic growth, brain development, and neurogenesis in 
Ts1Cje, Ts65Dn, and Dp16 mice.  
All images and data are generated at the level of the future somatosensory cortex. Mean 
data are shown ± S.E.M, *p<0.05, **p<0.01.  
(A) Representative images of euploid and Ts65Dn embryos at E15.5. 
(B) Quantification of body length in Ts1Cje, Ts65Dn, and Dp16 embryos showing only a 
decrease in Ts65Dn body length.   
(C) Representative images displaying the rostrocaudal (top) and mediolateral (bottom) 
measurements used to assess gross brain size at E15.5. 
(D) Gross brain measurements in Ts1Cje, Ts65Dn, and Dp16 showing that only Ts65Dn 
embryonic forebrains have a decreased rostrocaudal length.  
(E) Representative image showing the dorsal pallium in E15.5 brain. Dashed lines 
demarcate the different layers of the germinal zone: ventricular/subventricular zones 
(VZ/SVZ), intermediate zone (IZ), and subplate/cortical plate (SP/CP).  
(F) Measures of neocortical expansion in Ts1Cje, Ts65Dn, and Dp16 as a percent of their 
respective euploids. Ts65Dn show a consistent decrease in overall thickness, as well 
as thickness of the IZ and SP/CP (n.s., #p=0.10). Ts1Cje shows an increase in the size 
of the IZ that is not reflected in any other layer or in overall thickness. Dp16 show no 
change.  
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(G) Representative image showing EdU staining (green) in the dorsal pallium. Again, the 
layers of the dorsal germinal zone are demarcated.  
(H) Ts1Cje show no change in the percent of EdU+ cells by layer in the dorsal pallium 
compared to euploid littermates.  
(I) Ts65Dn show a decrease in the percent of EdU+ cells only in the VZ/SVZ of the 
dorsal pallium compared to euploid littermates.  
(J) Dp16 show no change in the percent of EdU+ cells by layer in the dorsal pallium 
compared to euploid littermates.  
(K)  Representative image showing OLIG2 (red) staining in the medial ganglionic 
eminence (MGE) of the ventral germinal zone at E15.5. Cell nuclei are stained with 
DAPI (blue).  
(L) Number of OLIG2+ cells per 100µm3 of MGE in Ts1Cje, Ts65Dn, Dp16, and their 
respective euploid littermates. Only Ts65Dn show a marked increase in OLIG2+ cells 
compared to euploid littermates.  
(M) Representative image showing phosphorylated Histone 3 (pH3) (green) staining 
in the MGE of the ventral germinal zone at E15.5. Cell nuclei are stained with DAPI 
(blue). 
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(N)  Number of pH3+ cells in the MGE of Ts1Cje, Ts65Dn, Dp16, and their respective 
euploid littermates. Only Ts65Dn show a significant increase in pH3+ cells compared 
to euploid littermates.  
(O-Q) Distribution of pH3+ into 20µm bins starting at the ventricular surface.  
(O) Ts1Cje mice show a decrease only in one bin at 160µm away from the ventricular 
surface compared to euploid littermates.  
(P) Ts65Dn show a consistent increase in the area corresponding to the SVZ of the MGE 
(bins 140-260µm away from the ventricular surface) compared to euploid littermates.  
(Q)  Dp16 shows no change in pH3+ cells by bin compared to euploid littermates.   
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Figure 2.3- Developmental milestones in male Ts1Cje, Ts65Dn, and Dp16 neonates. 
Graphs showing day on which criteria was met on each task in trisomic mice compared to 
euploid littermates. Mean data are shown ± S.E.M., *p<0.05. 
(A) On surface righting, only Ts1Cje and Ts65Dn show an impairment compared to 
euploids.  
(B) On negative geotaxis, only Ts65Dn show a marked impairment compared to euploid 
littermates.  
(C) On forelimb grasp, all trisomic mice perform similarly to their euploid littermates.  
(D) On cliff aversion, Ts1Cje and Ts65Dn show a significant impairment, while Dp16 
show an improvement compared to euploid littermates. 
(E) On open field, all trisomic mice perform similarly to their euploid littermates.  
(F) On eye opening, all trisomic mice perform similarly to their euploid littermates, 
showing that there was no confounds during testing from lack of vision in trisomic 
mice.  
(G)  On air righting, all trisomic mice show an impairment compared to euploids.  
(H)  On auditory startle, all trisomic mice show an impairment compared to euploids.  
(I) On ear twitch, only Dp16 show a minor impairment compared to euploid littermates.  
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Figure 2.4- Forebrain neuronal populations in P15 Ts1Cje, Ts65Dn, and Dp16 mice. 
(A) Representative images of Parvalbumin (PV, panel 1, red), Calretinin (CR, panel 2, 
green), and Somatostatin (SS, panel 3, green) inhibitory interneuron (IN) staining in 
the somatosensory cortex. All nuclei are counterstained with DAPI (blue).  
 
(B) Cell density by layer in P15 Ts1Cje neocortex compared to euploids. No change is 
observed in density or layer thickness (data not shown). Mean data are shown ± 
S.E.M., *p<0.05. 
 
(C-E) IN density as a percent of total cells. Each subtype is represented separately. Mean    
data are shown ± S.E.M., *p<0.05. 
 
(C) No change in overall density or density by neocortical layer (data not shown) is seen 
in Ts1Cje cortex compared to euploids.  
 
(D) An increase in PV+ and SS+ IN density is seen in Ts65Dn compared to euploids. No 
change is observed in CR+ INs.  
 
(E) A decrease in PV+ and SS+ IN density is seen in Dp16 compared to euploids. No 
change is observed in CR+ INs.  
  
83 
(F) Representative images PV+ (panel 1, red) and SS+ (panel 2, green) INs in the dorsal 
hippocampus. All nuclei are counterstained with DAPI (blue).  
 
(G) Ts1Cje (orange bars) and Dp16 (blue bars) show no change in IN populations in the 
hippocampus compared to euploids. Ts65Dn show an increase in both PV+ and SS+ 
INs in the hippocampus compared to euploids. Mean data are shown ± S.E.M., 
*p<0.05. 
 
(H) Representative images of Tbr1 (red) excitatory neuron staining in the somatosensory 
cortex. All nuclei are counterstained with DAPI (blue).  
 
(I) Ts65Dn show a significant decrease in excitatory neuron numbers in the 
somatosensory cortex compared to euploids (green bar). Dp16 show a trend towards a 
decrease in excitatory neuron numbers in the somatosensory cortex compared to 
euploids (blue bar). Ts1Cje show no change in overall number of excitatory neurons 
in the somatosensory cortex. However, a shift in distribution from Layer VI, favoring 
Layer IV is observed in these mice (J). Mean data are shown ± S.E.M., *p<0.05; 
#p=0.07. 
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Figure 2.5- Motor-based tasks in adult Ts1Cje, Ts65Dn, and Dp16 males.  
(A-C) Measurement of distance travelled in the center versus periphery of testing space 
during the open filed task. This measurement is a representation of exploratory behavior 
in animals. Mean data are shown ± S.D. *p<0.05, **p,0.01, ***p<0.001, ****p<0.0001. 
(A) Ts1Cje travel more distance in the periphery compared to euploid littermates. Travel 
in the center is similar between genotypes. 
(B) Ts65Dn also travel more distance in the periphery compared to euploid littermates. 
Travel in the center is similar between genotypes. 
(C) Dp16 show no change in distance traveled in both center and periphery compared to 
euploid littermates. 
(D-F) Latency to fall during the non-accelerating rotarod at three different speeds: 16 
RPM, 24 RPM, 32 RPM. This task measures motor coordination in animals. Mean data 
are shown ± S.D. *p<0.05, **p,0.01, ***p<0.001, ****p<0.0001. 
(D) Ts1Cje only show a deficit at the highest rotational speed of 32 RPM. 
(E) Ts65Dn show no difference in rotarod performance compared to a pooled cohort of 
F1 hybrid euploids at any speed.  
(F) Dp16 show a marked impairment in rotarod performance at every speed compared to 
euploid littermates.  
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(G-I) Latency to fall during the accelerating rotarod task, which gradually increase in 
rotational speed from 4 RPM- 40 RPM. This task measures motor coordination in 
animals. Mean data are shown ± S.D. *p<0.05, **p,0.01, ***p<0.001, ****p<0.0001. 
(G) Ts1Cje show significant impairment in accelerating rotarod task compared to euploid 
littermates. 
(H) Ts65Dn show no difference in rotarod performance compared to a pooled cohort of 
F1 hybrid euploids. 
(I) Dp16 show a marked impairment in rotarod performance to euploid littermates. 
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Figure 2.6- Hippocampal based tasks in adult Ts1Cje, Ts65Dn, and Dp16 males. 
(A-C) The Morris water-maze (MWM) test is comprised of two phases: acquisition and 
reversal. Both tests utilize a hidden platform to analyze learning (acquisition phase) and 
reversal learning (reversal phase). Mice are initially tested using a visible platform to 
exclude any confounds related to testing procedures or non-learning based deficits in the 
mice. Mean data are shown ± S.D., *p<0.05. 
(A) Ts1Cje males show no deficits in either phase of testing compared to euploids. 
(B) Ts65Dn males show no deficits during the acquisition period after the 4 days needed 
to stop thigmotaxic behavior and acclimate to the task (previously published189). 
However, these mice show a deficit in reversal learning compared to euploid mice. 
(C) Dp16 males show impaired learning on Days 1 and 5 of the acquisition phase. 
Additionally, these males also show a strong deficit in reversal learning compared to 
euploid mice.  
(D-I) The contextual fear conditioning (CFC) test is comprised of two phases: training 
and testing. During the training phase, mice are given two mild shocks 60s apart. On the 
following day, mice were placed in the same chamber but no shocks are applied. Freezing 
behavior is documented. 
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Figure 2.7- Number of DEX genes in adult Ts1Cje, Ts65Dn, and Dp16 brains by 
region. 
 
(A-C) Overall number of DEX in each model by region. Dp16 still displays lowest 
number of total DEX genes. Ts1Cje and Ts65Dn display a similar number of total DEX 
gene but there is a differential spatial clustering in each model. 
 
(A’-C’) Venn diagrams showing similar and dissimilar DEX genes among the models by 
brain region. 
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Figure 2.8- Number of DEX genes in adult Ts1Cje, Ts65Dn, and Dp16 brains by 
region. 
(A-C) Number of DEX genes by chromosome in each model, by brain region.  
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Figure 2.9- Schematic summarizing genetic basis of Ts1Cje, Ts65Dn, and Dp16 
mice. 
Cytogenetic make up of these Mmu16 segmental trisomy models differs substantially. 
This schematic summarizes how each model was designed as well as the number and 
identity of syntenic and nonsyntenic genes that were affected in the generation of each 
mouse model.  
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Chapter 2.8 – Summary Table 
 
 
 
 
Table 2.1- Summary table showing cross-model comparison across all metrics measured in this study.   
Ts1Cje Ts65Dn Dp16
Mmu16 Triplicated region Number of triplicated protein-coding genes ~71 ~104 ~119
E15.5 Somatic growth - ↓ -
E15.5 Brain growth - ↓ -
E15.5 Pallial expansion ↑ ↓ -
E15.5 Neurogenesis- dorsal telencephalon - ↓ -
E15.5 Neurogenesis- medial ganglionic eminence ↓ only in 1 bin in SVZ ↑ -
Embryonic transcriptome E15.5 Forebrain DEX genes, FDR: p< 4.5x10
-4 5↓|59↑ 4↓|60↑ 3↓|27↑
Embryonic miRNA expression E15.5 Forebrain, top 1% of dysregulated genes 6↓|3↑ 6↓|1↑ 5↓|32↑
P15 Interneurons- Cortex - ↑ ↓
P15 Interneurons- Hippocampus - ↑ -
P15 Excitatory Neurons- Cortex - ↓ ↓
Early Acquired Milestones ↓ ↓ -
Late Acquired Milestones ↓ ↓ ↓
Rotarod ↓ - ↓
Contextual Fear Conditioning ↓ ↓ ↓
Morris Water Maze - ↓ ↓
Open Field ↓ ↓ -
SHIRPA - - -
6-7mo Cortex DEX genes, FDR: p< 4.5x10
-4 4↓|15↑ 5↓|72↑ 1↓|7↑
6-7mo Hippocampus DEX genes, FDR:p< 4.5x10
-4 33↓|50↑ 2↓|30↑ 16↓|23↑
6-7mo Cerebellum DEX genes, FDR: p< 4.5x10
-4 24↓|59↑ 15↓|61↑ 0↓|4↑
6-7mo Cortex, top 1% of dysregulated genes 5↓|11↑ 18↓|1↑ 3↓|8↑
6-7mo Hippocampus, top 1% of dysregulated genes 5↓|2↑ 7↓|0↑ 5↓|2↑
6-7mo Cerebellum, top 1% of dysregulated genes 2↓|3↑ 14↓|3↑ 5↓|4↑
Adult Transcriptome
Adult miRNA expression
Adult Behavior
Milestones
Postnatal Neuronal 
Populations
Prenatal Development
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Chapter 2.9 – Supplementary Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2.1- List of DEX genes in E15.5 Ts1Cje, Ts65Dn, and Dp16 embryonic forebrain. 
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Table S2.2- List of affected genes matched to functional pathways by DAVID in E15.5 Ts1Cje embryonic 
forebrain.   
Pathway/Cellular Process Term
Number of 
genes 
dysregulated 
in Dp16 E15.5 
brain
Number of 
genes in 
DAVID 
Fold 
Enrichment
P-Value
Dysregulated genes in Ts1Cje Embryonic Brain                                                                                               
(Red: upregulated/Blue: downregulated
Phosphoprotein 103 180 1.7052821 9.71E-11
GO:0005524~ATP binding 25 149 1.9431975 0.00193
GO:0004672~protein kinase 
activity
11 149 2.4405679 0.01462
HUNK, CDK1, PLK1, PNCK, DYRK1A, RASSF2, BUB1, 
BUB1B, CDK6, AURKB, MELK
GO:0005886~plasma membrane 67 175 1.5468777 7.48E-05
PVR, GPR84, OLFR313, PCDHGA8, AQP4, OLFR803, 
OLFR559, OLFR151, OLFR748, RHOV, SLC7A5, 
PCDHGA2, MRGPRA5, PCDHGA1, PCDHGB1, OLFR197, 
OLFR198, OLFR656, CXCR5, OLFR318, GNG4, OLFR694, 
OLFR323, PCDHGA10, SLC3A2, PCDHGB4, KCNT2, 
CD59A, VEGFA, OLFR495, VMN2R60, OLFR213, FAIM2, 
OLFR331, MAL2, IFITM2, OLFR539, IFITM3, OLFR135, 
OLFR1377, LY6A, CDH9, OLFR1333, KLRA8, OLFR485, 
OLFR488, RASGRP2, PHLDA3, OLFR1408, LY6C1, 
DLGAP1, IRGM1, FLT1, VMN2R12, OLFR403, OLFR857, 
VMN2R50, CPNE6, H2-M1, SLC6A9, ATF4, SLC7A3, 
PENK, SLC7A1, OLFR584, VMN2R84, NMBR
GO:0007186~G-protein coupled 
receptor signaling pathway
31 163 2.0161734 2.47E-04
GPR84, CCL3, OLFR313, OLFR331, OLFR539, OLFR135, 
OLFR559, OLFR803, OLFR151, OLFR748, MRGPRA5, 
OLFR1377, OLFR197, OLFR656, OLFR198, OLFR1333, 
CXCR5, OLFR485, OLFR488, AGT, OLFR318, GNG4, 
OLFR694, OLFR1408, OLFR323, OLFR857, OLFR403, 
OLFR584, OLFR495, NMBR, OLFR213
GO:0007608~sensory perception 
of smell
24 163 2.3352173 2.14E-04
OLFR323, OLFR313, OLFR331, OLFR403, OLFR857, 
OLFR539, OLFR135, OLFR559, OLFR803, OLFR151, 
OLFR748, OLFR1377, OLFR197, OLFR656, OLFR198, 
OLFR1333, OLFR485, OLFR584, OLFR488, OLFR318, 
OLFR495, OLFR694, OLFR213, OLFR1408
GO:0004984~olfactory receptor 
activity
24 159 2.2834759 2.90E-04
OLFR323, OLFR313, OLFR331, OLFR403, OLFR857, 
OLFR539, OLFR135, OLFR559, OLFR803, OLFR151, 
OLFR748, OLFR1377, OLFR197, OLFR656, OLFR198, 
OLFR1333, OLFR485, OLFR584, OLFR488, OLFR318, 
OLFR495, OLFR694, OLFR213, OLFR1408
GO:0005634~nucleus 76 169 1.4659419 9.00E-05
GO:0006334~nucleosome 
assembly
5 158 5.4635322 0.01317
GO:0000775~chromosome, 
centromeric region
13 169 10.685265 3.28E-09
Acetylation 41 180 1.6432333 0.00134
GO:0000776~kinetochore 11 169 10.698964 7.96E-08
SPC25, PLK1, RASSF2, KIF18A, BUB1, CENPF, BUB1B, 
CENPE, AURKB, CENPK, ZWILCH
GO:0005876~spindle 
microtubule
5 169 14.233656 4.02E-04 CDK1, KIF11, PLK1, NUSAP1, AURKB
GO:0007094~mitotic spindle 
assembly checkpoint
4 158 24.154564 5.58E-04 PLK1, BUB1, BUB1B, CENPE
GO:0007049~cell cycle 27 158 5.0535445 1.83E-11
CEP55, AURKB, FAM83D, SPC25, MIS18A, BUB1, 
CDCA2, ZWILCH, ASPM, CDCA3, CDK1, KIF11, 
DLGAP5, NUSAP1, CDK6, CENPE, CDC25C, ESCO2, 
SMC4, SON, CCNB2, PLK1, RASSF2, BUB1B, MIS18BP1, 
CHAF1B, MELK
GO:0007067~mitotic nuclear 
division
20 158 8.2246722 4.07E-12
CDK1, KIF11, NUSAP1, CENPE, CEP55, AURKB, 
CDC25C, SMC4, FAM83D, SPC25, CCNB2, PLK1, 
MIS18A, BUB1, CDCA2, BUB1B, MIS18BP1, ZWILCH, 
ASPM, CDCA3
GO:0007091~metaphase/anapha
se transition of mitotic cell cycle
2 158 45.893671 0.04256 BUB1B, TACC3
Glycosylation
glycosylation site:N-linked 
(GlcNAc...)
39 124 1.5899704 0.00219
GPR84, MAL2, OBP2A, IGFBP7, LY86, ARSK, AQP4, 
TMEM62, SLC7A5, SLC1A4, CDH9, CXCR5, KLRA8, 
OLFR488, AGT, SERPINA1C, CATSPERG1, DKKL1, 
SPP1, FLT1, NCEH1, STC2, SLC6A11, SLC3A2, ECM1, H2-
Q9, VWF, SLC6A9, HEPACAM, SLC7A3, CD59A, 
SLC7A1, VEGFA, IFNA12, PLA2G7, OLFR495, NMBR, 
BPIFB9B, FAIM2
GO:0000166~nucleotide binding 32 149 1.9419918 3.31E-04
Nucleotide-binding 27 180 1.9437678 0.00133
Disulfide bond disulfide bond 24 124 1.3889217 0.08443
LY6C1, MUP4, CCL3, FLT1, OBP2A, IGFBP7, S100A11, 
SLC3A2, OLFR151, H2-Q9, LY6A, VWF, HEPACAM, 
CXCR5, PENK, KLRA8, CD59A, OLFR488, VEGFA, 
IFNA12, CPA3, NRGN, NMBR, OLFR495
GO:0021987~cerebral cortex 
development
4 158 6.8498016 0.02038 CDON, TACC3, ASPM, GART
GO:0043005~neuron projection 8 169 2.2231615 0.06844
PCP4, SYNJ1, SLC6A4, TSGA10, ITSN1, SOD1, TPH2, 
HDAC6
GO:0071542~dopaminergic 
neuron differentiation
3 163 11.504971 0.02752 VEGFA, OTX2, EN1
GO:0043524~negative 
regulation of neuron apoptotic 
process
5 163 3.4114946 0.05861 AGT, VEGFA, AARS, EN1, FAIM2
GO:0009953~dorsal/ventral 
pattern formation
3 163 6.8090647 0.07105 OTX2, EN1, SP8
GO:0006412~translation 11 163 3.0058033 0.00367
GO:0004812~aminoacyl-tRNA 
ligase activity
8 159 22.561522 5.19E-08
Cell adhesion 13 182 3.5431061 3.23E-04
IPR013164:Cadherin, N-
terminal
6 173 10.403116 2.73E-04
GO:0016491~oxidoreductase 
activity
11 149 2.1339841 0.03308
GO:0006749~glutathione 
metabolic process
3 158 7.0245415 0.06728
GO:0005759~mitochondrial 
matrix
5 169 3.0553921 0.08077 COASY, TYMS, ALAS2, H2-KE6, PIN4
Calcium 13 182 1.9593804 0.0338
PCDHGA10, HPCAL4, S100A11, PCDHGA8, ARSK, 
CACNG3, PCDHGA2, PCDHGB4, PCDHGA1, PCDHGB1, 
CDH9, RASGRP2, PLA2G4E
Calmodulin-binding 4 180 3.639968 0.09706 PHKA2, PCP4, PNCK, ASPM
IPR015373:Interferon 
alpha/beta receptor, beta chain
4 166 41.560241 1.04E-04 IFNAR2, IL10RB, IFNGR2, IFNAR1
GO:0035456~response to 
interferon-beta
2 163 24.714383 0.07763 IFITM2, IFITM3
GO:0006865~amino acid 
transport
5 163 13.239848 5.28E-04 SLC6A9, SLC7A3, SLC7A1, SLC3A2, SLC7A5
GO:0015175~neutral amino acid 
transmembrane transporter 
activity
3 159 23.568733 0.00687 SLC1A4, SLC3A2, SLC7A5
PI3K-Akt signaling pathway
mmu04151:PI3K-Akt signaling 
pathway
10 79 2.7840889 0.00856
VWF, EIF4EBP1, ATF4, FLT1, ITGB8, VEGFA, IFNA12, 
GNG4, SPP1, DDIT4
GO:0048514~blood vessel 
morphogenesis
3 163 9.5326906 0.03895
GO:0001569~patterning of 
blood vessels
3 163 8.3411043 0.04962
COASY, SCAF4, HPRT, SYNJ1, HLCS, AURKB, IGF2BP3, 
ACSS2, TYMS, KIF4, DDX3Y, BUB1, RBM28, TOP2A, 
CDK1, EIF2S3Y, KIF11, PNCK, KIF15, KIF18A, RCAN1, 
Protein kinase activity/ATP-
binding
Plasma membrane/G-protein 
coupled receptor signaling
Nucleus signaling
Kinetochore 
assembly/checkpoint
Cell cycle regulation
Nucleotide binding
HMGN1, SLC6A4, AURKB, ACSS2, ITSN1, VPS13C, 
MIS18A, CDCA2, HBB-B1, SLC4A1, ASPM, CDCA3, 
DSCAM, RCOR2, NEIL3, PNCK, EOMES, TACC3, ESCO2, 
ABCB1B, PHKA2, COASY, RNF17, IGF2BP3, PIN4, ACP1, 
TTC3, SPC25, DDX3Y, GLO1, DOPEY2, CELSR1, GART, 
KCNJ6, PLK1, ETS2, HIST1H3A, DYRK1A, TSGA10, 
RAD54B, CHAF1B, HIST1H3H, HDAC6, SLC5A3, HPRT, 
UTY, SYNJ1, GYPA, HLCS, FAM83D, URB1, 
ARHGAP11A, MAGEH1, TOP2A, CDK1, EIF2S3Y, KIF11, 
HIST1H1A, KIF15, NUSAP1, CDK6, IFNAR1, IFNAR2, 
BRWD1, RRM2, CLIC6, TXNRD3, BUB1B, H2-KE6, 
MELK, TPH2, HIST1H2AB, HIST1H2AG, CEP55, HMMR, 
TYMS, CBR1, MORC3, IL10RB, KIF4, BUB1, ZWILCH, 
RBM28, PSTPIP2, HIST1H2BC, DLGAP5, KIF18A, CENPE, 
RCAN1, SOD1, CDC25C, TPMT, SMC4, DNPEP, SON, 
PSMG1, 4930447C04RIK, PLEKHF2, CCNB2, RASSF2, 
HSPA4L, MIS18BP1, HIBCH
HMGN1, UTY, AURKB, PCP4, MIS18A, URB1, CDCA2, 
ATP5O, TOP2A, ASPM, KDM5D, CDK1, C2CD2, RCOR2, 
HIST1H1A, PNCK, NEIL3, OBOX2, EOMES, NUSAP1, 
CDK6, ESCO2, HUNK, BRWD1, RRM2, TXNRD3, BUB1B, 
1110004E09RIK, MELK, HIST1H2AB, RNF17, HIST1H2AG, 
DSCR3, IGF2BP3, PIN4, TTC3, TYMS, SPC25, CBR1, 
FLT1, VEGFA, TBX1
Translation
Blood vessel morphogenesis
Amino acid transport
Interferon signaling
Calcium signaling
Oxidoreductase activity
Cell adhesion
Central nervous system 
development
IARS, TARS, YARS, CARS, NARS, UCP2, AARS, GARS, 
SLC25A18, RPL29, MARS
PCDHGA10, IGFBP7, PCDHGA8, PCDHGA2, PCDHGB4, 
PCDHGA1, PCDHGB1, VWF, CDH9, HEPACAM, KLRA8, 
ITGB8, SPP1
CBR1, CYB5R1, UTY, RRM2, TXNRD3, IDH2, H2-KE6, 
CRYZL1, TPH2, KDM5D, GLO1
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Table S2.3- List of affected genes matched to functional pathways by DAVID in E15.5 Ts65Dn embryonic 
forebrain.   
Pathway/Cellular Process Term
Number of 
genes 
dysregulated 
in Dp16 
E15.5 brain
Number of 
genes in 
DAVID 
Fold 
Enrichment
P-Value
Dysregulated genes in Ts65Dn Embryonic Brain                                                                                               
(Red: upregulated/Blue: downregulated
GO:0005634~nucleus 77 171 1.4678595 7.66E-05
GO:0006355~regulation of 
transcription, DNA-templated
46 160 2.2848751 8.67E-08
GO:0000122~negative regulation of 
transcription from RNA polymerase 
II promoter
23 160 3.5310298 5.15E-07
DMBX1, BACH1, HBB-BH1, SOX14, FOXA1, EN1, PAX3, PAX7, 
NR0B2, TCF7L2, HBB-Y, SHOX2, T, GATA2, UXT, TAL1, PLK3, 
OLIG3, GATA3, TFAP2B, TFAP2A, POU4F1, HBA-X, SIM2
GO:0045944~positive regulation of 
transcription from RNA polymerase 
II promoter
16 153 1.8938447 0.021032
SATB2, NOS1, EOMES, IGF1, NFIX, PF4, NR4A3, DCN, PRDM9, 
OSR1, FOXC2, NEUROD6, SLC40A1, NHLH1, NFIA, NFIB
GO:0000978~RNA polymerase II 
core promoter proximal region 
sequence-specific DNA binding
9 162 2.6912896 0.018786
FEZF2, KDM6A, SATB2, RFX5, NR4A3, NEUROD6, TBX18, NFIA, 
NFIB
Homeobox 20 185 8.7907336 1.52E-12
DMBX1, IRX3, IRX5, ONECUT1, BARHL1, IRX2, OTX2, BARHL2, 
EN1, PAX3, EN2, RHOX4F, SHOX2, LHX1, PAX7, POU3F4, LHX5, 
POU4F1, LHX9, DBX1
GO:0005886~plasma membrane 60 174 1.3932249 0.003535
Transmembrane 75 186 1.3192478 0.003873
Glycoprotein 54 186 1.7267671 3.94E-05
glycosylation site:N-linked 
(GlcNAc...)
52 136 1.9329052 9.06E-07
chain:UDP-glucuronosyltransferase 
1-6
3 136 39.732353 0.002412
Disulfide bond Disulfide bond 44 186 1.7273825 2.93E-04
IGHG1, NRP1, ENPP1, LEPR, TNC, HS3ST1, TRHR, VTN, PF4, 
LPAR1, DCN, TNFSF12, CXCL12, DDR2, TLR8, ST3GAL1, ISLR, 
OGN, OLFML3, LY6G, CFH, UNC5D, PLTP, MRC1, LPL, LYZ1, 
SLC6A13, EFEMP1, H2-DMB1, IGF1, COLEC12, NPY1R, SLC3A1, 
GJB2, H2-Q9, OLFR498, TNFAIP6, CD55, LYVE1, PTGDS, COL1A2, 
CNTN2, PRL3D3, CACNA1E
GO:0005576~extracellular region 26 174 1.6794381 0.010672
GO:0005615~extracellular space 26 174 1.9339986 0.001767
GO:0007399~nervous system 
development
11 160 3.3146277 0.001812
APP, GRIK1, EPHA8, LHX1, GATA3, BARHL2, TFAP2A, POU4F1, 
PAX3, SIM2, DSCAM, SATB2, NRP1, EOMES, TNFSF12, DPPA3, 
GAS7, FEZF2, DAB2, OLFML3, ID2, FOXC2, UNC5D, ETL4, 
NEUROD6, TBX18, NHLH1
GO:0048646~anatomical structure 
formation involved in morphogenesis
4 160 18.883333 0.00117 FOXA2, LHX1, GATA3, FOXA1
GO:0030901~midbrain development 5 160 13.817073 4.48E-04 TAL2, BARHL1, OTX2, EN1, EN2
GO:0021549~cerebellum 
development
4 160 8.24 0.012448 LHX1, LHX5, EN1, GART
GO:0009953~dorsal/ventral pattern 
formation
4 160 9.2489796 0.009081 FOXA2, LHX1, OTX2, EN1
GO:0043025~neuronal cell body 11 171 2.3761417 0.017609
DDC, SNCG, PLK3, GRIK1, TIAM1, SLC6A3, TH, CHRNA4, PDE10A, 
PTPRN, KLHL1
GO:0030182~neuron differentiation 8 160 6.919084 1.57E-04 GATA2, TAL1, GATA3, OTX2, BARHL2, POU4F1, EN1, EN2
GO:0001709~cell fate determination 4 160 25.177778 4.90E-04 GATA2, GATA3, EBF2, BARHL2
GO:0048663~neuron fate 
commitment
4 160 14.1625 0.002725 GATA2, PAX7, OTX2, PAX3
GO:0001708~cell fate specification 3 160 14.778261 0.017141 FOXA2, OTX2, PPDPF
GO:0030424~axon 8 171 2.500832 0.041127 DDC, IRX3, SNCG, APP, PCP4, SLC6A3, TH, DSCAM
GO:0043005~neuron projection 8 171 2.1971596 0.071914 APP, EPHA8, PCP4, SLC6A3, SYNJ1, TH, POU4F1, ITSN1
GO:0048013~ephrin receptor 
signaling pathway
4 160 10.539535 0.00632 TIAM1, EPHA8, EPHA10, ITSN1
GO:0007413~axonal fasciculation 3 153 20.908881 0.008746
GO:0007411~axon guidance 5 153 4.0028264 0.035928
GO:0021960~anterior commissure 
morphogenesis
2 153 39.494553 0.049273 BHLHE22, NFIB
GO:0071542~dopaminergic neuron 
differentiation
4 160 15.627586 0.002046 FOXA2, OTX2, EN1, EN2
GO:0042416~dopamine biosynthetic 
process
3 160 28.325 0.004763 DDC, SLC6A3, TH
Cerebral cortex GABAergic 
interneuron migration
GO:0021853~cerebral cortex 
GABAergic interneuron migration
2 153 39.494553 0.049273 FEZF2, CNTN2
Negative regulation of neuron 
apoptotic process
GO:0043524~negative regulation of 
neuron apoptotic process
9 160 6.2558282 9.65E-05
PCP4, BARHL1, TFAP2B, TFAP2A, TFAP2D, POU4F1, EN1, EN2, 
ITSN1
GO:0019825~oxygen binding 4 158 16.397562 0.001772 HBB-BH1, TH, HBA-X, HBB-Y
GO:0015671~oxygen transport 3 160 33.99 0.003285 HBB-BH1, HBA-X, HBB-Y
IPR013783:Immunoglobulin-like 
fold
19 175 2.0354193 0.00551
PSG28, IGKV4-57-1, IGKV4-62, EPHA10, IGKV3-4, IFNAR1, IFNAR2, 
IGKV8-24, EPHA8, EBF3, EBF2, IGKV8-28, MADCAM1, IGHA, JAM2, 
H2-DMA, IGHV8-12, IFNGR2, DSCAM
GO:0006955~immune response 9 153 3.3323529 0.00565
ENPP1, IGKV6-17, H2-DMB1, VTN, COLEC12, PF4, TNFSF12, 
CXCL12, H2-Q9
GO:0032496~response to 
lipopolysaccharide
6 153 3.4177979 0.031011 NOS1, IGF1, PF4, GJB6, DCN, ABCC8
mmu04650:Natural killer cell 
mediated cytotoxicity
5 60 6.1269841 0.008292 IFNAR2, RAET1D, VAV3, IFNGR2, IFNAR1
IPR015373:Interferon alpha/beta 
receptor, beta chain
3 175 29.567143 0.004388 IFNAR2, IFNGR2, IFNAR1
Calcium Signaling Calcium 17 186 2.5071641 0.001262
MRC1, PCDHA7, NRP1, PCDHGA11, PCDHA2, ENPP1, F13A1, 
PCDHGA9, EFEMP1, PCDHGA8, COLEC12, PCDHGA4, PCDHGA2, 
PCDHGA1, NECAB1, COL1A2, CACNA1E
Cell adhesion 12 186 3.2002249 0.001385
TNFAIP6, PCDHA7, PCDHGA11, PCDHA2, TNC, PCDHGA9, 
PCDHGA8, CNTN2, VTN, PCDHGA4, PCDHGA2, PCDHGA1
IPR002126:Cadherin 8 178 7.441618 1.01E-04
PCDHA7, PCDHGA11, PCDHA2, PCDHGA9, PCDHGA8, PCDHGA4, 
PCDHGA2, PCDHGA1
BACH1, FOXA2, UTY, PAX3, RPS2, RHOX4F, GATA2, OLIG3, 
PCP4, TIAM1, PAX7, GATA3, MIS18A, URB1, POU4F1, ATP5O, 
USP16, KDM5D, KLK1B22, C2CD2, SOX14, BARHL1, BARHL2, 
OTX2, RMI2, NR0B2, ARID1B, GTF2H5, PTPRN, HUNK, UXT, 
BRWD1, FGFR1OP, TFAP2B, TFAP2A, TFAP2D, 1110004E09RIK, 
IRX3, IRX5, ONECUT1, IRX2, TH, DSCR3, TCF7L2, TAL2, GM5168, 
TAL1, T, LHX1, DDX3Y, POU3F4, LHX5, LHX9, DBX1, SIM2, 
AF366264, DMBX1, FOXA1, RCAN1, EN1, DONSON, EN2, PLEKHF1, 
SHOX2, SON, PSMG1, PLK3, RPS6KA2, EBF3, BNC2, EBF2, 
HIST1H3A, DYRK1A, MAB21L1, TDPOZ2, CHAF1B, MAB21L2, 
1700048O20RIK, TFB1M
IGHG3, ENPP1, TNC, LEPR, F13A1, VTN, PF4, TNFSF12, DCN, 
CXCL12, ST3GAL1, ISLR, OGN, CFH, ITIH5, PLTP, LPL, LYZ1, 
Extracellular region
Glycosylation
Plasma membrane
Nucleus/ Regulation of 
transcription
FEZF2, NRP1, CNTN2, UNC5D, NR4A3
Dopaminergic neurons
Oxygen binding and transport
IGHG1, PCDHA7, IGHG3, NRP1, PCDHA2, LEPR, SLC16A12, 
PCDHGA9, PCDHGA8, VMN1R90, OLFR457, MRGPRA9, LPAR1, 
IGHG1, IGHG3, NRP1, F13A1, LEPR, VTN, LPAR1, TNFSF12, 
PCDHGA4, DDR2, TLR8, ST3GAL1, OGN, OLFML3, TRAC, 
UGT1A7C, CFH, ITIH5, ETL4, SLC22A6, UNC5D, H2-DMB1, 
COLEC12, SLC3A1, OLFR498, TNFAIP6, PTGDS, COL1A2, CNTN2, 
SLC40A1, SLC2A12, ABCA9, ENPP1, TNC, HS3ST1, TRHR, PF4, 
Immune response
Cell Adehesion
Central nervous system 
development
Neuronal differentiation
Axon/Neuron Projection 
Development
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Table S2.4- List of affected genes matched to functional pathways by DAVID in E15.5 Dp16 embryonic 
forebrain.  
  
Pathway/Cellular Process Term
Number of 
genes 
dysregulated 
in Dp16 E15.5 
brain
Number of 
genes in 
DAVID 
Fold 
Enrichme
nt
P-Value
Dysregulated genes in Dp16 Embryonic Brain                                                                                               
(Red: upregulated/Blue: downregulated
mmu05206:MicroRNAs in cancer 21 60 9.789855 4.72E-15
GO:0035068~micro-ribonucleoprotein 
complex
12 132 16.75871 1.31E-10
GO:0035195~gene silencing by miRNA 6 128 15.17411 4.47E-05
GO:0010629~negative regulation of 
gene expression
10 128 5.324248 1.08E-04
GO:0004930~G-protein coupled 
receptor activity
24 113 2.112779 6.72E-04
GO:0007608~sensory perception of 
smell
21 128 2.602034 1.32E-04
GO:0004984~olfactory receptor 
activity
20 113 2.677527 1.29E-04
Immune Response IPR003599:Immunoglobulin subtype 9 129 2.782229 0.01546
NCAM2, IGKV10-94, VPREB1, IGHA, GM14548, JAM2, CEACAM2, 
IGKV3-12, DSCAM
GO:0000981~RNA polymerase II 
transcription factor activity, sequence-
specific DNA binding
5 113 4.447157 0.02565
GO:0001077~transcriptional activator 
activity, RNA polymerase II core 
promoter proximal region sequence-
specific binding
6 113 3.426444 0.03028
disulfide bond disulfide bond 18 78 1.656022 0.0342
SLC6A3, GCNT7, VPREB1, TNFSF12, H2-Q8, NCAM2, OLFR477, 
PRL3D1, IL10RB, PCP4, ADAM21, IGHA, DEFB35, JAM2, IGLC2, 
CEACAM2, HTR3B, IGKV3-12
GO:0030424~axon 7 132 2.83475 0.03675
GO:0030424~axon 8 173 2.471921 0.04334
GO:0031175~neuron projection 
development
5 158 4.187379 0.03136
GO:0005739~mitochondrion 36 173 2.371245 2.02E-06
Mitochondrion inner membrane 7 186 3.334086 0.01879
GO:0031410~cytoplasmic vesicle 17 173 3.246725 7.07E-05
Transport 29 186 1.860508 0.00162
mmu04142:Lysosome 7 71 6.238744 7.91E-04 AP1S1, CLTB, LAPTM5, PSAP, SMPD1, CTSD, AP4M1
extracellular exosome GO:0070062~extracellular exosome 34 173 1.434711 0.0271
LDHB, RPL14, ALDOC, RNH1, RAB1B, UBAC1, SLC1A4, C1RA, PEF1, 
AP1S1, GPX4, ENO2, ENTPD6, PRKACA, EHD1, PSAP, AP4M1, RFNG, 
RACGAP1, ABCB6, DCTN2, JUP, RAB35, TXNDC5, SMPD1, ALDH2, 
CTSD, ABAT, VAMP2, PCSK1N, AHSA1, GSTP1, TRMT112, HIST1H3H
GO:0005794~Golgi apparatus 19 173 1.817391 0.01635
GO:0003735~structural constituent of 
ribosome
8 157 3.288222 0.01096
response to estradiol GO:0032355~response to estradiol 7 158 6.274525 8.72E-04 ETS1, OPRL1, SPRR2B, ALDH2, MBD3, WNT7A, GSTP1
GO:0006629~lipid metabolic process 11 158 2.743643 0.00685
GO:0004767~sphingomyelin 
phosphodiesterase activity
3 157 41.7707 0.00214
translation GO:0006412~translation 10 158 2.819022 0.00912
YARS, RPL14, UCP2, EIF4H, ABTB1, SLC25A38, SLC25A39, VARS, 
MRPL20, RPL29
GO:0030672~synaptic vesicle 
membrane
4 173 7.476547 0.0162
mmu04721:Synaptic vesicle cycle 4 71 7.014993 0.01844
response to hypoxia GO:0001666~response to hypoxia 6 158 3.407946 0.03142 PRMT2, ETS1, UCP2, ABAT, SOX4, DDIT4
Gene silencing by MicroRNAs
mitochondrion
cytoplasmic vesicle
Axon/Neuron Projection 
Development
RNA polymerase II transcription 
factor activity
MIRLET7F-1, MIR135A-2, ROCK1, MIR7-1, MIR9-2, MIR99A, MIR181B-
1, MIRLET7A-1, MIR221, MIR15B, MIR23A, MIR194-1, MIR194-2, 
MIR143, MIR181A-2, MIR125B-1, MIR194-2, MIR449A, MIRLET7C-1, 
MIR128-2, MIR100, MIR19B-1, MIR361, MIR505, MIR196A-2,PDCD10, 
GATA3, MIR196B, MIR218-1
ZFP518A, SOX14, TFAP2B, POU4F2, TFAP2A, EBF3, GATA3, GABPA, 
NCAM2, KCNJ6, PCP4, SLC6A3, ADAM21, HTR3B, DSCAM, RAB3A, 
SARM1, CCK, ALDOC, LRRTM1, MGLL, HTR3A, CDK5, GPRIN1, 
TBC1D24, RAB35, EHD1
ATP5D, USP30, LDHB, MRPS34, CHCHD1, ALDOC, RNF185, SOX4, 
RAB1B, PTPMT1, VARS, MRPL20, STARD6, GPX4, MTCH1, EXOG, 
PRKACA, ADCK5, GABARAPL1, PSAP, BCL2L13, ABCB6, DDIT4, 
PRELID1, SARM1, HSDL1, 1700123O20RIK, UCP2, RAB35, SLC25A38, 
ALDH2, CTSD, ABAT, SLC25A39, PDZD4, GSTP1, PTPMT1
GABARAPL1, SVOP, CLTB, TAOK2, OPRL1, ABHD2, RACGAP1, 
SYNGR3, CAMKV, AP1S1, RAB35, SEMA4C, TBC1D7, VAMP2, 
TRAF7, EHD1, CLCN7, ATP5D, RAB3A, ARFGAP2, RAB1B, SLC1A4, 
KCNQ4, LAPTM5, STARD6, MTCH1, SLC35F2, HTR3A, RLBP1, PLTP, 
UNC119B, AP4M1, ABCB6, PRELID1, UCP2, COG8, SLC25A38, 
SLC25A39, CLCN7
SULT4A1, ISYNA1, MVD, PSAP, INSIG1, MGLL, ABHD2, PTPMT1, 
AACS, PLTP, SMPD2, SMPD1, SMPD4
SVOP, SEMA4C, VAMP2, SYNGR3, RAB3A, CLTB, ATP6V0E2synaptic vesicle membrane
lipid metabolic process
G-Protein Coupled Receptor 
Signaling
OLFR1371, OLFR243, VMN2R22, OLFR314, OLFR156, VMN2R14, 
OLFR316, OLFR172, OLFR787, OLFR457, OLFR1099, OLFR113, 
OLFR765, OLFR137, MRGPRA5, OLFR767, OLFR446, OLFR692, 
OLFR477, VMN2R2, OLFR487, OLFR524, OLFR205, OLFR91
SLC16A13, ARFGAP2, GABARAPL1, B4GALT2, RAB1B, AP4M1, 
RFNG, UBAC1, ABCB6, APLP1, AP1S1, COG8, TMEM43, ENTPD6, 
PRKACA, CALN1, B4GALNT4, PCSK1N, SMPD4,  MRPS34, RPL14, 
UCP2, GM8973, SLC25A38, SLC25A39, MRPL20, RPL29
Golgi apparatus
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Table S2.5.1- Summary of dysregulated pathways in E15.5 Ts1Cje, Ts65Dn, and Dp16 embryonic forebrain. 
GO-term / KEGG pathway
Ts1Cje 
E15.5
Ts65Dn 
E15.5
Dp16 
E15.5
human chr21q22
G-protein coupled receptor signaling pathway
olfactory receptor activity
neuron differentiation
axon guidance
neuron fate commitment
dopaminergic neuron differentiation
sympathetic nervous system development
cerebellar Purkinje cell-granule cell precursor cell 
negative regulation of neuron apoptotic process
cerebellum development
cerebral cortex development
aminergic neurotransmitter loading into synaptic vesicle
amino acid transport
dopamine biosynthetic process
cell division
translation
gene silencing by miRNA
immune response
mmu04630:Jak-STAT signaling pathway
circadian rhythm
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Table S2.5- List of DEX non-Hsa21 orthologues unique to E15.5 Ts65Dn forebrain that are triplicated in 
Ts65Dn.  
Functional relevance and available transgenic mice as found in other work are included 
for reference.  
Gene 
Name
Fold Change 
Ts65Dn/WT                
E15.5 
Forebrain
Function and literature
Transgenic mice/Jax Stock 
number
Rps6ka2 1.37
* Ser/Thr kinase that acts downstream Mapk1/Erk2 and 
Mapk3/Erk1. Regulates of cell proliferation, survival and 
differentiation (Uniprot database)                                                                                                                  
* Axon growth in motoneurons (PMID 19555761)                                                     
* Tumor suppressor in epithelial ovarian cancer cells (PMID 
16878154)
No transgenic mice created
Tmem242 1.36 No information available No transgenic mice created
Tfb1m 1.35
* Methyltransferase of mitochondrial 12S rRNA (Uniprot)                                  
* Regulates apoptosis and causes inherited deafness in 
human (PMID 22341444)                                                                                                                      
* Cardiac hypertrophy (PMID 19096125)
* Stock 018021:                                      
Tg(CAG-Tfb1m) AGsha/J 
Knock-out
Fgfr1op 1.33
* Centrosome protein implicated in cell cycle regulation                                          
* Myeloproliferative syndrome ( PMID 21198859)                                                    
* Lung cancer (PMID 17888034)
No transgenic mice created
Arid1b 1.33
* Developmental delay and intellectual disability in human 
(PMID 25674384, 25356899)                                                                                                     
* Childhood neuroblastoma (PMID 23202128)                                                            
* Speech impairment and autism (PMID 21801163)
No transgenic mice created
Gtf2h5 1.32
* Cell cycle/DNA repair and meningioma (PMID 18270339)                                      
* Depression/Serotonin/Neuroegeneration (PMID 25600110)
No transgenic mice created
Scaf8 1.29
* RNA splicing (PMID 9528809)                                                                                      
* Interaction with RNA polymerase II (PMID 20818393)  
No transgenic mice created
Tulp4 1.28
* Sonic Hedge Hog signaling (PMID 21722349)                                                             
* Short stature in human (PMID 24065112)
No transgenic mice created
Serac1 1.34
 * Phosphatidyl glycerol remodeling essential for 
mitochondrial function (Uniprot database)                                                                                                         
* Mitochondrial encephalopathy in human (PMID 
25345337)                              
* MEGDEL syndrome/psychomotor delay (PMID 
24997715, 25051967)              
* Male sterility (PMID 15722415)
No transgenic mice created
Pde10a 1.32
* Synaptic plasticity/striatum (PMID 25762721)                                                            
* Progression of Parkinson disease (PMID 26210536)                                             
* Schizophrenia (PMID 21355834)                                                                            
* Huntington’s disease (PMID 19281846)
* Stock 008210: B6.D1-
Pde10atm1Pfi/J knock-out         
* Pde10a (DBA) knock-out 
(PMID 18061215)
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Table S2.6- List of DEX non-Hsa21 orthologues unique to E15.5 Ts1Cje forebrain that are monosomic in 
Ts1Cje. 
Functional relevance and available transgenic mice as found in other work are included 
for reference. 
  
Gene Name
Fold Change 
Ts65Dn/WT                
E15.5 
Forebrain
Function and literature Transgenic mice/Jax Stock number
Dnahc11 
(Translocation 
breakpoint)
9.34
* DNAHC11 is important for developmental control of 
organ positioning in the left-right axis (PMID: 10556073)                                                                                             
* Mutation in the DNAHC11 causes primary cilia dyskenesia 
characterized by bronchiectasis and upper respiratory tract 
infections (PMID: 12142464)                                                                                                 
* DNAHC11 plays an important role in selective chromatid 
segregation (PMID: 17204651)      
* Stock 018220: Dnah11b2b1775Clo/J                        
* Stock 018196: Dnah11b2b1289Clo/J                                     
* Stock 013696: Dnah11b2b1279Clo/J                                
* Stock 000773: 129T-Dnah11iv/J                   
* Stock 018237: Dnah11b2b1727Clo/J                         
* Stock 013659: Dnah11b2b598Clo/J                             
* Stock 018223: Dnah11b2b1203Clo/J                                                                         
* Stock 001045: SI/Col Tyrp1b Dnah11iv/J
Itgb8 0.63
* Most Itgb8(-/-) mice die in utero, and surviving Itgb8-/- 
mice have a severe growth delay and die by 6 weeks (PMID: 
21281793).                                                                        
* Reduced expression of ITGB8 is associated with human 
chronic obstructive pulmonary disease, cancers, and brain 
vascular malformations.
Itgb8 Knock-out
Tmem196 0.74
* TMEM196 is hypermethylated in lung cancer (PMID: 
15487509) 
* TMEM196 knockdown increases proliferation and 
inhibited apoptosis and cell-cycle arrest (PMID: 26056045) 
No transgenic mice created
Sp4 0.78
* Sp4 is highly expressed in embryos in the developing 
central nervous system (CNS). Expression in later embryos 
is detected throughout the CNS as well as in other structures 
(PMID: 8660867)                                                                                    
* Sp Knock-out mice display reduced cell proliferation in 
the hippocampus, but not cerebellum. They show decreased 
dendritic growth and arborization of dentate granule cells in 
the hippocampal cultures from knock-out mice (PMID: 
16899055)
* Stock 003119: Sp4tm1Ssp/J
Sp8 0.78
* Sp8 is a transcription factor which plays a key role in limb 
development. Sp8 regulates Fgf8 expression in the apical 
ectodermal ridge (AER) and contributes to limb outgrowth 
in embryos.                                                                        
* Sp8 regulates cell proliferation in the mid- and hindbrain 
(PMID: 16571633)                                                                                                                                   
* Transcription factor Sp8 plays an important role in the 
patterning of the developing telencephalon along the 
anteroposterior gradients of Emx2 and Pax6. Sp8 is also 
essential for the maintenance of ventral cell identity in the 
septum and medial ganglionic eminence (MGE) (PMID: 
17470284)                 
* Stock 023415: Sp8tm2Smb/J
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Table S2.7- List of affected miRNAs in Ts1Cje, Ts65Dn, and Dp16 embryonic forebrain. 
Information regarding proposed functions, targets, and upstream regulators provided by 
bioinformatics mining are included for reference.    
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Table S2.8- Continuation of list of affected miRNAs in Ts1Cje, Ts65Dn, and Dp16 embryonic forebrain. 
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Table S2.9- List of DEX genes in cortex of 6-7mo old Ts1Cje, Ts65Dn, and Dp16 males. 
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Table S2.10- List of DEX genes in hippocampus of 6-7mo old Ts1Cje, Ts65Dn, and Dp16 males. 
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Table S2.11- List of DEX genes in cerebellum of 6-7mo old Ts1Cje, Ts65Dn, and Dp16 males. 
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Table S2.12- Summary of dysregulated pathways in 6-7mo old Ts1Cje, Ts65Dn, and Dp16 brains by region. 
  
GO-term / KEGG pathway
Adult 
Ts1Cje 
Cx
Adult 
Ts65Dn 
Cx
Adult 
Dp16  
Cx
Adult 
Ts1Cje 
Hp
Adult 
Ts65Dn 
Hp
Adult 
Dp16  
Hp
Adult 
Ts1Cje 
Cb
Adult 
Ts65Dn 
Cb
Adult 
Dp16  
Cb
human chr21q22
G-protein coupled receptor signaling pathway
olfactory receptor activity
neuron differentiation
axon guidance
neuron fate commitment
dopaminergic neuron differentiation
sympathetic nervous system development
cerebellar Purkinje cell-granule cell precursor cell 
negative regulation of neuron apoptotic process
cerebellum development
cerebral cortex development
aminergic neurotransmitter loading into synaptic vesicle
amino acid transport
dopamine biosynthetic process
cell division
translation
gene silencing by miRNA
immune response
mmu04630:Jak-STAT signaling pathway
circadian rhythm
mixeddownregulatedupregulated
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Table S2.13- List of affected miRNAs in 6-7mo old Ts1Cje, Ts65Dn, and Dp16 brains by region. 
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Table S2.14- SHIRPA results in adult Ts1Cje, Ts65Dn, and Dp16 males. 
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Table S2.15- Raw data for open filed, contextual fear conditioning, and rotarod in adult Ts1Cje, Ts65Dn, and 
Dp16 males.   
Un-pooled rotarod data for Ts65Dn F1 hybrid euploid littermates are shown here. 
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Experiment 
Ts1Cje Strain Ts65Dn Strain Dp16 Strain 
Euploid Ts1Cje Euploid Ts65Dn Euploid Dp16 
E15.5 Global 
Gene 
Expression 
5 5 6 5 6 6 
E15.5 Body and 
Brain Growth 
11 13 20 7 19 26 
E15.5 
Neuroanatomy 
6 6 9 9 10 11 
E15.5 Brain 
Growth in F1 
Hybrid 
18 6 - - 9 7 
P15 
Neuroanatomy 
6 6 4 4 5 4 
Neonatal 
Behavior 
32 64 23 34 30 72 
Adult Behavior 15 13 12 12 17 18 
Adult Global 
Gene 
Expression 
5 5 5 5 5 5 
 
Table S2.16- Summary of number of subjects used per experiment. 
  
  
113 
Chapter 2.10 – Supplementary Figures 
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Figure S2.1 – Heatmap of affected genes and miRNA in embryonic and adult 
Ts1Cje, Ts65Dn, and Dp16 brains. 
(A) Heatmap showing how a subset of top 1% affected genes that cluster in manipulated 
chromosomes in Dp16 (panel 1), Ts65DN (panel 2), and Ts1Cje (panel 3).  Panel 4 
shows a schematic of these manipulated chromosomes: Mmu16 only in Dp16, Mmu16 
and Mmu17 in Ts65Dn, Mmu16 and Mmu12 in Ts1Cje. Scale shows the range of 
relative expression values. 
(B) Heatmap showing expression of miRNAs enriched in the top 1% of affected genes.   
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Figure S2.2- Brain growth and adult behavior in F1 hybrid Ts1Cje and Dp16 mice. 
(A-B) Gross brain measurements in Ts1Cje and Dp16 B6C3H hybrid E15.5 embryos. No 
change is seen compared to euploid littermates. Data are shown as mean S.E.M. Subjects 
used: n= 18 euploid, 6 Ts1Cje; n= 9 euploid, 7 Dp16. 
(C-F) Rotarod, open field, and contextual fear conditioning showing no difference 
between adult Ts1Cje B6C3H hybrid males and euploid littermates.   
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Figure S2.3- Developmental milestones in Ts1Cje males and females. 
(A)  Body weight measurements showing a consistent decrease in body weight of Ts1Cje 
pups compared to euploid littermates. 
(B) Body length measurements showing a consistent decrease in body weight of Ts1Cje 
pups compared to euploid littermates. 
(C-K) Percent of mice meeting criteria in each developmental milestone task showing 
that when males and female subjects are analyzed jointly, Ts1Cje neonates display severe 
impairment on early- and late-acquired tasks.   
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Figure S2.4- Developmental milestones in Ts65Dn males and females. 
(A) Body weight measurements showing a consistent decrease in body weight of Ts65Dn 
pups compared to euploid littermates. 
 (B-J) Percent of mice meeting criteria in each developmental milestone task showing 
that when males and female subjects are analyzed jointly, Ts65Dn neonates display 
severe impairment on early- and late-acquired tasks. 
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Figure S2.5- Developmental milestones in Dp16 males and females. 
(A)  Body weight measurements showing a consistent decrease in body weight of Dp16 
pups compared to euploid littermates. 
(B) Body length measurements showing a consistent decrease in body weight of Dp16 
pups compared to euploid littermates. 
(C-K) Percent of mice meeting criteria in each developmental milestone task showing 
that when males and female subjects are analyzed jointly, Dp16 neonates display severe 
impairment only on late-acquired tasks and perform better than euploid on the cliff 
aversion task.  
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Figure S2.6- Developmental milestones in female Ts1Cje, Ts65Dn, and Dp16 
neonates. 
Graphs showing day on which criteria was met on each task in trisomic mice compared to 
euploid littermates. Notably, Ts65Dn females show a much milder (if any) phenotype 
compared to male Ts65Dn neonates. Mean data are shown ± S.E.M, *p<0.05. 
(A) On surface righting, no trisomic mice show impairment.   
(B) On negative geotaxis, only Ts65Dn and Dp16 show an impairment compared to 
euploid littermates.  
(C) On forelimb grasp, all trisomic mice perform similarly to their euploid littermates.  
(D) On cliff aversion, Ts1Cje and Ts65Dn show a significant impairment, while Dp16 
show an improvement (n.s.) compared to euploid littermates. 
(E) On open field, all trisomic mice perform similarly to their euploid littermates.  
(F) On eye opening, Ts1Cje and Ts65Dn mice perform similarly to their euploid 
littermates, but Dp16 show a delay in opening their eyes compared to euploids.  
(G)  On air righting, Ts1Cje and Dp16 mice show an impairment compared to euploids.  
(H)  On auditory startle, Ts1Cje and Dp16 show an impairment compared to euploids.  
(I) On ear twitch, Ts1Cje and Dp16 show an impairment compared to euploid 
littermates.  
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Figure S2.7- Expanded MWM and open field training in adult Ts1Cje, Ts65Dn, and 
Dp16 males.  
(A-I) More detailed MWM data showing probe trials following the acquisition and 
reversal learning phases. In these tests, the platform is removed and the percent of time 
spent in each quadrant is analyzed. Both Ts65Dn and Dp16 show decreased time in the 
correct quadrant (where the hidden platform was in previous trials) compared to euploids. 
Ts1Cje mice show no impairment in these probe trials.  
(J-L) Acclimation to the open field chamber prior to testing shows that Ts65Dn travel 
more distance than euploid littermates. This is unlike Ts1Cje and Dp16 males who 
perform similarly to their euploid littermates.  
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CHAPTER 3: ANALYSIS OF SPINAL CORD DEVELOPMENT AND 
CYTOARCHITECTURAL ORGANIZATION OVER THE LIFESPAN OF THE 
TS65DN MOUSE MODEL OF DOWN SYNDROME 
The work presented below is the result of a collaborative effort by Nadine Aziz and Dr. 
Luis Olmos Serrano.  
 
Specific experimental contributions by Nadine Aziz are as follows: 
 Animal husbandry, tissue generation, and tissue processing for all embryonic 
Ts65Dn spinal cord experiments 
 Animal husbandry tissue generation, and tissue processing for all postnatal 
Ts65Dn experiments  
 Gene expression and immunohistochemical analyses of Ts65Dn at all ages  
except for quantification of Nodes of Ranvier at P30 (Figure 3.3D) 
 Postnatal behavioral experiments (1 of 2 cohorts) 
 
Chapter 3.1 – Introduction  
Down syndrome (DS) is one of the most prevalent developmental disorders world-wide. 
In the United States, DS occurs with an incidence of approximately 1 in 793 live births 
and underlies profound cognitive and motor impairments as well as idiosyncratic general 
health complications 3, 218. While the etiology of these observed deficits is likely to arise 
from the dosage imbalance of the 550 genes present on the supernumerary copy of 
chromosome 21, the contribution of individual genes has thus far been extremely 
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challenging to uncover207, 258. This is primarily due to the inability to study single gene 
dysregulations within the complex genetic landscape of trisomy where cis and trans 
epigenetic regulation contributes to the manifestation of phenotypes associated with the 
syndrome221. Notably, by investigating the transcriptomes of identical twins discordant 
for DS, recent studies have uncovered a widespread dysregulation in gene expression 
organized in domains along all chromosomes224 pointing to vast and chromosomally-
unrestricted genetic abnormalities. Additionally, necessary genetic manipulation to target 
individual genes in context cannot be conducted in human patients, creating a reliance on 
mouse models to sustain the majority of DS research in the laboratory. By exploiting the 
synteny between human chromosome 21 (Hsa21) and segments of murine chromosomes 
(Mmu) 16, 17, and 10, several mouse models of DS have been developed and 
successfully utilized to study central nervous system (CNS) aberrations259. Of these, the 
Ts65Dn is the most widely used and best characterized model to date.  
 
Importantly, Ts65Dn mice exhibit many phenotypic similarities to individuals with DS. 
Of relevance to this study are phenotypes arising from CNS abnormalities, specifically 
cognitive and motor deficits. While cognitive deficits tend to be rather profound, 
alterations in motor behavior are more subtle and nuanced but are still quite impactful on 
the quality of life of individuals with DS. As such, work focused on the etiology of DS-
related motor deficits is essential and yet largely scarce, with an overwhelming majority 
solely focused on the cerebellum137, 260-262. While the cerebellum is a logical and proven 
source of motor dysfunction in DS, recent work has showed that rescuing cerebellar 
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volume and hypocellularity did not improve motor function or motor learning260. Thus, a 
shift in focus to include other motor control centers within the CNS is now necessary. 
Furthermore, a gene critically involved in the formation of the spinal cord (SC)95, known 
as Oligodendrocyte transcription factor 2 (OLIG2), is triplicated in both people with DS 
and mouse models of DS250. The triplication of OLIG2 coupled with its role in SC 
development and function points to the necessity of an interrogation of the SC in the 
context of DS. This idea is further supported by a small body of work on: 1) cultured 
dorsal root ganglion neurons from fetuses with DS263; and 2) cultured spinal cord neurons 
(mixed culture) from another mouse model of DS known as the Ts16264. Data from these 
studies indicate that, as a result of aberrant calcium signaling, passive and active 
electrical properties are altered in trisomic fetal spinal neurons cultured from both human 
fetuses and Ts16 embryos263-265. Furthermore, acetylcholine synthesis was shown to be 
dysregulated in cultured spinal cord neurons from Ts16 mice266. Thus, due to: 1) the 
global lack of substantial work on the SC in DS to expand on data outlining cellular 
defects found in culture; 2) the reported non-reversal of motor deficits in response to 
cerebellar-specific therapies; and 3) the foundational role that OLIG2, a gene on Hsa21, 
plays in SC development and neuron fate commitment, this study is the first to focus on 
the link between SC morphogenesis and maturation, the specific role of OLIG2 (and its 
close relative OLIG1) triplication in SC development and function, observed motor 
deficits in the Ts65Dn mouse model of DS, and reported motor deficits in people with 
DS.  
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As mentioned above, congruencies in motor behavior exist between both people with DS 
and the Ts65Dn mice. Extensive studies demonstrate that individuals born with DS 
exhibit disturbances in movement production and postural control, and are severely 
hypotonic during early postnatal development244, 267, 268. As such, acquisition of motor 
skills is significantly delayed in DS patients, negatively impacting their gait and fine 
motor control throughout the course of their lives268. Notably, children with DS exhibit 
clumsy sequences of movements; poor motor control, timing, and force; and delays in 
achieving motor developmental milestones related to grasping, rolling, sitting, standing, 
and walking269. Similarly, Ts65Dn mice exhibit several motor abnormalities related to the 
use of fore- and hind-limbs for stride production and walking270. Furthermore, many 
indices of gait dynamics in Ts65Dn mice correspond to previously reported findings in 
children with DS270, validating the use of this mouse model to study the link between SC 
abnormalities and motor deficits in DS.  
 
By focusing on OLIG2 and OLIG1, the current work can begin to elucidate the molecular 
players involved in SC abnormalities seen in DS. OLIG1/2 are closely related 
transcription factors originally thought to be glial-specific genes271. As members of the 
helix-loop-helix family of transcription factors, OLIG gene products have been shown to 
regulate progenitor identity in the ventral SC in response to a sonic hedgehog (SHH) 
gradient124. Both transcription factors are co-expressed in parts of the neuroepithelium of 
the embryonic spinal cord as well as the telencephalon271. These genes are then 
subsequently expressed throughout the life of oligodendroglia271.  
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In the SC, the OLIG2+ progenitor domain (known as the pMN domain), which arises in 
the ventral neural tube of developing embryos, gives rise to a bipotential population of 
cells that can differentiate into either motor neurons (MNs) or oligodendrocytes (OLs)92, 
95. Spinal MNs are the lowest point of motor control whose projections directly synapse 
onto muscle fibers. Generally, information from cortical and subcortical upper motor 
control centers is consolidated within the SC, and in turn, innervation of muscle by the 
spinal MN is achieved. Upon differentiation, MNs migrate away from the midline to the 
gray matter of the ventral SC, known as the ventral horn (VH), where they partake in 
local networks with interneurons (INs) and also send long-range axons to muscles in a 
topographical manner. On the other hand, while OLs also originate in the ventral SC, 
they migrate through several migratory streams to form several distinct SC white matter 
tracts. Even though both OLIG1 and OLIG2 are co-expressed in this bipotential 
population, only loss of OLIG2 causes a loss of the pMN domain121. OLIG2 selectively 
heterodimerizes, first with the NGN2 transcription factor to allow MN differentiation 
from neuroepithelial progenitor cells (NEPs), then with the NKX2.2 transcription factor 
to allow for the commencement of oligodendrogenesis95, 105, 110, 272. Thus, OLIG2 acts as a 
master switch in the designation and proper allocation of MNs and OLs and is therefore 
essential in the laying of a functional landscape of neural circuits within the cord. 
Furthermore, due to cross-repressive signals to define strict boundaries between 
progenitor domains273, studies show that altered expression of OLIG2 impacts the cells 
that comprise the ventrally and dorsally adjacent progenitor domains121. These cells are 
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marked by the expression of the NKX2.2 and IRX3 transcription factors, and give rise to 
several classes of INs92.  Importantly, OLIG2 is the only major determinant of cell fate 
within the SC that belongs to Hsa21 and Mmu16 and is thus triplicated in both DS 
patients and Ts65Dn animals.  
 
By crossing Ts65Dn animals with Olig1/2+/- heterozygotes to specifically correct the 
gene dosage of both Olig genes, we can explore the impact of these two closely-related 
genes on SC development in the context of trisomy. While OLIG1 and OLIG2 both mark 
the pMN domain in early and mid-embryogenesis, only ablation of Olig2 results in 
complete loss of this domain and subsequent absence of spinal MNs and OLs101, 120, 274. 
On the contrary, Olig1 loss has only a mild impact on proper development of the SC124. 
In fact, recent work in Olig1-/- mutants has shown that OLIG1 is non-essential in the 
production, maturation, and function of spinal MNs and both spinal and cortical OLs121, 
271. Thus, since only OLIG2 loss perturbs progenitor populations, we believe that the 
contribution of OLIG1 to SC morphogenesis is minimal.   
 
Studies have shown that timing of neurogenesis further contributes to the diversification 
of neuronal and glial populations in the SC116. Along with dorsoventral morphogen 
gradients affecting transcription factor expression, birthdating experiments show that 
dorsoventral and rostrocaudal temporal gradients of neurogenesis specify neuronal 
subtypes, especially in locomotor circuits within the SC116-118. This birthdate-dependent 
generation of spinal cord cellular populations is further illustrated by the sequential 
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generation of MNs and OLs from the pMN domain in the ventral cord106, 119-122. Studies 
show that due to combinatorial transcription factor expression and differential 
phosphorylation states of serine 147 in the OLIG2 protein, MNs are first generated from 
NEPs within this domain from E9.5 (5 gestational weeks in humans) to approximately 
E11.5, then on E12.5 oligodendrogenesis begins122. Thus, systematic temporal analysis is 
essential to identify dynamic changes in neuro- and glio-genesis occurring early in SC 
development.  
 
To date, no other study has recognized the link between the SC and the observed motor 
abnormalities in individuals with DS. Because the SC has been largely overlooked in the 
DS field, this work is the first to elucidate the role of the SC in DS-related motor deficits. 
Additionally, by targeting the Olig genes, we present a possible molecular player 
underlying the motor deficits in DS with potential for therapeutic exploitation to correct 
such debilitating and impactful life-long deficits.  
 
Chapter 3.2 – Materials and Methods 
Colony Information and Mouse Breeding 
All murine experiments were conducted according to international ethical standards and 
approved by the Institutional Animal Care and Use Committees (IACUC) of Boston 
University. Animals were housed in cages with standard bedding and a nestlet square. 
Rodent chow and water were available ad libitum. The colony was maintained on a 12:12 
light/dark cycle, with lights on at 7:00 AM. 
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B6EiC3Sn.BLiA-Ts(1716)65Dn/DnJ (Ts65Dn; stock number 005252) mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME). Ts65Dn female mice were 
bred with B6EiC3Sn.BLiAF1/J (F1 hybrid; stock number 003647) males. The parental 
Olig1/2+/- heterozygous mice were a gift from Dr. David Anderson. Gene dosage rescue 
animals were generated as follows: 1) by crossing C57BL/6JN Olig1/2+/- heterozygous 
females to a C3SnHeSnJ euploid male to generate an B6EiC3Sn.BLiAF1/JN F1 
generation, then 2) by crossing male Olig1/2+/- B6EiC3Sn.BLiAF1/JN hybrid filial with 
Ts65Dn females to generate Ts65DnOlig1/2+/+/- B6EiC3Sn.BLiAF1/JN 
(Ts65DnOlig1/2+/+/-) animals. 
 
Studies were performed at embryonic days (E) 12.5, 14.5, 16.5, at postnatal days (P) 15, 
30, 60, and in older animals at 10-11 months of age. 
 
Genotyping 
Phenol/chloroform DNA extraction was performed on embryonic limb buds or postnatal 
tail clippings after digestion with proteinase K (Denville Scientific). Genotyping and 
determination of sex were performed by PCR using primers specific for the Ts65Dn 
Mmu16/17 translocation breakpoint (Reinholdt et al., 2011), the SRY region, GFP and 
LacZ that are present only in heterozygous Olig1/2+/- animals, and an internal positive 
control to ensure the success of each reaction (Table 3.1). 
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Tissue Collection 
Embryonic Spinal Cord Collection- Gene Expression 
Breeding pairs were established so that vaginal plugs could be checked twice daily. The 
presence of a vaginal plug was designated as E0.5. A 10% weight gain at E10 was used 
to confirm pregnancy 194. Pregnant dams were euthanized at desired ages. Embryos were 
extracted, identified as the correct embryonic age using Theiler staging 
(http://www.emouseatlas.org) and decapitated in ice-cold DEPC-treated 1x phosphate 
buffered solution (PBS). Embryonic SCs were rapidly removed from the developing 
spinal column and snap frozen in liquid nitrogen before storage at -80°C. Prior to 
dissections, all surfaces and tools were treated with an anti-RNase solution. 
 
Embryonic Spinal Cord Collection- Histology/Neuroanatomy 
Embryos resulting from timed-pregnancies were collected, viscera and limbs were mostly 
removed, and embryos were fixed for 1-2h in 4% paraformaldehyde (PFA) at 4°C. 
Embryos were then washed three times in 1x PBS, placed in 30% sucrose for 16-24h at 
4°C, then frozen in Optimal Cutting Temperature Compound (OCT; Sakura, Torrance, 
CA). Tissue blocks were stored at -80°C until use. 16μm thick serial coronal sections 
were cut using a cryostat, mounted on Superfrost® Plus charged slides (Fisher Scientific), 
and stored at -80°C. 
 
Adult Tissue Collection- Gene Expression 
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For adult gene expression studies, P60 male mice were anesthetized with 2.5% isoflurane 
in a 3/7 O
2
/N
2
O mixture and euthanized by decapitation. SCs were removed from the 
spinal column, placed into ice-cold DEPC-treated 1xPBS, then dissected into cervical, 
thoracic, lumbar, and cervical segments. SC subsections were then snap frozen in liquid 
nitrogen and stored at -80°C. Prior to dissections, all surfaces and tools were treated with 
an anti-RNase treatment. 
 
Postnatal Spinal Cord Collection- Histology 
Male mice were anesthetized with a xylazine/ketamine cocktail according to IACUC 
regulations. Mice were transcardially perfused with 4% PFA in 1x PBS, SCs were 
extracted, and post-fixed for 16h in 4% PFA at 4°C. SCs were then prepared as described 
above.  
 
Gene Expression Studies 
For gene expression studies, total RNA was isolated from the developing forebrain using 
Trizol® following the manufacturer’s instructions (Thermo Fisher Scientific, MA). 
Genomic DNA was first removed using DNase Treatment and Removal Kit. Purified 
RNA was quantified then reverse-transcribed into cDNA using High Capacity cDNA 
Reverse Transcription Kit per manufacturer’s instructions (Thermo Fisher Scientific, 
MA). qRT-PCR was then achieved using SYBR® Green reagents (Thermo Fisher 
Scientific, MA) and validated QuantiTect exon-spanning primers for genes of interest 
(Qiagen, GER). Trisomic and euploid samples from the same cohort were analyzed side 
  
137 
by side to avoid batch errors. All values were first normalized to the housekeeping gene 
GAPDH, then presented as a relative quantity (RQ) of euploid samples. N=3-6 was used 
per genotype and data are shown as mean ± SE. A Student’s t-test was used to assess 
significance at p<0.05.   
 
Immunohistochemistry 
When necessary, depending on the tissue-penetrance and antigen recognition ability of 
the antibody used, antigen retrieval was performed by microwaving slides in 10 mM 
sodium citrate buffer for 1 min at maximum power, followed by 10 min at minimum 
power. Slides were then washed in 1x PBS and incubated in blocking solution (5% 
normal donkey or normal goat serum, 0.2% Triton® X-100 in 1x PBS) for 1h at room 
temperature. This was followed by incubation in primary antibody overnight at room 
temperature. Slides were washed 3 times in 1x PBS and incubated with secondary 
antibody solution for 1h at room temperature. Slides were mounted in Vectashield with 
DAPI (Vector Laboratories). Primary antibodies used: rabbit anti-Oligodendrocyte 
Transcription Factor 2 (1:300, Millipore, AB9610), rat anti-Somatostatin (1:50, 
Millipore, MAB354), rabbit anti-Parvalbumin (1:1000, Swant, PV25), rabbit anti-
Calretinin (1:1000, Swant, 769913), mouse anti-Hb9 (1:10, DSHB, 81.5c10-s), rabbit 
anti-Islet 1 (1:300, Abcam, AB20670), goat anti-Choline Acetyltransferase (1:50, 
Millipore, AB144p), mouse anti-Nkx6.1 (1:50, DSHB), mouse anti-CC1/APC86 (1:500, 
Calbiochem, OP80), guinea-pig anti-NG286 (1:2000, gift from Dr. William Stallcup), 
CASPR and NF186 (gifts from Dr. Manzoor Bhat, used according to previously 
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published protocol189). Secondary antibodies (1:250 dilution, Thermo Fisher Scientific): 
donkey anti-rabbit 555 (A31572), donkey anti-goat 488 (A11055), donkey anti-mouse 
488 (A21202), goat anti-rabbit 546 (A11035), goat anti-rabbit 488 (A11008), goat anti-
Guinea pig 546 (A11074), and goat anti-rat 488 (A11006). 
 
Confocal Microscopy and Cell Population Analysis in Embryonic and Postnatal Tissue 
All sections were imaged using a Zeiss LSM 710 confocal microscope system (Carl 
Zeiss, GER). Sixteen 1μm thick z-stacks (1024x1024 resolution) of each region of 
interest were acquired using a 20x objective (N.A=0.8). Labelled cells were then either 
automatically counted using Volocity (Improvision) software following manual 
validation of randomly selected samples, or manually counted using ImageJ and LSM 
Image Browser software. In postnatal tissue, analysis was limited to the ventral portion 
(as determined by bisecting the central canal), dorsal corticospinal tract (DCST), and 
lateral funiculus (LF) of the lumbar spinal cord. In embryonic tissue, more mid to caudal 
portions of the SC were imaged. DAPI staining was used to determine neocortical and 
hippocampal layer boundaries.  
 
Behavioral Studies  
Motor coordination and strength were assessed using the hindlimb reflex task and the 
hanging wire task as previously described189. All experiments were conducted in the light 
phase between 10:00 AM and 1:00 PM. All behavioral tests were performed blindly 
without prior knowledge of genotype. Care was taken to minimize animal stress by 
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allowing a standard period of habituation to the testing room each day prior to the start of 
testing. Additionally, spatial and olfactory cues were minimized by utilizing the same 
area of testing and cleaning with ethanol after each use by an animal. N=4-8 subjects per 
genotype were used. Two separate cohorts were used for this study- 1) animals from a 
Ts65Dn x euploid cross; and 2) animals from a Ts65Dn x Olig1/2+/- cross.  
 
Statistical Analysis 
For all assessments, unpaired Student’s t-tests were performed to determine statistical 
significance between trisomic animals and their euploid controls. All data points were 
included except those deemed as outliers using Tukey’s boxplot method. Statistical 
significance was reached with a p-value < 0.05. 
 
Chapter 3.3 – Results 
In order to assess the cell populations in Ts65Dn SC that may be impacted by perturbed 
Olig2 expression, we focused on subsets of postmitotic cells that arise from the OLIG2+ 
progenitor domain as well as the progenitor domains directly adjacent to it that are 
marked by Nkx2.2 and Irx3 expression (Figure 3.1A). We further limited our scope to the 
ventral portion of the lumbar SC to specifically analyze neuronal populations that 
participate in CPGs and produce motor output related to locomotion. We also sampled an 
ascending and a descending white matter tract, the LF and DCST, respectively, to analyze 
OL maturation within the lumbar SC. Utilizing a combinatorial screen dependent on 
markers of cell identity and/or function, we designed a comprehensive assessment over 
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the lifespan of Ts65Dn mice to interrogate SC development and cytoarchitecture (Figure 
3.1B). Additional experiments utilizing Ts65DnOlig1/2+/- mice allowed us to specifically 
isolate the role of OLIG1/2 in motor function of trisomic mice (Figure 3.5).  
 
At P60, gene expression analysis showed a 2.0±0.5-fold relative expression of Hb9 in 
Ts65Dn whole SC preparation compared to euploid littermates (Figure 3.2A). At this 
time, Irx3 expression was 0.58±0.04-fold that of euploid littermates, while Olig2 gene 
expression was unchanged (Figure 3.2A). Immunohistochemical staining of choline 
acetyltransferase (ChAT) in the ventral horn (VH) of the lumbar SC trended towards a 
decrease in Ts65Dn mice (Figure 3.2B-C).  No change was seen in Parvalbumin (PV) or 
Calbindin (CB) immunoreactive ventral INs. Interestingly, while the MN decrease was 
not statistically significant at P60, by 10-11 months of age, the number of ChAT+ MNs 
became significantly decreased along with the number of CB+ INs in the VH (Figure 
3.2E). Previous work has shown that CB specifically marks a subset of V1 INs known as 
Renshaw cells118, 275. These cells are known to participate in local networks that lead to 
recurrent inhibition loops involving MNs276, 277. The coincident decrease in both cell 
populations in 10-11 month Ts65Dn SCs may or may not be related, but it suggests that 
at least two cell types within the spinal CPGs are defective. In contrast, Calretinin (CR) 
and PV immunoreactive ventral INs were unchanged in Ts65Dn SCs (Figure 3.2E). 
 
Along with neurons, oligodendroglia also participate in proper function of the SC. Due to 
the major contribution of OLIG1/2 to differentiation and maturation of OLs, and recent 
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work highlighting OL maturation defects in Ts65Dn brains and in brains from individuals 
with DS158, we assessed OL maturation and white matter properties in Ts65Dn SCs. 
Using OLIG2 as a marker of all OLs in the DCST, we quantified the CC1+/NG2-  mature 
OL population and the CC1-/NG2+ immature OL population in Ts65Dn SCs (Figure 
3.3A). Data showed that at P30 and P60 overall number of OLIG2+ OLs in the DCST did 
not differ between Ts65Dn mice and euploid littermates (Figure 3.3C). However, at P30 
there was a 16.3±8% decrease in mature OLs and at P60 there was a 4.1±1.6% shift in 
favor of immature OLs in Ts65Dn SCs (Figure 3.3C).  Along with the maturation block 
in OLs, disorganization in the Nodes of Ranvier was observed at P30 in Ts65Dn DSCT 
and LF (Figure 3.3D). Quantification of the number of nodes and paranodes in a coronal 
section of SC uncovered a marked decrease in Ts65Dn compared to euploids (Figure 
3.3D). Further analysis is necessary to better characterize whether this deficit is related to 
misexpression of proteins necessary for proper nodal organization, improper nodal 
distribution, or overall loss of myelination. Gene expression data of Caspr and Nf186 
showed that there was no change in relative abundance of transcript of either gene in P60 
Ts65Dn whole SC preparation (Figure 3.3E).   
 
Analysis of SC morphogenesis during embryonic development showed that irregularities 
in spinal populations arise as early as E12.5 (Figure 3.4 and S3.1). OLIG2 
immunohistochemical staining of E12.5 SC showed a qualitative increase in size the 
pMN domain in Ts65Dn mice (Figure 3.4A-A’). Quantification of the OLIG2+ 
progenitors at this age showed an approximate 1.5-fold increase in cell number in 
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Ts65Dn cords (Figure 3.4B). This was accompanied by a similar increase in gene 
expression of Olig2 and a 1.3-fold increase in gene expression of Hb9 (Figure 3.4C). 
Interestingly, no changes were seen in gene expression of Nkx2.2 and Irx3 (Figure 3.4C). 
By E14.5, gene expression of Olig2 and Hb9 returned to euploid levels, yet expression of 
Nkx2.2 in Ts65Dn cords decreased to 0.8-fold that of euploids (Figure 3.4D). 
Collectively, these data show that early changes in gene expression and progenitor 
populations are taking place in Ts65Dn SCs and that these changes are dynamic in 
nature.  
 
Since widespread and temporally dynamic changes were observed in Ts65Dn SCs during 
development and in adulthood, measures of motor behavior were needed to better 
characterize motor dysfunction. We chose to test motor strength which engages all motor 
control systems within the CNS, and reflexive behavior which is largely independent of 
cortical motor control (Figure 3.5A-B’). Both the hanging wire and the hindlimb reflex 
tasks showed a defect in Ts65Dn mice (Figure 3.5A’-B’). Furthermore, in order to test 
whether Olig1/2 gene dosage plays a role in the observed motor phenotype in trisomic 
mice, we repeated the hindlimb reflex and hanging wire tasks in euploid, Ts65Dn, 
Olig1/2+/-, and Ts65DnOlig1/2+/+/- animals resultant from the Ts65Dn x Olig1/2+/- cross. 
As seen from our other Ts65Dn cohort, a significant defect was observed in Ts65Dn mice 
from this cohort while no change was seen in Olig1/2 heterozygotes (Figure 3.5C-D). 
Importantly, a partial correction of phenotype was observed in animals (Figure 3.5C-D, 
white bars).  
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Chapter 3.4 – Discussion 
SC organization is known to be extremely stereotyped. During development, positions of 
MN soma in the spinal cord become organized based on the relative position of target 
muscles112, 113. This musculotopic patterning of the cord is intrinsic and depends on 
genetic cues that determine neuronal subtype identity as well as establish a pattern of 
migration and connectivity112, 114, 115. Therefore, subtype-specific expression of 
transcription factor codes is integral for proper organization and function of the SC. 
Importantly, the central pattern generators (CPGs) that drive stereotyped locomotor 
behavior are dependent on proper wiring and firing of all classes of ventral interneurons 
that then send inputs, directly or indirectly, to MNs112, 278-280. In fact, each subclass of INs 
within the CPG circuit governs a specific modular aspect of locomotion and proper 
concerted firing of all is integral for successful motor output112, 281, 282. Additionally, 
spinal INs stratify in different ways than cortical INs do, typically spanning multiple 
categories of classification (e.g., based on transcriptional, spatial, functional, and 
neurotransmitter properties)283. In fact, unlike cortical INs, spinal INs can form long-
range as well as local connections116.This illustrates the necessity of perfectly tuned gene 
expression as well as other patterning cues to the functional output of spinal circuitry. IN-
MN connections are also integral in sensing and correcting muscle tone as well in 
reflexive behaviors284, 285. Therefore, due to their essential roles in SC CPGs, reflexes, 
and muscle tone regulation, we elected to analyze ventral IN and MN populations in the 
SC. 
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Our data show that gene expression abnormalities exist in P60 Ts65Dn mice. At this age 
neuronal and glial cells in the SC are postmitotic, and neuronal populations are fully 
mature. Relative expression of Hb9 is 2-fold in Ts65Dn mice compared to euploid 
littermates while relative expression of Irx3 is approximately half. Although Olig2 
expression is unchanged at this age, the data suggest that the trisomic genetic landscape 
in Ts65Dn has: 1) generated an ectopic HB9+ neuronal population at the expense of the 
IRX3+ interneuronal populations, 2) increased expression of Hb9 in cells derived from 
the pMN domain and decreased expression of Irx3 in cells arising from progenitor 
domains dorsal to pMN, 3) created spatial abnormalities in multiple regions of the SC 
(this may be a confound since gene expression results are from whole cord homogenate), 
or 4) disallowed the downregulation of Hb9, which was previously shown to be important 
for the allocation of maturing MNs to specific motor columns109. To further explore these 
possibilities, future studies should sample other regions of the SC along its rostrocaudal 
axis and quantify HB9+ and IRX3+ cell populations and their mediolateral/dorsoventral 
distribution patterns within coronal SC slices.  
 
Initial studies of MN and IN population have yielded interesting data. Mainly, our work 
shows that while at P60 there are no changes in ChAT+ MNs or in ventral IN populations 
expressing PV and CB, both MN and CB+ cell population numbers are decreased in 10-
11 months old Ts65Dn SCs. This cellular loss may either be due to degeneration as a 
result of the accelerated aging commonly associated with DS, or it may be due to a 
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cellular loss/reorganization as a result of a decrease in the amount neuromuscular 
junctions and/or target muscles. Muscular abnormalities have been observed in older 
Ts65Dn mice286. As such, loss of muscle fibers may create a feedback mechanism to 
promote loss or reorganization of innervating circuitry. This concept is commonly 
observed in development and as a result of injury287-290.  
 
Further analysis of adult SC tissue in Ts65Dn mice showed that a block in OL maturation 
occurs in these mice. This is seen at both P30 and P60 in the DCST at lumbar levels. An 
increase in the number of OPCs and/or immature OLs at the expense of mature and/or 
myelinating OLs is observed. This shift in population is also accompanied by a decrease 
in the number of nodes of Ranvier. One major limitation to the methods utilized to count 
these nodes arises from the plane of the sections in which the nodes were analyzed. 
Coronal sectioning of the SC unavoidably cuts through white matter tracts that run along 
the rostrocaudal axis of the body. This in turn disallows the proper quantification of 
internodal distance and nodal distribution along each tract. Disorganization in nodal and 
paranodal domains may also be taking place. Gene expression analysis of Caspr and 
Nf186 show no changes in Ts65Dn whole cords compared to euploid littermates. This 
indicates that translational or post-translational modifications may be playing a role if 
changes in protein products are occurring.  
 
Analysis of SC development during gestation indicates that there is a possible embryonic 
origin to the population deficits seen in mature Ts65Dn animals. By E12.5 when 
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neurogenesis and specification of MNs has ended, there are already alterations in the size 
of the OLIG2+ pMN progenitor domain and in the number of OLIG2+ cells.  Gene 
expression aberrations in Olig2 and in the MN marker Hb9 at E12.5 further illustrate that 
changes in this particular population are taking place in Ts65Dn SCs. By E14.5, Olig2 
and Hb9 expression is normalized. This is perhaps due to compensatory downregulation 
of transcription of these genes or loss of ectopic neurons that arose from previous 
expression of these genes. In contrast, the observed decrease in Nkx2.2 expression, a 
marker of the ventrally adjacent progenitor domain, at E14.5 may be a sign of increased 
cross-repression of the V3 IN cellular identity designated by this domain.  This cross-
repression typically exits to create strict boundaries between progenitor domains to 
disallow hybrid cell identities272, 273, 291. In order to better understand the dynamic 
changes taking place during this significant time in development, several experiments are 
still needed (see Future Directions below). Despite the necessity of more in-depth 
analyses of embryonic SC tissue in Ts65Dn mice, data already indicate a dysregulation in 
patterning genes. Coupled with the reported decrease in mitogenic response of Ts65Dn 
mice to SHH during CNS development137, 260, 292, our work indicates that abnormal 
dorsoventral patterning of the SC as a result of increased OLIG2+ cells is taking place. 
This embryonic defect may underlie the abnormal cellular composition in mature cords 
and the deficits in reflexive behavior and motor strength. Our data further pinpoint a 
possible link between the dynamic changes in gene expression and observed cellular and 
behavioral phenotypes in a way that is temporally restricted, i.e. life-stage specific. 
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To determine whether SC changes in Ts65Dn are specifically due to Olig2 expression, 
gene dosage rescue animals were generated. The animals are identical to Ts65Dn mice 
but contain only two alleles for Olig1/2. Utilizing this cohort of animals, we show that 
partial rescue of motor function is achieved when Olig1/2 dosage is normalized. While 
these data are promising, more cellular-level analyses are needed. Furthermore, 
limitations in the study design must be considered when interpreting the data. Chiefly, 
data may be confounded by the fact that restoration of Olig1/2 dosage is occurring in 
tandem and in a non-tissue specific manner. Therefore, a conditional knockout (cKO) of 
only Olig2 is needed in order to definitively determine its role in SC development in 
Ts65Dn mice. Once this is achieved, temporally-restricted SC changes should be 
investigated utilizing cKO of Olig2 at distinct time points over the lifespan of Ts65Dn 
mice. 
 
Chapter 3.5 – Future Directions 
A more comprehensive assessment of NKX2.2+, OLIG2+, AND IRX3+ cells is 
necessary, starting at E10.5 when only motor neurons are generated from pMN 
progenitors, continuing onto E12.5 and E14.5 when oligodendrogenesis is taking place, 
and ending at E16.5 when no new cells are generated from ventral progenitor domains96, 
122, 293. Detailed quantification of cell numbers can offer evidence of impactful shifts in 
populations. Additionally, analysis of apoptotic waves can show whether ectopic cells are 
lost or maintained as postmitotic neurons and glia. Determination of physical size of each 
progenitor domain may also be useful for understanding patterning defects during 
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embryonic SC formation. In addition, time-lapse imaging of live SC tissue is necessary to 
track migration patterns and terminal locations of neuronal and glial subtypes that may be 
unique to the trisomic cord. Expanded gene expression analysis is also necessary. 
Additional markers for subclasses of INs are available and these should prove 
advantageous in pinpointing the exact populations that may be perturbed as a result of 
trisomy. Importantly, DNA/chromatin binding properties, microRNA interactions, as well 
as phosphorylation status of Olig2 and other pertinent transcription factors should be 
determined in order to better understand the molecular etiology underlying observed 
cellular phenotypes.  
 
More detailed postnatal analyses of affected cellular groups is also still needed. This 
should be coupled with functional readouts of the SC. One example of a powerful 
functional assay is the use of explants showing single neuron-muscle connections to 
investigate cell-autonomous defects in MNs. Slice cultures and primary cell cultures are 
additional in vitro methods that can shed light on functional defects specific to MNs. 
Larger scale functional studies relying on electrophysiology to show excitation/inhibition 
patterns and conduction velocity in axons whose myelin may be altered in Ts65Dn SCs, 
would also be beneficial. Moreover, to better characterize the myelin defects in Ts65Dn 
SCs, ultrastructural information via electron microscopy is needed. Furthermore, 
pharmacological promotion of myelination and differentiation of OPCs could also be 
used to analyze the role that the block in maturation plays in behavioral and functional 
abnormalities in Ts65Dn mice (Appendix A).   
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Finally, all cellular, molecular, and functional experiments should be repeated in 
Ts65DnOlig1/2+/+/- mice to assess whether gene dosage normalization of Olig1/2 
ameliorates observed SC phenotypes. 
 
Chapter 3.6 – Conclusions  
Overall, our data uncover cellular and molecular SC alterations that occur during 
development and present a potential target for therapeutic intervention. Disproportionate 
cellular representation of MNs and IN subtypes has wide implications for organization of 
locomotor CPGs in the cord. Moreover, OL dysfunction in SC mimics that observed in 
brains of people with DS and in Ts65Dn mice, pointing to a CNS-wide defect. Due to the 
severity and impact of motor dysfunction on cognition and on the quality of life of people 
with DS, this novel study has major implications for interventional approaches aimed at 
improving CNS development and general health in people with DS. 
  
  
150 
Primer Name Primer Sequence 
Ts65Dn Chr17 Forward GTGGCAAGAGACTCAAATTCAAC 
Ts65Dn Chr16 Reverse TGGCTTATTATTATCAGGGCATTT 
LacZ Forward CCAGCTGGCGTAATAGCGAA 
LacZ Reverse CGCCCGTTGCACCACAGATG 
GFP Forward GAGAGGGTGAAGGTGATGCC 
GFP Reverse CGGGTCTTGTAGTTCCCGTC 
Rosa Internal Control Forward AAAGTCGCTCTGAGTTGTTAT  
Rosa Internal Control Reverse GGAGCGGGAGAAATGGATATG 
SRY Forward GCTGGGATGCAGGTGGAAAA 
SRY Reverse TGATGGCATGTGGGTTCCTG 
Table 3.1- List of primers used for genotyping mouse cohorts. 
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Chapter 3.6 – Figures 
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Figure 3.1- Overview of progenitor domains, postmitotic cells, and their specific 
markers in the SC.   
(A)  A simplified schematic of the early transcription factors involved in the 
determination of the progenitor domains which give rise to MNs, OLs, and INs. Cross-
repression between these patterning genes allows for the formation of distinct boundaries 
between domains. Cells expressing OLIG2 give rise to MNs and OLs while cells from the 
adjacent progenitor domains give rise to the ventral and dorsal INs.  
 
(B) Markers used to specifically label and analyze αMNs, OLs, and ventral INs.  
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Figure 3.2-Analysis of cell populations and associated gene expression in adult SC 
(A) Gene expression analysis in whole cord of P60 animals showing that Olig2 
expression is unchanged, while Hb9 is increased, and Irx3 expression is decreased.  
 
(B) Choline acetyltransferase (ChAT) staining of MNs in the ventral horn of the lumbar 
SC.  
 
(C) Quantification of the number of ChAT+ neurons in P60 mice showing a trend 
towards a decrease in Ts65Dn mice compared to euploids.  
 
(D) Quantification of MNs and several types of inhibitory INs using ChAT and calcium 
binding proteins, respectively, showing a significant decrease in ChAT+ and CB+ cells in 
10-11 months old Ts65Dn mice.  
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Figure 3.3-Analysis of white matter in postnatal SC 
(A) Immunohistochemical staining of oligodendrocytes (OLs) in the dorsal corticospinal 
tract (DCST) using a combination of OLIG2 (magenta), NG2 (blue), and CC1 (green).  
 
(B) Quantification of OLs at P30 (top panel) and P60 (bottom panel) showing a 
significant decrease in the percentage of Olig2+/CC1+ (mature) OLs in the DCST of 
Ts65Dn mice compared to euploid controls. This decrease is accompanied by an increase 
in the percentage of Olig2+/CC1- (immature) OLs. Mean numbers are shown ± SD. 
 
(C) Staining of nodes and paranodes in the DCST using NF186 (green) and CASPR 
(red), respectively. Inset is showing staining at high magnification.  
 
(D) A significant reduction in the number of nodes of Ranvier in the DCST and lateral 
funiculus (LF) is shown in P30 Ts65Dn animals. Mean numbers are shown ± SD. 
 
(E) Gene expression of Nf186 and Caspr in P60 SC, showing no changes in T65Dn cords 
compared to euploids.  
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Figure 3.4-Gene expression and cell number analysis in embryonic SC 
(A) Immunohistochemical staining of the OLIG2+ (red) domain in E12.5 spinal cord 
showing localization in the ventral portion of the cord.  
 
(A’) A 40x magnification showing OLIG2+ cells (red) clustered at the midline in euploid 
and Ts65Dn E12.5 mice.  
 
(B) Cell count data showing a significant increase in the number of OLIG2+ cells per 
spinal cord section at E12.5 in Ts65Dn mice compared to euploid littermates.  
 
(C) Gene expression at E12.5 showing a 1.5 fold increase in Olig2 gene expression in 
Ts65Dn animals compared to euploid controls. This increase is accompanied by an 
increase in Hb9 expression in trisomic animals.  
 
(D) Gene expression at E14.5 showing normalization in expression of Olig2 and Hb9 but 
a decrease in Nkx2.2 expression in Ts65Dn animals.  
  
  
159 
 
  
* 
  
160 
Figure 3.5- Behavioral analysis of Ts65Dn and Ts65DnOlig1/2+/+/- mice. 
(A) Image of hanging wire test.  
 
(A’) Adult Ts65Dn mice fall more rapidly than their euploid controls.  
 
(B) Image of the hindlimb reflex: animals that splay their hindlimbs are given a score of 
2, animals that gently retract their hindlimbs or only retract one of their hindlimbs are 
given a score of 1, and animals that clasp their hindlimbs to each other or very close to 
their bodies are given a score of 0.  
 
(B’) Ts65Dn mice have a higher incidence of clasping and/or retracting their hindlimbs 
than euploid controls.  
 
(C & D) Hidlimb reflex and hanging wire tests in a cohort of Ts65Dn mice, Ts65Dn mice 
with Olig1/2 gene dosage correction [Ts65DnOlig1/2+/+/-], Olig1/2+/+/- heterozygous 
mice, and euploid mice. Significant deficits in the Ts65Dn motor performance are 
partially rescued in the Ts65DnOlig1/2+/+/-. (R = -0.509, p=0.03: moderate negative 
correlation between gene dosage and hindlimb reflex performance; R=-0.366, p=0.1: n.s. 
weak correlation between gene dosage and hanging wire performance). 
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Euploid Ts65Dn 
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Figure S3.1- Migration of OLIG2+ Progenitors in Embryonic SC 
Representative images showing division and migration of pMN progenitors during 
embryonic development. OLIG2 is shown in red while NKX6.1 is shown in green. Inset 
is depicting a magnified view of the OLIG2+ pMN domain in a E12.5 Ts65Dn mouse 
and its euploid littermate. 
 
  
  
163 
CHAPTER 4 – OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION 
IN THE BRAIN OF TS65DN MICE 
The work presented below is entirely based on protein expression analysis conducted by 
Nadine Aziz with technical assistance from Dr. Kyle Trudeau. 
 
Chapter 4.1 – Introduction 
Reactive metabolites are ubiquitously present in cells as a byproduct of aerobic 
respiration294. While reactive oxygen and nitrogen species (ROS and RNS) can cause 
oxidative damage to lipids, proteins, and DNA, growing evidence has uncovered an 
evolutionary role for ROS in triggering adaptive responses to changes in nutrient levels 
and cues in the environment295-297. These cellular “sensors” transduce signals affecting 
proliferation, differentiation, and migration and when aberrant, can lead to pathological 
outcomes298. Thus, to achieve cellular homeostasis, the cell has to rapidly cycle between 
oxidation and reduction of macromolecules. These processes are collectively known as 
redox reactions298.  On the other hand, if an imbalance in the amount of reactive 
metabolites and cellular antioxidant defenses occurs, the cell is said to be experiencing 
oxidative stress (OS)294 (Illustration 4.2).  
 
Oxidative stress is well documented in DS. Early hypotheses regarding the root cause of 
OS in DS were formulated based on the fact that Hsa21 contains the gene which encodes 
superoxide dismutase 1 (SOD1), an antioxidant enzyme involved in the breakdown of the 
strong oxidant superoxide299-301. Aerobic respiration by the mitochondria produces this 
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superoxide, which through a series of reducing reactions can be converted into water. 
Following initial reduction by SOD1, catalase (CAT) and glutathione peroxidase (GPX) 
are needed to fully reduce superoxide. Therefore, researchers posited that the 
upregulation of SOD1 in DS would lead increased reduction of superoxide into hydrogen 
peroxide; however, due to insufficient amounts of GPX and CAT, an accumulation of 
noxious hydrogen peroxide would occur302 (Illustration 4.4).  
 
Mitochondria are the main contributors to and targets of OS (Illustration 4.2 and 4.3). 
Oxidative phosphorylation (OXPHOS), which takes place in the inner mitochondrial 
membrane by the respiratory chain enzyme complexes (also referred to as the electron 
transport chain (ETC), is the sequential oxidation of nutrients into ATP and the 
predominant method by which energy is generated in aerobic organisms. During 
OXPHOS, potential energy is generated through the shuttling of electrons between 
electron donors and electron acceptors and the coupled transfer of protons against their 
concentration gradient. Stores of protons then flow across the inner mitochondrial 
membrane down their electrochemical gradient, thus generating ATP. The last electron 
acceptor in the chain is oxygen which upon accepting the electron within the 
mitochondrial matrix is converted to superoxide and then hydrogen peroxide through 
dismutation by SOD1303. Thus, when endogenous antioxidant enzymes are dysfunctional, 
buildup of free radicals (i.e., an increase in ROS) within the mitochondrial matrix occurs, 
impacting mitochondrial function and structure. In fact, a strong link between alterations 
in mitochondrial morphology, OXPHOS, and ultimately ATP generation in response to 
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OS has been well described. Several studies have shown that mitochondrial morphology 
is intimately tied to mitochondrial function304, 305, and as such mitochondria can undergo 
remodeling due to energy requirements and in response to cellular stress306. Specifically, 
it has been observed that mitochondrial fragmentation is correlated with reduced ATP 
production and increased ROS307. Additionally, ROS can damage the respiratory chain 
complexes themselves, leading to inefficient shuttling of electrons and protons, 
eventually impacting mitochondrial membrane potential.  Thus, it is widely accepted that 
mitochondrial dysfunction and OS are related in a cyclical feedback loop, even though 
precipitating events for the initiating dysfunction are still largely unknown in most 
disease states. 
 
OS stress and mitochondria studies in DS can be organized into several broad groups 
based on the context in which experiments were run: 1) human fetal tissue; 2) human 
tissue-derived cells; 3) human “in vivo” measurements (blood/urine/amniotic fluid); 4) 
mouse tissue; and 5) mouse tissue-derived cells. Below is a summary of findings in each 
group. 
 
Utilizing postmortem fetal brain tissue, investigators measured activity of SOD1 and 
found that, as hypothesized, it was significantly increased while GPX activity was 
unchanged301. Additionally, these investigators found an increase in global lipid 
peroxidation in the cerebral cortex of fetuses with DS301. Others have also shown that 
expression levels of mitochondrial enzymes involved in intermediary metabolism 
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(namely, within the citric acid cycle) were abnormal in cortices of fetuses with DS308. 
Mitochondrial assessments in follow-up studies have shown an increase in mitochondrial 
DNA mutations, alteration in mitochondrial DNA repair systems, and a decrease in key 
respiratory chain proteins in DS brain tissue309. 
 
In vitro investigation of cultured neurons and fibroblasts from postmortem fetal tissue 
confirmed and expanded upon studies utilizing cortical tissue. Again, an increase in 
mitochondrial DNA mutations due to oxidative damage and aberrant mitochondrial DNA 
repair were observed in fibroblasts310 and astrocytes311 derived from fetuses with DS.  
Fibroblasts also exhibited a decrease in activity of a respiratory chain complex as well as 
an increase in intracellular ROS312. In cultured astrocytes, mitochondria exhibited altered 
membrane potential, oxidoreductase activity, and morphology313. Additionally, in 
cultured neurons, increased ROS, lipid peroxidation, and apoptosis were observed314. 
Increases in OS hallmarks and sensitivity were also seen in induced pluripotent stem cells 
(iPSCs) and iPSC-derived neurons obtained from individuals with DS315, 316. In addition, 
microarray analyses of neural progenitor cells (NPCs) isolated from fetal frontal cortices 
of individuals with DS indicated an association between altered genome-wide gene 
expression and increased ROS317. In these NPCs, activation of stress response kinases 
and apoptosis were highly prevalent317.   
 
Readouts of in vivo biochemical changes were also utilized by investigators to measure 
OS in people with DS. These analyses relied on available resources that are relatively 
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non-invasive to patients, namely blood donated by individuals with DS or amniotic 
fluid318 obtained for karyotyping from pregnant mothers. Activity levels of SOD1, CAT, 
and GPX were measured along with other markers for OS in blood samples from children 
and teenagers with DS319. A significant dysregulation in antioxidant and pro-oxidant 
agents leading to OS was observed in DS samples319, 320. On the other hand, investigation 
of the prenatal period, yielded compelling evidence that OS is present as early as the 
second trimester of gestation321, 322. Microarray analysis of amniotic fluid samples 
showed altered activity of OS-associated genes and follow-up proteomic analysis showed 
an elevation in lipid peroxidation, alteration in antioxidant protein levels, and induction 
of the heat shock protein response, an indication of cytopathology321, 322.   
 
In addition to human samples, researchers have relied on the use of mouse models to 
validate and further explore the underlying etiology of increased OS in DS. Mouse 
studies began several decades ago when a group used the Ts16 mouse model of DS to 
investigate lipid peroxidation, SOD1 activity,  and GPX activity299. While SOD1 activity 
was shown to be increased299, 300, GPX activity as well as lipid peroxidation were 
unchanged299.  This lack of cellular damage was puzzling and compelled the authors to 
use two newly developed mouse models, Ts1Cje and Ts65Dn, to better investigate the 
relationship between SOD1 and OS. Follow-up studies in Ts1Cje mice showed that, 
similar to humans and despite unaltered gene dosage of SOD1, there was an increase in 
ROS, lipid peroxidation, and mitochondrial dysfunction in primary cultured neurons and 
astrocytes323. Furthermore, brains from these Ts1Cje mice also exhibited an increase in 
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ROS, lipid peroxidation, and oxidation of proteins involved in ATP generation, 
cytoskeleton, and antioxidant defenses323. An increase in OS was also observed in brains 
from four months old Ts65Dn mice324. On the other hand, mitochondria-centric studies 
showed that, despite earlier studies on OS stress, Ts16 cerebellar neuron cultures 
exhibited elongated mitochondria more ubiquitously than control neurons325. Analysis of 
isolated mitochondria from these mice showed that mitochondrial respiration was 
decreased and expression of respiratory chain complexes was altered326. Taken together, 
these studies show that regardless of SOD1 expression, OS is present in the brains of 
people with DS as well as in the brains of mouse models of the syndrome.  
 
Recent studies have presented a new hypothesis describing the role of mitochondria in 
OS in DS. Using cultured primary astrocytes and neurons, Helguera et al. 
comprehensively assessed mitochondrial morphology and function327. They found that in 
cultured DS astrocytes, mitochondria are more fragmented and exhibited reduced 
mitochondrial membrane potential, oxidoreductase activity, and ATP generation. 
Surprisingly, these mitochondrial were capable of sustaining increased activity when 
stimulated with nutrients. However, restored mitochondrial function resulted in increased 
ROS generation, cellular damage (namely, lipid peroxidation), and eventually cell death. 
Gene expression in these astrocytes showed that they were subjected to a chronic pro-
oxidant environment. These findings were recapitulated in DS neurons. Furthermore, 
fragmented mitochondria in DS neurons seemed to co-localize with lysosomes, 
suggesting an increase in dysfunction and active mitophagy. Thus, these authors show 
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that mitochondria in DS cells possess the capacity to increase ATP production to normal 
levels under metabolic stimulation, but in pro-oxidant conditions morphology and 
function are purposely altered as a part of an adaptive response for avoiding excessive 
ROS generation and cellular injury327. This concept is known as hormesis309. The authors 
suggest that the activation of this adaptive response early on in life may translate into 
longer survival; however, additional stress, such as that arising from normal aging in DS, 
may lead to accelerated manifestation of age-related conditions like Alzheimer’s disease 
and general dementia309, 328. Based on the growing body of evidence linking OS and DS, 
antioxidant supplementation as a therapy has recently become a focus in the DS research 
community.  
 
Several antioxidant treatment paradigms have been tested in the Ts65Dn mice, and while 
no comprehensive testing or mechanistic studies were conducted, amelioration of select 
behavioral and anatomical deficits seemed promising324, 329.  However, translation of 
preclinical testing of antioxidant supplementation into a clinical trial for people with DS 
failed to show therapeutically-driven improvement in disease phenotypes330. The failure 
of free radical scavengers to ameliorate the OS burden in people with DS led to the 
investigation of another class of OS-related therapies—nutrients and molecules targeting 
the mitochondria331. One such molecule is Epigallocatechin-3-gallate (EGCG) which was 
shown in vitro to restore mitochondrial OXPHOS and to promote mitochondrial 
biogenesis in DS brain-derived cells and to abrogate behavioral deficits in Ts65Dn249, 330. 
In fact, a clinical study reported that EGCG-treated young adults with DS showed a mild 
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cognitive enhancement and/or improved behavioral control over a wide array of 
cognitive/behavioral skills249. However, beneficial effects of EGCG are still 
controversial332. Given the complex relationship between mitochondrial dysfunction and 
OS in DS, along with target discovery, timing of administration should be a principal 
consideration in antioxidant therapeutic development.  
 
Determining the extent of mitochondrial dysfunction in vivo and in vitro would aid in the 
development of more efficacious therapies for OS in DS. More detailed analysis of 
oxidative cellular damage, mitochondrial dynamics, mitochondrial quality control, and 
mitochondrial respiration would allow us to pinpoint specific targets in a spatiotemporal 
context. Utilizing the Ts65Dn mouse model of DS, we can measure regional protein and 
gene expression, track mitochondrial motility in live tissue, assess ATP synthesis and 
mitochondrial respiration, analyze mitophagy, pinpoint the relationship between 
mitochondrial dysfunction and observed DS-related phenotypes, and test potential 
therapies over the entire lifespan starting during embryonic development. 
 
Chapter 4.2 – Materials and Methods 
Colony Information and Mouse Breeding 
All murine experiments were conducted according to international ethical standards and 
approved by the Institutional Animal Care and Use Committees (IACUC) of Boston 
University. Animals were housed in cages with standard bedding and a nestlet square. 
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Rodent chow and water were available ad libitum. The colony was maintained on a 12:12 
light/dark cycle, with lights on at 7:00 AM. 
 
B6EiC3Sn.BLiA-Ts(1716)65Dn/DnJ (Ts65Dn; stock number 005252) mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME). Ts65Dn female mice were 
bred with B6EiC3Sn.BLiAF1/J (F1 hybrid; stock number 003647) males. Studies were 
performed at postnatal day 60 (P60). 
 
Genotyping 
Phenol/chloroform DNA extraction was performed on embryonic limb buds or postnatal 
tail clippings after digestion with proteinase K (Denville Scientific). Genotyping was 
performed by PCR using primers specific for the Ts65Dn Mmu16/17 translocation 
breakpoint (Reinholdt et al., 2011).  
 
Tissue Collection 
For adult gene expression studies, P60 male mice were anesthetized with isoflurane and 
rapidly euthanized by decapitation. Surfaces were treated with an anti-RNase solution 
and all other solutions were DEPC-treated and autoclaved. Brains were immediately 
removed and placed into ice-cold 1x phosphate buffered solution (PBS), bisected on a 
cold platform into hemispheres along the medial longitudinal fissure, and further 
dissected into the following subsections: cortex, hippocampus, cerebellum, and 
subcortical tissue (comprised of the striatum and all limbic structures except the 
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hippocampus). These subsections were then rapidly snap frozen in liquid nitrogen and 
stored at -80°C. A total of 5 euploids and 5 Ts65Dn mice were used in all studies.  
 
Gene Expression Analysis 
For gene expression studies, total RNA was isolated from each brain region. Genomic 
DNA was first removed using DNase Treatment and Removal Kit. Purified RNA was 
quantified then reverse-transcribed into cDNA using High Capacity cDNA Reverse 
Transcription Kit per manufacturer’s instructions (Thermo Fisher Scientific, MA). qRT-
PCR was then achieved using Taqman® primers and reagents (Thermo Fisher Scientific, 
MA). Trisomic and euploid samples from the same cohort were analyzed side by side to 
avoid batch errors. All values were first normalized to a housekeeping gene, then 
presented as a relative quantity (RQ) of euploid samples. N=5 was used per genotype and 
data are shown as mean ± SD. A Student’s t-test was used to assess significance at 
p<0.05.   
 
Western Blot Analysis 
Tissue Preparation 
Each brain region was processed separately to avoid protein degradation and sample loss. 
All samples from both genotypes were prepared on the same day to avoid batch effects. 
Frozen tissue was placed into ~300µL of lysis buffer containing a protease inhibitor 
cocktail. Each tissue sample was homogenized until no large particles were seen then 
spun down at 12,000 RPM in 4ºC for 10min. The supernatant was then removed and 
  
173 
protein content was quantified using a BCA kit according to manufacturer’s protocol 
(Thermo Fisher Scientific, MA). Samples were then diluted to a concentration of 2µg/µL 
in complete lysis buffer, mixed with a 4x Laemmli sample buffer (Thermo Fisher 
Scientific, MA), and boiled for 5min at 95ºC. Prepared samples were either used 
immediately in gel electrophoresis or frozen in -80ºC for storage. 
 
Gel Electrophoresis and Blotting 
Ready-made NuPAGE 4-12% Bis-Tris Gels were prepared for electrophoresis according 
to manufacturer’s protocol. 30µg of protein were loaded per well. 4µL of a dual-stained 
molecular weight ladder was used for reference (BioRAD, CA). 1x MES SDS running 
buffer was used and gels were run at 200V for 45min (Thermo Fisher Scientific, MA). 
GAPDH and β-actin were used as loading controls. After desired separation was 
achieved, gel was transferred onto a PVDF membrane using a NuPAGE transfer buffer 
(Thermo Fisher Scientific, MA). Transfer proceeded at 5V (per gel) for 18-20 hours in a 
4ºC cold-room.  
 
Membrane Staining 
After transfer, membranes were blocked for 1 hour in 3% milk-PBST solution at room 
temperature (RT) with constant shaking. After a brief rinse from the milk solution, 
membranes were placed in the primary antibody solution made of 3% BSA-PBST 
overnight at 4ºC. Primary antibodies used and their concentration can be found in Table 
4.1. Membranes were then washed 3 times for 5min in 1xPBST at RT. Species-specific 
  
174 
secondary antibodies were then diluted 1:3000 in 3%-PBST solution. Membranes were 
incubated with the secondary antibody solution for 1 hour at RT. Following washes in 
PBST, membranes were incubated with an ECL solution (Thermo Fisher Scientific, MA) 
and visualized using Fuji Imager (Fuji, JAP).   
 
Image Analysis 
All image and densitometry analyses were performed using ImageJ (NIH, MD). Raw 
values for band density were normalized first to the house keeping proteins then to 
euploid samples to derive a relative quantity of target proteins. All data are presented as a 
mean by genotype ± S.E.M. Student’s t-test was used to analyze significant which was 
set at p<0.05. 
 
Chapter 4.3 – Results  
Gene expression analysis of Sod1, Sod2, and Cat1 in Ts65Dn brain shows a 2-fold 
upregulation in Sod1in cortex and cerebellum, and a 3-fold upregulation in subcortex in 
trisomic mice compared to euploid littermates (Figure 4.1, p<0.05). Interestingly, no 
change in Sod1 gene expression is observed in Ts65Dn hippocampus (Figure 4.1). Sod2 
gene expression is unchanged in all brain regions (Figure 4.1). Expectedly, Cat 
expression is also unchanged in all Ts65Dn brain regions sampled (Figure 4.1). Protein 
expression of CAT is similar in euploid and Ts65Dn cerebellum (Figure 4.4). These 
findings align with previously reported findings in brains and primary cells from people 
with DS and mouse models of DS.  
  
175 
Analysis of mitochondrial fusion and fission proteins in Ts65Dn cerebellum and 
subcortex shows only a 0.5-fold downregulation in MFN2 in Ts65Dn cerebellum 
compared to euploids (Figure 4.2, p<0.05). OPA1, another fusion protein, and FIS1, a 
fission protein, are unchanged in both cerebellum and subcortical tissue from Ts65Dn 
mice (Figure 4.2) 
 
Analysis of mitochondrial membrane proteins, including the ETC proteins, indicates 
widespread functional aberrations. Data show that there is a 1.5-fold upregulation in 
expression of Translocase of outer mitochondrial membrane 20 (TOMM20) in Ts65Dn 
cerebellum, suggesting that there may be an increase in mitochondrial mass (Figure 4.3, 
p<0.05). Ts65Dn cerebellar tissue shows a more consistent phenotype, with an increase 
in both Complex I and Complex IV protein expression and a decrease in Complex 
V/ATP-synthase protein expression (Figure 4.3, p<0.05). Normalizing values of Complex 
I and Complex IV to TOMM20 normalizes their expression (data not shown). However, 
similar normalization of Complex V to TOMM20 shows an exaggerated downregulation 
of TOMM20 (data not shown). This might indicate that the upregulation of Complex I 
and IV may be due to increased mitochondria in Ts65Dn cerebellum, yet despite this 
increase, ATP-synthase levels are still significantly lower than in euploid cerebellum. 
Prohibitin, Complex 4 subunits 1 and 4 are unchanged in Ts65Dn cerebellum and 
subcortex compared to euploids (Figure 4.3). 
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Although autophagy was not assessed directly in Ts65Dn brain tissue, a 1.5-fold increase 
in p62 protein level may indicate a possible decrease in autophagic function in 
subcortical tissue (Figure 4.4, p=0.07). This trend towards an increase in p62 is not 
observed in Ts65Dn cerebellum compared to euploids (Figure 4.4). 
 
Chapter 4.4 – Discussion 
Our findings indicate that, as expected, gene expression of Sod1 is upregulated in cortex, 
cerebellum, and subcortex of Ts65Dn mice. This upregulation is not accompanied by an 
increase in Sod2 or Cat expression. Surprisingly, alteration in gene expression levels of 
Sod1, Sod2, and Cat is not seen in hippocampal tissue. Along with gene expression 
abnormalities, widespread protein expression changes are present in Ts65Dn cerebellum 
and subcortical tissue. These proteins span multiple facets of mitochondrial function. 
Namely, there is an observed dysregulation in proteins related to mitochondrial fusion, 
OXPHOS/ETC, ATP synthesis, autophagy, and overall mitochondrial mass.  
 
Our data recapitulate previous findings showing an upregulation in SOD1 without a 
concomitant change in CAT in human brain tissue299-301. This may indicate that there is 
an increase in H2O2 leading to a pro-oxidant state in Ts65Dn brains; however, more 
information is needed to verify this assumption. Additional experiments analyzing the 
activity of SOD1 and CAT along with the levels of intracellular H2O2 would provide 
more direct evidence that, as hypothesized, triplication of Sod1 leads to increase in SOD1 
activity which in turn results in an accumulation of H2O2 at rates faster than non-elevated 
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CAT can catabolize. Additionally, more experiments are needed to test for the presence 
of oxidative damage to lipids, proteins, and DNA.   
 
Observed changes in mitochondrial proteins may be indicative of dysfunction in 
mitochondrial morphology, function, and quality control. Since mitochondrial 
morphology and motility are strongly tied to mitochondrial function, the observed 
mitofusin 2 (MFN2) downregulation in Ts65Dn cerebellum may have functional 
implications for bioenergetics (Illustration 4.1). Neurons in particular have high energy 
demands, and as such have a critical reliance on mitochondria333. Mitochondrial 
trafficking is essential and allows for a cued enrichment of mitochondria within the soma, 
axon hillock, nerve terminal, and Nodes of Ranvier where they can provide high amounts 
of localized ATP and regulate intracellular calcium concentrations333-335. Because of the 
dynamic shuttling of mitochondria in neurons, fusion, fission, and motility, which all rely 
in part on MFN2, play an integral role in neuronal health333. Interestingly, MFN2 
mutations have been linked to several neuropathies334, 335. Examination of pathogenesis 
related to these mutations may shed light on how MFN2 is linked to DS-related 
phenotypes. One neurological disorder that is associated with MFN2 gene mutations is 
Charcot-Marie-Tooth disease type 2A (CMT2A). This disease affects axonal integrity 
within the entire CNS and manifests as a complex and idiosyncratic set of phenotypes334, 
336. CMT2A primarily impacts distal lower and distal upper limbs and results in muscle 
weakness, sensory impairments, skeletal abnormalities, and difficulty in walking334, 335. 
Specific mutations in MFN2 can lead to different severities of the disease and additional 
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systemic defects. In few cases, several phenotypes similar to those observed in DS 
manifest, including white matter alterations, areflexia, altered gait, and cognitive 
impairment334. This suggests that MFN2 function may be itself, or via downstream 
effectors, important for white matter integrity, cognition, and motor function. 
Unfortunately, due to the complex genetic underpinnings of DS, correlation between 
altered expression of MFN2 and phenotype cannot be easily determined. However; it is 
likely that MFN2 downregulation impacts mitochondrial dynamics and in turn affects 
neurons and oligodendrocytes (OLs) which have increased energy demands, contributing 
in turn to DS phenotypes. Additionally, MFN2 is a key regulator of mitochondrial 
networks, and disruption of such networks has been linked to neurodegenerative 
diseases334, 337-339. Since early onset AD is prevalent in DS, it may be the case that MFN2 
is playing a role in the DSAD population. Additional experiments tracking mitochondrial 
dynamics in live brain-derived cells are necessary to understand the impact of decreased 
MFN2 expression. Furthermore, MFN2 expression level needs to be measured in human 
brain tissue from DS patients. Gain of function experiments where MFN2 expression is 
restored in vitro could also help identify the specific impact of MFN2 downregulation on 
the health of neurons and OLs.  
 
Other affected proteins in Ts65Dn cerebella are Translocase of outer mitochondrial 
membrane 20 (TOMM20), and complex 1 (CoI), complex IV (CoIV), and complex 
V/ATP synthase (CoV) of the respiratory chain. Analyzing the role of these proteins in 
bioenergetics may elucidate how mitochondrial defects relate to observed DS 
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phenotypes. TOMM is a ubiquitous transmembrane complex that allows protein import 
through the outer mitochondrial membrane340. Recognition and recruitment of the pro-
proteins necessary for the assembly of the TOMM complex is dependent on two receptor 
proteins, one of which is TOMM20340. TOMM20 was also shown to play a role in 
mRNA tethering to the mitochondria and in recognition of mitochondria-destined 
polypeptide chains in the cytoplasm341. Therefore, TOMM20 is always associated with 
mitochondria and can be used as a proxy for the overall mitochondrial mass. Our data 
show that there is an increase in mitochondrial mass in Ts65Dn cerebellum. This finding 
may be interpreted in several different ways. First, the increase in mitochondrial mass 
may be related to an accumulation of dysfunctional mitochondria that are somehow 
overlooked for clearance through regular mitochondrial dynamics. Mitophagy, or the 
targeting of dysfunctional mitochondria for degradation through the autophagy-lysosome 
system, is an integral process for cellular health342, 343. Thus, aberrant identification or 
targeting of defective mitochondria for mitophagy can disturb the tightly regulated 
quality control processes that ensure enough healthy mitochondria are functioning at 
optimal levels to meet cellular energy demands342. This assumption may also be 
corroborated by a trend towards an increase in the autophagy marker, p62. p62 is a 
cytoplasmic protein that can recognize and bind cellular waste and is cleared only 
through autophagy344. An increase in expression of p62 can therefore indicate a decrease 
in its clearance, i.e. decreased autophagy344. Our data show that p62 levels are increased 
in Ts65Dn cerebella, indicating that perhaps the link between increased mitochondrial 
mass and increased p62 expression is defective autophagy. Conversely, an increase in 
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TOMM20 may indicate an increase in mitochondrial biogenesis, perhaps as a means of 
compensating for the mitochondria’s decreased capacity to produce energy in Ts65Dn 
tissue345. Live tissue experiments where mitochondria are labelled and observed in a 
time-dependent manner would allow us to analyze motility and turnover and are therefore 
necessary for careful characterization of mitochondrial dynamics and quality control in 
Ts65Dn brains and in primary cultured neurons and OLs from human donors.  
 
Aside from TOMM20 and p62, CoI, CoIV, and CoV expression is dysregulated in 
Ts65Dn cerebella. These three proteins are part of the respiratory chain complex in the 
inner mitochondrial membrane. Proper function of each component is necessary for 
optimal respiration and energy generation without contribution to the OS burden of the 
cell. CoI and CoIV are upregulated in Ts65Dn cerebella which might indicate a level of 
compensation for the downregulation of CoV, the complex responsible for ATP 
synthesis. 
 
CoI is the first and largest of the complexes in the respiratory chain346. Prior studies show 
that dysfunction in this complex is linked to Parkinson’s disease346. In addition, studies 
show that chemical inhibition of CoI leads to cell death and altered mitochondrial 
morphology346, 347. Therefore, proper expression and function of CoI are essential for 
cellular health and survival, especially in neurons. Downregulation of CoI has been 
shown in fetal and adult brain tissue from individuals with DS348, 349. On the contrary, our 
data show an upregulation of CoI in Ts65Dn cerebellum. Since our samples showed an 
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increase in overall mitochondrial mass, it may be the case that protein levels of CoI and 
CoIV are elevated only because there is a larger amount of mitochondria in Ts65Dn 
cerebellar tissue. Indeed, if we normalize CoI and CoIV expression to TOMM20 
expression, we see that the increase in both proteins disappears. On the other hand, 
previous studies on human tissue showed that CoI activity is decreased in DS samples312; 
therefore, the upregulation may serve as a compensatory mechanism to overcome 
deficient activity of the enzyme complex. In contrast to literature pointing to 
downregulation of CoI in various neuropathologies, upregulation of CoIV (and in fact 
TOMM20) was reported in brains of AD patients with a high accumulation of Tau350. 
CoIV and TOMM20 were also upregulated in brains from hTAU transgenic mice with 
impaired mitophagy350. Mechanisms underlying these protein expression increases are 
largely unknown; however, compensation is an attractive potential explanation. Taking 
the principle of hormesis into account, one can rationally posit that mitochondrial 
biogenesis, quality control, and capacity for ATP production interact concertedly to 
maximize energy production with a small OS footprint. Importantly, to address questions 
related to respiration and energy production, live cell imaging and respirometry are 
necessary.  
 
Another dysregulated member of the ETC in Ts65Dn brains is CoV, or ATP synthase. 
ATP synthase is a large multimeric protein complex comprised of multiple subunits that 
together form a proton pump and several rotating subcomplexes351. Using H+ ions to 
power its rotational movement, ATP synthase generates ATP from ADP and inorganic 
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phosphates351. Thus, its primary role is to convert the electrochemical potential energy 
generated by other members of the electron transport chain into chemical energy that can 
be used by the cell330. Our data show that in Ts65Dn mice ATP synthase is 
downregulated in both cerebellar and subcortical tissue.  This is in concordance with 
previous studies showing a decreased protein expression of ATP synthase subunits and 
concomitant decrease in ATP production352. This downregulation of CoV may be 
attributable to hormesis or may be a byproduct of molecular perturbations arising from 
gene dosage imbalance or mitochondrial dysfunction due to OS. Again, additional 
experiments are needed to better parse out causality.  
 
Chapter 4.5 – Future Studies 
OS and decreased energy output by mitochondria have major implications for cellular 
health. Previous studies show that compromised bioenergetics contribute to and/or 
underlie multiple developmental and neurodegenerative diseases, and as such 
mitochondria should be the focus of careful analysis in DS.  
 
Expanded gene expression analyses of other molecular markers for OS, OS response, and 
mitochondrial function are needed in cerebellum and subcortex but also in cortex and 
hippocampus of Ts65Dn and euploid mice at various ages. A longitudinal analysis of 
gene expression would help pinpoint the developmental time-window when pro-oxidant 
cellular conditions arise and when antioxidant defenses engage in Ts65Dn brains. In 
addition, mitochondrial respiration in brain slices and/or isolated neurons/OLs is needed 
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to better characterize the extent and impact of mitochondrial dysfunction in Ts65Dn 
mice. Live tissue/cell imaging is integral for these studies. Using similar preparations, 
mitochondrial dynamics, motility, and turnover could also be analyzed along with 
mitochondrial ROS. These experiments would allow us to more directly analyze 
mitochondrial defects and their contribution to the overall OS burden in brain tissue. 
Further analysis by electron microscopy would provide more precise information 
regarding mitochondrial distribution and morphology in Ts65Dn brains. Moreover, due to 
the close proximity of mitochondrial DNA (mtDNA) to the respiratory chain, mtDNA 
can exhibit mutations as a direct result of increased ROS production during OXPHOS353. 
Furthermore, mtDNA mutations have been observed in brains of fetuses with DS309. 
Therefore, regional mtDNA mutations should also be carefully analyzed inTs65Dn brains 
to better characterize impaired mitochondrial gene expression that may lead to further 
dysfunction309, 353, 354.  In other neurodevelopmental and neurodegenerative diseases, it 
has been observed that the ratio of normal to mutated mtDNA is spatiotemporally distinct 
and may be an indicator of phenotype severity309, 354. Along with these proposed Ts65Dn 
studies, similar mitochondrial analyses in post-mortem human tissue and tissue-derived 
primary cells are necessary.  These studies would confirm and expand upon findings in 
the mouse model, and validate its potential use for drug discovery experiments targeting 
the mitochondria. 
 
Lastly, recent work has uncovered a specific reliance of tangentially migrating 
interneurons, but not radially migrating excitatory neurons, on mitochondria during 
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typical brain development355. Furthermore, other studies have shown that OL precursors 
have an increased susceptibility to OS and cellular injury due to a decrease in antioxidant 
enzymes compared to their mature counterparts356, 357. Thus, in certain hypomyelination 
diseases, myelinogenesis is decreased due to a prenatal block in OL differentiation 
resulting from increased precursor death after exposure to OS356. OL differentiation is 
also tightly linked with changes in mitochondrial gene expression and heavily reliant on 
the metabolic processes carried out by the mitochondria to generate metabolites 
necessary for cholesterol biosynthesis and myelin production358. Interestingly, a block in 
OL maturation and aberrant myelination have been recently reported in Ts65Dn brains, 
brains of fetuses with DS, and even in brains of adults with DS158. As such, it is necessary 
to carefully consider how mitochondrial defects and increased OS may govern brain 
development by differentially impacting neuronal and glial subtypes in brains of Ts65Dn 
mice and of people with DS. 
 
Chapter 4.6 – Conclusions 
OS is detectable as early as the second trimester in fetuses with DS. Due to this increased 
OS burden, it is possible that hormesis already taking place at this early developmental 
stage, impacting mitochondrial function. In fact, previous work has shown that 
mitochondrial dysfunction is observable in tissue from fetuses with DS, but the 
connection between OS and mitochondrial abnormalities is still tenuous and 
directionality of causation is unknown. By utilizing the Ts65Dn mouse model we can 
better understand how the cyclical relationship between mitochondrial defects and OS 
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originates and how it relates to DS phenotypes. Furthermore, early aging phenotypes in 
DS may relate to defects in bioenergetics and increased cellular stress despite hormesis; 
therefore, the temporal profile of mitochondrial function and OS should be thoroughly 
studied in both mouse models DS of and in people with DS. Our data indicate that 
mitochondrial abnormalities exist in adult Ts65Dn mice and future studies will expand 
upon these findings to better characterize functional, molecular, and morphological 
abnormalities in mitochondria. 
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Chapter 4.7 – Illustrations 
 
Image adapted by permission from Dr. Kyle Trudeau 
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Illustration 4.1-Overview of mitochondrial life cycle and turnover. 
Fusion and fission events are continuously occurring in functional mitochondria, mainly 
to exchange nutrients, proteins, and DNA. In order to undergo fusion and fission, 
mitochondria need to be motile. These dynamic processes of fusion and fission are also 
used to identify and sequester damaged mitochondria for degradation via autophagy.  
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Illustration 4.2-Definition of oxidative stress. 
Schematic depicting oxidative stress which is defined as the accumulation of free radicals 
and reactive metabolites due to a deficiency in antioxidant defenses.  This imbalance 
leads to oxidative damage of macromolecules in the cell, ultimately culminating in 
cellular and mitochondrial dysfunction and cell death.  
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Illustration 4.3-Relationship between OS and mitochondria. 
ROS is a normal byproduct of mitochondrial function and under physiological conditions 
can serve as a signal to drive cellular adaptation to the environment. Typically, if 
unneeded, ROS can be cleared quickly by antioxidant molecules within the cell. 
However, when these antioxidant defenses are low (such as in disease states, for 
example) ROS production by the mitochondria can lead to oxidative damage to 
macromolecules in the cell, starting with mitochondrial proteins, membranes, and DNA 
that are in close proximity. This, in turn, impairs the ability of mitochondria to synthesize 
ATP and carry out necessary metabolic functions. Mitochondrial oxidative damage can 
also induce mitochondrial-based activation of the cell's apoptotic machinery. Thus, under 
OS, cyclical feedback between ROS and mitochondria takes place and can lead to an 
amplified cellular dysfunction.  
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Illustration 4.4-Current theory linking oxidative stress and Down syndrome-related 
early aging phenotypes. 
Schematic of how triplication of Hsa21 may lead to gene expression abnormalities and a 
cyclical accumulation in oxidative stress (OS) in neurons. Coupled with oligomeric Aβ 
accumulation, this increase in cellular OS may lead to early aging and early onset 
Alzheimer’s pathology and dementia.   
  
  
194 
Chapter 4.9 – Tables 
Protein 
Molecular 
Weight (kDa) 
Dilution 
Factor 
Cellular 
Localization 
Species 
OPA1 86 1:1000 Mitochondria Mouse 
MFN2 85 1:1000 Mitochondria Mouse 
P62 62 1:1000 Cytosol Rabbit 
Complex V 60 1:1000 Mitochondria Mouse 
Catalase 60 1:1000 Mitochondria Rabbit 
Actin 43 1:2000 Loading control Rabbit 
Complex IV subunit 1 38 1:1000 Mitochondria Mouse 
GAPDH 37 1:1000 Loading control Rabbit 
Prohibitin 30 1:1000 Mitochondria Rabbit 
Complex I 22 1:2000 Mitochondria Mouse 
Complex IV 18 1:500 Mitochondria Mouse 
FIS1 18 1:500 Mitochondria Rabbit 
Tomm20 20 1:1000 Mitochondria Rabbit 
Complex IV subunit 4 16 1:1000 Mitochondria Mouse 
Table 4.1- List of antibodies used in study. 
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Chapter 4.10 – Figures 
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Figure 4.1- Gene expression of anti-oxidant enzymes in the hippocampus, cortex, 
subcortical tissue, and cerebellum in P60 mice. 
n=5 per genotype. Data shown as mean ± S.D. *p<0.05. 
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Figure 4.2-Mitochondrial fusion and fission protein expression in cerebellum and 
subcortical tissue in P60 animals. 
n=5 per genotype. Data shown as mean ± S.E.M. *p<0.05.  
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Figure 4.3-Mitochondrial membrane and electron transport chain protein 
expression in cerebellum and subcortical tissue in P60 animals. 
n=5 per genotype. Data shown as mean ± S.E.M. *p<0.05. 
*Prohibitin plays a role as a chaperone for the ETC proteins and as a scaffolding protein 
in the inner mitochondrial membrane359.  
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Figure 4.4-p62 and catalase expression in cerebellum and subcortical tissue in P60 
mice. 
n=5 per genotype. Data shown as mean ± S.E.M. p=0.07.  
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CHAPTER 5: GENERAL DISCUSSION 
Chapter 5.1 – Summary of Findings 
Histological data at E15.5 show that several aspects of embryonic development are 
altered in Ts65Dn embryos but not in Ts1Cje or Dp16 embryos. Additionally, gene 
expression at E15.5 shows that Dp16 embryonic brain displays approximately half the 
number of DEX genes compared to Ts1Cje and Ts65Dn embryonic brains. Further 
analysis of the top 1% affected genes shows that miRNAs are significantly enriched in 
Dp16 E15.5 embryonic forebrains, but not in those from Ts1Cje or Ts65Dn. This 
prominent difference may reflect compensatory mechanisms in Dp16 embryonic brains 
and thus may offer an explanation for the low number of DEX genes in this model 
compared toTs1Cje and Ts65Dn, despite the additional triplicated Mmu16 genes. 
However, in adult Dp16 mouse tissue, the number of DEX genes is also lower than in the 
corresponding Ts65Dn or Ts1Cje tissue, despite lack of miRNA enrichment in the top 
1% affected genes. This indicates that other or additional (epi)genetic mechanisms are 
involved here. 
 
Comparison of developmental milestones between Ts1Cje, Ts65Dn, and Dp16 mice also 
shows distinct patterns of behavioral deficits. In our combined cohort of males and 
females, Ts65Dn and Ts1Cje mice exhibit significant delays in achieving both early- and 
late- acquired milestones, whereas Dp16 mice exhibit delays in achieving only late-
acquired milestones. Sex differences are observed between males and females with a 
magnitude that varies by model. In order to assess whether histological abnormalities 
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accompany late-acquired developmental milestone deficits, which are present in all three 
models, we analyzed excitatory and inhibitory neuronal populations in the somatosensory 
cortex and hippocampus of Ts1Cje, Ts65Dn, and Dp16 P15 pups. By P15, all trisomic 
mice show developmental milestone delays. We found an increase in specific subtypes of 
inhibitory interneurons in Ts65Dn cortex and hippocampus; however, in contrast to the 
Ts65Dn pups, Dp16 cortex contains a decreased number of inhibitory interneurons.  
Additionally, we found a decrease in excitatory neurons in Ts65Dn cortex and a trend 
towards a decrease in excitatory neurons in Dp16 cortex. Interestingly, these population-
level aberrations are not present in Ts1Cje cortex or hippocampus. 
 
Analysis of adult behavior paints an even more complex picture of the relationship 
between perinatal histological findings, gene expression, and functional outcomes in 
Ts1Cje, Ts65Dn, and Dp16 mice. While all three models exhibit behavioral abnormalities 
compared to euploid mice, Ts65Dn mice show the most comprehensive behavioral 
deficits with abnormalities in learning and memory, anxiety, and some motor tasks. 
Furthermore, adult gene expression data show that the Ts65Dn and Ts1Cje brains display 
a larger overall number of DEX genes compared to Dp16 brains. Regional alterations in 
gene expression are different among the three models. For example, the largest 
proportion of DEX genes are found in Ts65Dn cortex and cerebellum, and in Ts1Cje 
hippocampus and cerebellum. On the other hand, Dp16 displays the largest number of 
DEX genes in the hippocampus. Consistent with fetal expression patterns, Dp16 adult 
brains display the largest proportion of miRNAs, although the magnitude of this effect is 
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diminished compared to fetal brains. Pathway analyses utilizing the top 1% affected 
genes yielded more differences than similarities among the models, but showed that more 
pronounced perturbation to gene expression is occurring during embryonic development 
compared to adulthood in all 3 models.  
 
Furthermore, in Ts65Dn mice, our data uncover cellular and molecular SC alterations 
originating during development and present OLIG2 as a potential target for therapeutic 
intervention. Disproportionate cellular representation of MNs and IN subtypes has wide 
implications for organization of locomotor CPGs in the cord. Moreover, OL dysfunction 
in SC mimics that observed in brains of people with DS and in forebrains of Ts65Dn 
mice, pointing to a CNS-wide defect.  
 
Lastly, Western blot data indicate that widespread dysfunction in mitochondrial 
fusion/fission and OXPHOS occurs with regional specificity in brains of Ts65Dn mice.  
 
Chapter 5.2 – Model Selection for Preclinical Studies 
Existing surgical and medical therapies have been successful at alleviating symptoms 
arising from organ system abnormalities; however, neurocognitive interventions have 
been lagging far behind in DS129. While several preclinical trials of potential 
neuropharmacotherapies have been conducted in mouse models of DS, none have been 
fully vetted to show comprehensive rescuing of brain defects in the mice and, to date, no 
resultant human clinical trials have been successful130, 131, 360. Because DS-related 
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neuropathology evolves in a spatiotemporal manner, therapies or a combination of 
therapies that target distinct periods over the lifespan are integral in combating the 
associated ID132, 133, 189. A notable exception would be treatment that can fully silence the 
extra chromosome during gestation361. Furthermore, while it is still not fully understood 
how brain changes during fetal development relate to postnatal behavior and later 
observed brain defects, over the past 5 years interest in prenatal therapy has been growing 
within the DS research community134-136. Recent studies have shown that 
neuropharmacotherapies are more restorative and have longer lasting effects when 
administered during phases of neural development than when given to adult mice133, 134, 
137. With the advent of highly accurate noninvasive prenatal testing as early as 10 weeks 
of gestation and rapid developments in personalized medicine, clinicians are now for the 
first time uniquely positioned to therapeutically target the prenatal window in order to 
exploit the critical period of fetal development when the CNS is experiencing dynamic 
changes and rapid growth138, 139. Along with dosage, timing of administration may be 
integral for the success of a proposed therapy130.  
 
Preclinical trials showing clear and incontrovertible efficacy of proposed therapeutics are 
essential. As such, model selection is a critical first step for establishing an experimental 
paradigm with high translational value255, 256. Our cross model comparison sheds light on 
commonalities and differences among the Ts1Cje, Ts65Dn, and Dp16 mouse models and 
how they compare to human phenotypes and their timing of onset.  These data will aid in 
model selection based on the proposed drug’s mechanism of action and timing of 
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administration.  Spatiotemporal targeting of therapeutic intervention is likely to be the 
most effective in ameliorating life-stage specific DS phenotypes; therefore, models 
should be chosen carefully based on the onset and magnitude of DS-relevant phenotypes 
for preclinical trials. Additionally, a standardized rigorous screen of phenotypic changes 
should be adopted when analyzing drug efficacy. Establishing proper endpoints is key 
when determining the translational value of a therapeutic. Our cross-strain study provides 
a framework for such a screen, showing combinatorial data regarding gene expression, 
histology, and behavior at key points over the lifespan of Ts1Cje, Ts65Dn, and Dp16 
mice. These can aid in establishing endpoints and biomarkers in future drug screens.  
 
Chapter 5.3 – Common Mechanisms 
Two major threads tying observed defects in Ts65Dn mice, from subcellular fitness to 
behavioral performance, are sonic hedgehog insensitivity and bioenergetic dysfunction.  
 
Previous work has implicated SHH signaling in multiple integral developmental 
processes, including the regionalization of the neural tube, the patterning of the forebrain 
and SC, the designation of cell-fate in MNs, INs, and OLs, and importantly, the 
regulation of cell cycle dynamics and mode of cell division in cortical progenitors28, 69, 72, 
89, 119, 123, 362-367. Our data in Ts65Dn mice show aberrant patterning in the SC (Chapter 3), 
a shift in allocation of excitatory neurons and inhibitory INs (Chapter 2), a block in 
maturation of OLs (previously published158 and Appendix A), pronounced neurogenesis 
defects (previously published186, 187 and Chapter 2), and a misallocation of intermediate 
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progenitors during neurogenesis57, all of which are processes directly or indirectly 
mediated by SHH. In fact, recent work has shown that Ts65Dn mice do indeed have a 
SHH insensitivity and that a single injection of a SHH agonist at P0 can promote partial 
rescue of specific cerebellar and behavioral phenotypes (cortex and SC were not 
investigated)137, 260. The question becomes whether SHH plays an equally substantial role 
in primate, and in particular human, CNS development. After all, human data show that 
widespread neurogenesis abnormalities lead to regional hypoplasia and microcephaly in 
fetuses with DS, and to abnormal myelination perinatally and throughout life125, 145, 153, 
158. Another open question is whether modulation of SHH prior to the onset of 
neurogenesis and throughout neural and glial specification would be fully restorative in 
DS. Since noninvasive prenatal testing can determine a DS karyotype as early as 
10GW138, although the onset of neurogenesis is around 5GW19, there is a critical window 
during CNS developmental that can be exploited during embryogenesis. Future work 
should investigate these questions since SHH may be an attractive candidate for a unique 
culprit in the myriad of observed phenotypes in Ts65Dn mice and people with DS.   
 
Another systematic abnormality in DS is the increase in OS and the accompanying 
mitochondrial dysfunction. OS has been shown in people with DS and in some mouse 
model of DS309, 310, 314, 321-323, 331. Several studies investigating the role of mitochondria in 
that OS burden have shown widespread mitochondrial defects in brain tissue from both 
individuals with DS and mouse models of DS4, 311, 326, 330, 331, 368. Our data support these 
findings. Furthermore, mitochondria have been shown to autonomously downregulate 
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their function as an adaptive response to the mounting intracellular ROS327. Other work 
has shown that there is a selective dependence of radially migrating excitatory neurons 
and tangentially migrating INs on ATP and mitochondria355. Moreover, due to its lipid 
synthesizing properties, OL have increased metabolic demands and have a high density 
of mitochondria356. Lastly, ROS has been shown to modulate OPC differentiation356, 357. 
Given the cell population abnormalities in there three cell types in our study, the 
mitochondria may serve as an additional unifying mechanism underlying DS phenotypes. 
 
Chapter 5.4 – A Mouse Is Not a Human! 
While the use of mouse models in biomedical research has been immensely fruitful, 
several caveats exist in modeling brain development and function of high ordered 
organisms, such as non-human primates and humans, in mice. Many of the processes 
described in this work are similar between mice and humans, however, detailed analyses 
of murine and primate brain development and cytoarchitecture uncover multiple 
inconsistencies that should be considered when interpreting data.  
 
First, germinal zone complexity differs immensely between mice and human/non-human 
primates, with primates exhibiting an increase in the types of neural progenitors and in 
the physical size of the germinal zone, which likely relate to the increased neuronal 
heterogeneity and elevated cognitive capacity in primates369, 370. Additionally, while the 
origins of INs are similar between mice and primates, INs make up approximately 15% 
of cortical neurons in mice, yet that population balloons to approximately 25-30% in 
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humans 371, 372. Furthermore, the proportional representation of each IN subtype within 
the entire IN population differs between species. For example, while PV+ and SS+ 
inhibitory INs make up the majority of INs in the mouse cortex, CR+ INs are the largest 
population in primates371, 372. Moreover, excitatory neurons, in particular layer III 
pyramidal cells, also fundamentally differ in their structural and physiological properties 
between mice and primates373. Specifically, while murine pyramidal populations are 
uniform between cortical areas, primate pyramidal cells differ significantly in size, 
dendritic structure, and electrophysiological properties373. Therefore, unlike in mice, a 
prototypical neuron does not exist in primate brains and findings related to firing activity 
and network integration are not generalizable between cortical areas373. Lastly, the 
process of myelination differs greatly between mice and humans. Myelinogenesis begins 
around mid-gestation in humans but postnatally in mice19, 374, 375. Importantly, 
myelination is complete at approximately P21 in mice but not until the fourth decade of 
life in humans11, 19, 376. Lastly, spatiotemporal distribution of OL differentiation signals 
also differ between mouse and human and may in fact underlie the unique vulnerability 
of humans to demyelinating diseases375.  
 
Thus, while many concepts learned from mouse brain studies are generalizable to 
humans, careful attention should be paid when modeling development, organization, and 
function of human CNS in mice.  
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Chapter 5.5 – Conclusions 
 Only Ts65Dn recapitulate the DS phenotypic repertoire from embryonic development 
and into adulthood. 
 Ts65Dn phenotypes are not confounded by background strain of uterine environment. 
Ts1Cje and Dp16 mice show no measurable parental brain phenotypes. 
 Ts1Cje and Dp16 mice may instead be useful in elucidating phenotypes that arise 
independently from prenatal neurogenesis abnormalities. 
 Limitations to the study disallow definitive conclusions about the contribution of an 
additional chromosome (aneuploidy) or non-orthologous triplicated genes in Ts65Dn 
to observed phenotypes. 
 Ts65Dn show SC patterning defects that arise during embryonic development and 
extends into old age 
 Gene dosage rescue of Olig2 shows partial restoration in motor behavior of adult 
Ts65Dn mice. 
 Only Ts65Dn mice, compared to Ts1Cje and Dp16, show OL maturation defects. 
Proof of principle experiments (described in Appendix A) show a possible class of 
pharmacoagents that can drive OL differentiation in these mice.  
 Ts65Dn mice show mitochondrial dysfunction, however, further analysis is still 
needed. 
 Bioenergetic instability may underlie observed cellular phenotypes in Ts65Dn. 
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 Ts1Cje, Ts65Dn, and Dp16 exhibit a complex pattern of behavioral abnormalities 
starting perinatally and continuing into adulthood  
 Aside from the rotarod and SHIRPA tasks, Ts65Dn are impaired on every behavioral 
metric used for assessment. 
 Gene expression data shows more dissimilarities than commonalities among the three 
model. 
 This disallowed us from pinpointing a common mechanism underlying the distinct 
phenotypes observed in these mice. 
 Sonic hedgehog may serve as an attractive therapeutic target.  
 Differences between human and mouse brain development should be considered 
when interpreting data.  
 Phenotypic instability arises with successive breeding of transgenic mice. 
  
213 
APPENDIX A: WHITE MATTER ABNORMALITIES 
White matter deficits have been observed in Ts65Dn cortex and in people with DS158. 
Specifically, alterations in oligodendrocyte (OL) maturation and in gene expression 
signatures in cells within the OL lineage have been reported158. Here, we utilize the cross-
model comparison platform to assess OL maturation in the corpus callosum of Dp16 at 
P7, P15, P30, and P60 and in Ts1Cje at P15 to compare with previous finding at those 
ages in Ts65Dn corpus callosum (Appendix Figure 1A-D).  
 
Furthermore, additional findings from this study suggest that these OL maturation 
abnormalities are associated with abnormal myelin-related gene expression, altered 
myelination of axons in the neocortex, and a decrease in conduction velocity of action 
potentials in Ts65Dn158. Data also show that similar alterations in myelin and OL-specific 
gene expression are seen in brains of people with DS across the lifespan158. As such, the 
observed block in OL maturation may underlie DS-related cognitive phenotypes; 
therefore, pharmacological alleviation of this maturation block may prove advantageous 
for people with DS. Here, we present a pharmacological approach to pushing OL 
maturation in euploid mice at P15. Histological experiments provide a proof of principle 
that an FDA-approved, commercially available pharmacological agent can be used as a 
basis for the development of a therapeutic molecule with a similar mechanism of action 
and increased specificity to normalize OL maturation. Data show that daily 
intraperitoneal injections of compound MZ led to an increase in CC1+ mature OLs in the 
corpus callosum of P15 mice (Appendix A Figure 1E-F).  
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Appendix A Figure 1- Oligodendrocyte maturation in Ts1Cje, Ts65Dn, and Dp16. 
(A-D) Oligodendrocyte maturation in Ts1Cje, Ts65Dn, and Dp16 corpus callosum at P7, 
P15, P30, and P60. Data shown as mean ± S.E.M, *p<0.05. 
 
(E-F) Increase in oligodendrocyte maturation (# of CC1+ cells, green) in the corpus 
callosum of euploid mice in response to intraperitoneal injections of a pharmacological 
agent. Data shown as mean ± S.E.M, *p<0.05. 
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APPENDIX B: PUBLISHED CO-AUTHORED MANUSCRIPTS 
 
Absence of prenatal forebrain defects in the Dp(16)1Yey/+ mouse model of Down 
syndrome 
Accepted: Journal of Neuroscience 
Joseph W. Goodliffe*, Jose Luis Olmos-Serrano*, Nadine M. Aziz, Jeroen L.A. Pennings, 
Faycal Guedj, Diana W. Bianchi, and Tarik F. Haydar 
*co-first authors 
Abstract 
Studies in humans with Down syndrome (DS) show that alterations in fetal brain 
development are followed by postnatal deficits in neuronal numbers, synaptic plasticity 
and cognitive and motor function. This same progression is replicated in several mouse 
models of DS. Dp(16)1Yey/+ (hereafter called Dp16) is a recently developed mouse model 
of DS in which the entire region of mouse chromosome 16 that is homologous to human 
chromosome 21 has been triplicated. As such, Dp16 mice may more closely reproduce 
neurodevelopmental changes occurring in humans with DS. Here we present the first 
comprehensive cellular and behavioral study of the Dp16 forebrain from embryonic to 
adult stages. Unexpectedly, our results demonstrate that Dp16 mice do not have prenatal 
brain defects previously reported in human fetal neocortex and in the developing forebrains 
of other mouse models, including microcephaly, reduced neurogenesis and abnormal cell 
proliferation. Nevertheless, we found impairments in postnatal developmental milestones, 
fewer inhibitory forebrain neurons and deficits in motor and cognitive performance in 
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Dp16 mice. Thus, while this new model does not express prenatal morphological 
phenotypes associated with DS, abnormalities in the postnatal period appear sufficient to 
produce significant cognitive deficits in Dp16. 
 
Role in work:  
 Gross brain and pallial expansion analyses at E14.5, E15.5, and E16.5. 
 Immunohistochemical analysis of E14.5 MGE 
 Development of EdU injection and staining protocols 
 Development and validation of automatic EdU counting algorithm 
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APPENDIX C: GENOMIC INSTABILITY IN THE TS65DN MOUSE COLONY 
AND LOSS OF NEUROPATHOLOGICAL HALLMARKS 
Loss of phenotype in transgenic mouse colonies is a common phenomenon. Researchers 
posit that this phenotypic fragility arises from genomic instability accumulating over time 
from inbred crossings. Despite the controlled breeding and maintenance, inbred lines are 
not completely isogenic, experiencing both single-gene as well as multi-gene 
polymorphisms.  After several rounds of hereditary transmission of these mutations along 
generations, genetic drift may be taking place in the colony. (Reviewed in Casellas, 
2011)377. 
 
Despite the fact that our Ts65Dn mouse colony is not an inbred colony because mating 
between siblings do not occur, changes in body size, brain size, and loss of phenotype 
were observed (Appendix C Figure 1). While we cannot propose a mechanism for why 
this took place, it is important to note that such a loss of phenotype can take place in 
Ts65Dn colonies.  
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Appendix C Figure 1- Loss of phenotype in Ts65Dn mice. 
All data shown as mean ± S.E.M. 
 
Analysis of gross brain measurements in 4 Ts65Dn litters (n=22, n= 8 Ts65Dn) at E15.5 
showing lack of gross brain phenotypes.  
 
Analysis of and two combined E14.5 litters (n=5 euploid, n=5 Ts65Dn) showing lack of 
pallial expansion phenotype. For reference analysis of one E14.5 litter from a previous 
colony is included to illustrate magnitude of phenotype (left panel, *p<0.05). 
 
(Not shown: loss of hindlimb reflex and grip strength behavioral phenotypes.) 
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